




(86) Date de dépôt PCT/PCT Filing Date: 2013/02/15
(87) Date publication PCT/PCT Publication Date: 2013/08/22
(45) Date de délivrance/Issue Date: 2021/01/26
(85) Entrée phase nationale/National Entry: 2014/08/15
(86) N° demande PCT/PCT Application No.: US 2013/026446
(87) N° publication PCT/PCT Publication No.: 2013/123401
(30) Priorité/Priority: 2012/02/17 (US61/600,374)

(51) Cl.Int./Int.Cl. *C07D 401/12* (2006.01),
A61K 31/506 (2006.01), *A61P 11/00* (2006.01),
C07D 239/32 (2006.01), *C07D 401/14* (2006.01),
C07D 403/12 (2006.01), *C07D 405/14* (2006.01),
C07D 409/14 (2006.01), *C07D 413/12* (2006.01),
C07D 417/14 (2006.01)

(72) Inventeurs/Inventors:
DEKHTYAR, TATYANA, US;
GOMTSYAN, ARTHUR, US;
MOLLA, M-AKHTERUZZAMAN, US;
VASUDEVAN, ANIL, US;
NG, TERESA (JOK CHAN), US;
SHAFEEV, MIKHAIL, US

(73) Propriétaire/Owner:

(54) Titre : DIAMINOPYRIMIDINES UTILISEES EN TANT QU'INHIBITEURS DU VIRUS SYNCYTIAL RESPIRATOIRE (VSR) DE L'HOMME
(54) Title: DIAMINOPYRIMIDINES USEFUL AS INHIBITORS OF THE HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV)



(57) **Abrégé/Abstract:**

This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

(73) Propriétaires(suite)/Owners(continued):ABBVIE INC., US

(74) Agent: TORYS LLP

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau(10) International Publication Number
WO 2013/123401 A1(43) International Publication Date
22 August 2013 (22.08.2013)

(51) International Patent Classification:

C07D 401/12 (2006.01) *C07D 409/14* (2006.01)
C07D 239/32 (2006.01) *C07D 413/12* (2006.01)
C07D 401/14 (2006.01) *C07D 417/14* (2006.01)
C07D 403/12 (2006.01) *A61K 31/506* (2006.01)
C07D 405/14 (2006.01) *A61P 11/00* (2006.01)

(21) International Application Number:

PCT/US2013/026446

(22) International Filing Date:

15 February 2013 (15.02.2013)

(25) Filing Language:

English

(26) Publication Language:

English


(30) Priority Data:

61/600,374 17 February 2012 (17.02.2012) US

(71) Applicant: **ABBVIE INC.** [US/US]; 1 North Waukegan Road, North Chicago, Illinois 60064 (US).(72) Inventors: **DEKHTYAR, Tatyana**; 1220 Briarwood Ln, Libertyville, Illinois 60048 (US). **GOMTSYAN, Arthur**; 104 Adair Ct, Vernon Hills, Illinois 60061 (US). **MOLLA, M-Akhteruzzaman**; 1249 Vista Dr, Gurnee, Illinois 60031 (US). **VASUDEVAN, Anil**; 105, 13th Avenue, Union Grove, Wisconsin 53182 (US). **NG, Teresa (Iok Chan)**; 3229 N. Walker E, Arlington Heights, Illinois 60004 (US).**SHAFEEV, Mikhail**; 100 Abbott Park Road, Bld AP06A-1/V377, Abbott Park, Illinois 60064 (US).(74) Agents: **DAVIS, Bradley E** et al.; 100 Abbott Park Road, Bld AP06A-1/V377, Abbott Park, Illinois 60064 (US).(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: DIAMINOPYRIMIDINES USEFUL AS INHIBITORS OF THE HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV)

(57) Abstract: This disclosure relates to: (a) compounds and salts thereof that, *inter alia*, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

WO 2013/123401 A1 

Published:

— *with international search report (Art. 21(3))*

— *with amended claims (Art. 19(1))*

DIAMINOPYRIMIDINES USEFUL AS INHIBITORS OF THE HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV)

TECHNICAL FIELD

This disclosure is directed to: (a) compounds and salts thereof that, *inter alia*, are useful for
5 inhibiting human respiratory syncytial virus (RSV) infection and/or replication; (b) intermediates
useful for the preparation of such compounds and salts; (c) compositions comprising such compounds
and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e)
methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds,
salts, and compositions.

10

BACKGROUND

Human respiratory syncytial virus (RSV) is a pneumovirus in the *Paramyxoviridae* family. It
is an enveloped, nonsegmented, negative-stranded RNA virus. Its 15.2 kb genome has been
completely sequenced and it contains 10 mRNAs encoding 11 distinct proteins. RSV has three
15 transmembrane surface proteins (F, G, SH) essential for attachment and entry, two nonstructural
proteins (NS1, NS2), a matrix (M) protein, a nucleocapsid (N) protein that encapsidates the viral RNA
genome, a phosphoprotein (P), and an RNA polymerase (L). In addition, the RSV M2 mRNA
encodes both the M2-1 and M2-2 proteins.

RSV is the leading cause of serious lower respiratory tract infection in infants and young
20 children. Most infected infants and children suffer only mild symptoms, but 25-40% of them develop
lower respiratory signs indicative of a viral bronchiolitis or pneumonia. Severe lower respiratory tract
RSV infection can lead to consequences of different severity, ranging from increased risk of
developing childhood asthma to death. Following RSV infection, immunity is incomplete and re-
infections can occur throughout life. It is estimated that RSV causes approximately 60 million
25 infections and 160,000 deaths worldwide each year. RSV infection results in up to 125,000
hospitalizations of infants annually in the United States, which is equivalent to approximately 0.1-
0.2% of hospital admission of infants from this age group. The infants most at risk of severe RSV
disease are those born prematurely, and those with bronchopulmonary dysplasia, congenital heart
disease, or immunodeficiency. Hospital admission rates with these conditions range between 5% and
30%. The mortality rate among children admitted to hospital is approximately 3% for those with
heart and lung diseases and up to 1% for those without these risk factors. RSV infection is also a
significant cause of morbidity in the elderly and immunocompromised populations. In the
hospitalized elderly, mortality can be as high as 10-20%, and in the severely immunocompromised
patients with RSV pneumonia, the rate is approximately 50%.

35

RSV epidemics occur every winter in temperate climates. There are two groups (also referred
to as subgroups) of RSV, A and B. Both groups A and B may co-circulate within an epidemic, but
their relative proportion may vary from year to year. The predominant epidemic group may also

change in different years, with group A having a somewhat higher incidence of being the predominant group. The sequence homology between the two groups varies in the different viral proteins. For example, the F and N proteins are highly conserved with 91% and 96% amino acid identity between the two groups, respectively. The sequence of the G protein, on the other hand, is significantly
 5 different between the two groups, with the amino acid identity being only 53%. There is conflicting data regarding the virulence differences between the two groups of RSV. Some studies found no difference in the clinical severity of the illness caused by the two groups, while others reported that group A appeared to be associated with more severe disease.

At present, there is no clinically approved vaccine or effective antiviral therapy for the
 10 treatment of RSV. Attempts to develop a safe and efficacious RSV vaccine have not been successful thus far partly due to challenges associated with the treatment of at-risk subjects (including infants, the elderly and the immunocompromised) who usually have low tolerance to the side effects of a vaccine and who tend to mount reduced immune responses due to their immature or weaker immune systems.


Ribavirin has been used to treat RSV infection but requires a prolonged aerosol
 15 administration, and there are doubts as to its safety and its efficacy in the treatment of RSV infection. In addition, ribavirin is associated with undesirable side effects such as anemia, fatigue, irritability, skin rash, nasal stuffiness, sinusitis, cough and even birth defects.

Palivizumab/Synagis[®] is a humanized murine monoclonal antibody directed against the RSV
 20 F protein that has been used as passive immunoprophylaxis to prevent the spread of the virus to the lower respiratory tract. Although palivizumab has been used successfully to reduce the frequency of hospitalizations for RSV infection in high risk populations, the antibody has only been approved for prophylactic use in infants who are at risk of developing serious symptoms from RSV infection, such as those born prematurely, and/or with congenital heart or lung disease.

Therefore, there is a significant need for compounds for the prevention and treatment of RSV
 25 infection and for therapies that extend safe and effective treatment to at-risk adults and children with acute RSV infections.

SUMMARY

30 Disclosed herein are compounds of formula (I), and methods of making such compounds,



wherein:

R¹ is C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₃-C₈-cycloalkyl, C₃-C₈-cycloalkyl-C₁-C₆-alkyl, phenyl,
 35 bicyclic aryl, phenyl-C₁-C₆-alkyl, heterocyclyl, heterocyclyl-C₁-C₆-alkyl, monocyclic heteroaryl, or

- monocyclic heteroaryl-C₁-C₆-alkyl; wherein the C₃-C₈-cycloalkyl, the C₃-C₈-cycloalkyl of C₃-C₈-cycloalkyl-C₁-C₆-alkyl, heterocyclyl, and heterocyclyl of heterocyclyl-C₁-C₆-alkyl are optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkynyl, C₁-C₁₀-haloalkyl, C₂-C₁₀-haloalkenyl, C₂-C₁₀-haloalkynyl, halogen, oxo,
- 5 cyano, hydroxy, -O-C₁-C₆-alkyl, -O-C₁-C₆-haloalkyl, -C₁-C₃-alkylene-O-H, -C₁-C₃-alkylene-O-C₁-C₆-alkyl, -C₁-C₃-alkylene-O-C₁-C₆-haloalkyl, -C₁-C₃-alkylene-NH₂, -NH₂, -C(O)O-C₁-C₆-alkyl, -N(R^{bl})C(O)R^{bl}, -CON(R^{al})(R^{bl}), -C(O)R^{bl}, -OC(O)R^{bl}, -OS(O)₂N(R^{al})(R^{bl}), -CO₂H, -CO₂R^{bl}, -N(R^{bl})C(O)N(R^{bl})₂, -S-R^{bl}, -S(O)₂R^{bl}, -S(O)R^{bl}, -SO₂N(R^{al})(R^{bl}), -N(R^{al})(R^{bl}), -N(R^{bl})S(O)₂R^{bl}, -N(R^{bl})C(O)O(R^{bl}), -N(R^{bl})S(O)₂O(R^{bl}), -L^{1a}-O-R^{bl}, -L^{1a}-CN, -L^{1a}-N(R^{bl})C(O)R^{bl},
- 10 -L^{1a}-CON(R^{al})(R^{bl}), -L^{1a}-C(O)R^{bl}, -L^{1a}-OC(O)R^{bl}, -L^{1a}-CO₂H, -L^{1a}-CO₂R^{bl}, -L^{1a}-N(R^{bl})C(O)N(R^{bl})₂, -L^{1a}-S-R^{bl}, -L^{1a}-S(O)₂R^{bl}, -L^{1a}-S(O)R^{bl}, -L^{1a}-SO₂N(R^{al})(R^{bl}), -L^{1a}-N(R^{al})(R^{bl}), -L^{1a}-N(R^{bl})S(O)₂R^{bl}, and -L^{1a}-N(R^{bl})C(O)O(R^{bl}); wherein the phenyl, the bicyclic aryl, the phenyl of phenyl-C₁-C₆-alkyl, the monocyclic heteroaryl and monocyclic heteroaryl of monocyclic heteroaryl-C₁-C₆-alkyl are optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen,
- 15 C₁-C₆-alkyl, C₁-C₆-haloalkyl, -OCH₂O-, -O-R^b, -CN, -N(R^b)C(O)R^b, -CON(R^a)(R^b), -C(O)R^b, -OC(O)R^b, -OS(O)₂N(R^a)(R^b), -CO₂H, -CO₂R^b, -N(R^b)C(O)N(R^b)₂, -S-R^b, -S(O)₂R^b, -S(O)R^b, -SO₂N(R^a)(R^b), -N(R^a)(R^b), -N(R^b)S(O)₂R^b, -N(R^b)C(O)O(R^b), -N(R^b)S(O)₂O(R^b), -L¹-O-R^b, -L¹-CN, -L¹-N(R^b)C(O)R^b, -L¹-CON(R^a)(R^b), -L¹-C(O)R^b, -L¹-OC(O)R^b, -L¹-CO₂H, -L¹-CO₂R^b, -L¹-N(R^b)C(O)N(R^b)₂, -L¹-S-R^b, -L¹-S(O)₂R^b, -L¹-S(O)R^b, -L¹-SO₂N(R^a)(R^b), -L¹-N(R^a)(R^b),
- 20 -L¹-N(R^b)S(O)₂R^b, and -L¹-N(R^b)C(O)O(R^b);
- R² is methyl or ethyl;
- R³ is methyl or ethyl;
- R⁴ and R⁵ are independently selected from the group consisting of hydrogen, C₁-C₆-alkyl, and C₁-C₆-haloalkyl;
- 25 R⁶ is selected from the group consisting of hydrogen, C₁-C₆-alkyl, and C₁-C₆-haloalkyl;
- G¹ is phenyl or monocyclic heteroaryl, wherein the phenyl or monocyclic heteroaryl are optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, C₁-C₆-alkyl, C₁-C₆-haloalkyl, -O-R^f, -CN, -N(R^f)C(O)R^f, -CON(R^e)(R^f), -C(O)R^f, -OC(O)R^f, -CO₂H, -CO₂R^f, -N(R^f)C(O)N(R^f)₂, -S-R^f, -S(O)₂R^f, -S(O)R^f, -SO₂N(R^e)(R^f), -N(R^e)(R^f), -N(R^f)S(O)₂R^f,
- 30 -N(R^f)C(O)O(R^f), -L³-O-R^f, -L³-CN, -L³-N(R^f)C(O)R^f, -L³-CON(R^e)(R^f), -L³-C(O)R^f, -L³-OC(O)R^f, -L³-CO₂H, -L³-CO₂R^f, -L³-N(R^f)C(O)N(R^f)₂, -L³-S-R^f, -L³-S(O)₂R^f, -L³-S(O)R^f, -L³-SO₂N(R^e)(R^f), -L³-N(R^e)(R^f), -L³-N(R^f)S(O)₂R^f, and -L³-N(R^f)C(O)O(R^f);
- X is selected from O, S, NR^g, or C(R^hRⁱ);
- 35 R^a, at each occurrence, is each independently hydrogen, C₁-C₆-alkyl, C₁-C₆-haloalkyl, or C₃-C₈-cycloalkyl, wherein the C₃-C₈-cycloalkyl is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen, oxo, C₁-C₃alkyl, and C₁-C₃-haloalkyl;

R^{al}, at each occurrence, is each independently hydrogen, C₁-C₆-alkyl, C₁-C₆-haloalkyl, or C₃-C₈-cycloalkyl, wherein the C₃-C₈-cycloalkyl is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen, oxo, C₁-C₃alkyl, and C₁-C₃-haloalkyl;

R^b is each independently hydrogen, C₁-C₆-alkyl, or C₁-C₆-haloalkyl;

5 R^{bl} is each independently hydrogen, C₁-C₆-alkyl, or C₁-C₆-haloalkyl;

R^e, at each occurrence, is each independently hydrogen, C₁-C₆-alkyl, C₁-C₆-haloalkyl, or C₃-C₈-cycloalkyl, wherein the C₃-C₈-cycloalkyl is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen, oxo, C₁-C₃alkyl, and C₁-C₃-haloalkyl;

R^f is each independently hydrogen, C₁-C₆-alkyl, or C₁-C₆-haloalkyl;

10 R^g is hydrogen or C₁-C₆-alkyl.

R^h and Rⁱ are independently hydrogen, C₁-C₆-alkyl, or C₁-C₆-haloalkyl;

L¹, at each occurrence, is each independently C₁-C₆-alkylene or C₃-C₈-cycloalkyl, wherein L¹ is each optionally substituted with 1, 2, 3, or 4 halogen or 1 or 2 hydroxy;

L^{1a}, at each occurrence, is each independently C₁-C₆-alkylene or C₃-C₈-cycloalkyl, wherein

15 L^{1a} is each optionally substituted with 1, 2, 3, or 4 halogen or 1 or 2 hydroxy; and

L³, at each occurrence, is each independently C₁-C₆-alkylene or C₃-C₈-cycloalkyl, wherein L³ is each optionally substituted with 1, 2, 3, or 4 halogen.

20 This disclosure also relates to pharmaceutical compositions comprising therapeutically effective amount of one or more compound(s) described herein or pharmaceutically acceptable salts, solvates, or salts of solvates thereof, in combination with one or more pharmaceutically acceptable carrier(s).

25 This disclosure also is directed to compositions (including pharmaceutical compositions) that comprise one or more of the disclosed compounds and/or salts, and, optionally, one or more additional therapeutic agents.

This disclosure also is directed to kits that comprise one or more of the disclosed compounds and/or salts, and, optionally, one or more additional therapeutic agents.

This disclosure also is directed to methods of use of the compounds, salts, compositions, and/or kits to, for example, inhibit replication of an RNA virus (including RSV).

30 This disclosure also is directed to a use of one or more of the disclosed compounds and/or salts to prepare a medicament. The medicament optionally can comprise one or more additional therapeutic agents. In some embodiments, the medicament is useful for treating RSV infection.

The compounds, compositions comprising the compounds, pharmaceutically acceptable salts, solvates, or salts of the solvates thereof, and methods for treating or preventing conditions and


35 disorders by administering the compounds or compositions thereof, are further described herein.

These and other objectives are described further in the following paragraphs. These objectives should not be deemed to narrow the scope of the disclosure.

DETAILED DESCRIPTION

This detailed description is intended only to acquaint others skilled in the art with the disclosed embodiments, their principles, and their practical application so that others skilled in the art may adapt and apply the embodiments in their numerous forms, as they may be best suited to the requirements of particular uses. This description and its specific examples are intended for purposes of illustration only. This disclosure, therefore, is not limited to the embodiments described in this patent application, and may be variously modified.

- 10 The present disclosure describes compounds of formula (I) and methods of preparing such compounds,



- 15 wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , G^1 and X are as defined herein. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

In various embodiments, compounds described herein may contain variables that occur more than one time in any substituent or in the compound described or any other formulae herein. Definition of a variable on each occurrence is independent of its definition at another occurrence.

- 20 Further, combinations of variables are permissible only if such combinations result in stable compounds. Stable compounds are compounds that can be isolated from a reaction mixture.

Definitions

- The term "alkenyl", means a straight or branched hydrocarbon chain containing at least one carbon-carbon double bond. The term " C_2 - C_{10} -alkenyl" means an alkenyl group containing 2-10 carbon atoms. Non-limiting examples of alkenyl include buta-2,3-dienyl, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-1-heptenyl, and 3-decenyl.

- The term "alkenylene" means a divalent group derived from a straight or branched chain hydrocarbon and contains at least one carbon-carbon double. " C_2 - C_6 -alkenylene" means an alkenylene group containing 2-6 carbon atoms. Representative examples of alkenylene include, but are not limited to, $-C(=CH_2)-$, $-CH=CH-$ and $-CH_2CH=CH-$.

- The term "alkyl" as used herein, means a straight or branched, saturated hydrocarbon chain. For example " C_1 - C_{10} -alkyl" means a straight or branched chain, saturated hydrocarbon containing 1 to 10 carbon atoms. For example " C_1 - C_3 -alkyl" means a straight or branched chain, saturated hydrocarbon containing 1 to 3 carbon atoms. Examples of alkyl include, but are not limited to,

methyl, ethyl, *n*-propyl, *iso*-propyl, *n*-butyl, *sec*-butyl, *iso*-butyl, *tert*-butyl, *n*-pentyl, isopentyl, neopentyl, *n*-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, *n*-heptyl, *n*-octyl, *n*-nonyl, and *n*-decyl.

The term "alkylene" means a divalent group derived from a straight or branched, saturated hydrocarbon chain. Examples of alkylene include, but are not limited to, -CH₂-, -CH₂CH₂-, -CH₂CH₂CH₂-, -CH₂CH₂CH₂CH₂-, -CH(CH₃)-, and -CH₂CH(CH₃)CH₂-.

The term "alkynyl", means a straight or branched chain hydrocarbon group containing at least one carbon-carbon triple bond. The term "C₂-C₁₀-alkynyl" means an alkynyl group containing from 2 to 10 carbon atoms. Representative examples of alkynyl include, but are not limited, to acetylenyl, 1-propynyl, 2-propynyl, 3-butyne, 2-pentyne, and 1-butyne.

The term "aryl" as used herein, means phenyl or a bicyclic aryl. For example, "C₆-C₁₀-aryl" refers to an aryl group that may have from six to ten carbon atoms. The bicyclic aryl is naphthyl, or a phenyl fused to a monocyclic cycloalkyl, or a phenyl fused to a monocyclic cycloalkenyl. Non-limiting examples of the aryl groups include dihydroindenyl, indenyl, naphthyl, dihydronaphthalenyl, and tetrahydronaphthalenyl. The aryl groups can be unsubstituted or substituted, and the bicyclic aryl is attached to the parent molecular moiety through any substitutable carbon atom contained within the bicyclic ring system.

The term "aryalkyl," as used herein, refers to an aryl group attached to the parent molecular moiety through an alkyl group.

The term "cyano" means -CN, which also may be depicted as -C≡N.

The term "cycloalkenyl" or "cycloalkene" as used herein, means a monocyclic or a bicyclic hydrocarbon ring system. The monocyclic cycloalkenyl has four-, five-, six-, seven- or eight carbon atoms and zero heteroatoms. The four-membered ring systems have one double bond, the five- or six-membered ring systems have one or two double bonds, and the seven- or eight-membered ring systems have one, two, or three double bonds. Representative examples of monocyclic cycloalkenyl groups include, but are not limited to, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. The bicyclic cycloalkenyl is a monocyclic cycloalkenyl fused to a monocyclic cycloalkyl group, or a monocyclic cycloalkenyl fused to a monocyclic cycloalkenyl group. The monocyclic or bicyclic cycloalkenyl ring may contain one or two alkylene bridges, each consisting of one, two, or three carbon atoms, each linking two non-adjacent carbon atoms of the ring system. Representative examples of the bicyclic cycloalkenyl groups include, but are not limited to, 4,5,6,7-tetrahydro-3aH-indene, octahydronaphthalenyl, and 1,6-dihydro-pentalene. The monocyclic and bicyclic cycloalkenyl can be attached to the parent molecular moiety through any substitutable atom contained within the ring systems, and can be unsubstituted or substituted.

The term "cycloalkyl" or "cycloalkane" as used herein, means a monocyclic, a bicyclic, or a tricyclic cycloalkyl. The monocyclic cycloalkyl is a carbocyclic ring system containing three to eight carbon atoms, zero heteroatoms and zero double bonds. Examples of monocyclic ring systems

include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. The bicyclic cycloalkyl is a monocyclic cycloalkyl fused to a monocyclic cycloalkyl ring. Tricyclic cycloalkyls are exemplified by a bicyclic cycloalkyl fused to a monocyclic cycloalkyl. The monocyclic or bicyclic cycloalkyl ring may contain one or two alkylene bridges, each consisting of one, two, or three carbon atoms, each linking two non-adjacent carbon atoms of the ring system. Non-limiting examples of such bridged cycloalkyl ring systems include bicyclo[3.1.1]heptane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, bicyclo[3.3.1]nonane, bicyclo[4.2.1]nonane, tricyclo[3.3.1.0^{3,7}]nonane (octahydro-2,5-methanopentalene or noradamantane), and tricyclo[3.3.1.1^{3,7}]decane (adamantane). The monocyclic, bicyclic, and tricyclic cycloalkyls can be unsubstituted or substituted, and are attached to the parent molecular moiety through any substitutable atom contained within the ring system.

The term "cycloalkylalkyl," as used herein, refers to a cycloalkyl group attached to the parent molecular moiety through an alkyl group.

The term "halo" or "halogen" as used herein, means Cl, Br, I, or F.

The term "haloalkyl" as used herein, means an alkyl group, as defined herein, in which one, two, three, four, five or six hydrogen atoms are replaced by halogen. The term "C₁-C₁₀-haloalkyl" means a C₁-C₁₀ alkyl group, as defined herein, in which one, two, three, four, five or six hydrogen atoms are replaced by halogen. Representative examples of haloalkyl include, but are not limited to, chloromethyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, trifluoromethyl, difluoromethyl, pentafluoroethyl, 2-chloro-3-fluoropentyl, trifluorobutyl (such as, but not limited to, 4,4,4-trifluorobutyl), and trifluoropropyl (such as, but not limited thereto, 3,3,3-trifluoropropyl).

The term "haloalkenyl", as used herein, refers to an alkenyl group, as defined herein, substituted by one, two, three, or four halogen atoms.

The term "haloalkynyl", as used herein, refers to an alkynyl group, as defined herein, substituted by one, two, three, or four halogen atoms.

The term "heterocycle", "heterocyclyl", or "heterocyclic" as used herein, means a monocyclic heterocycle, a bicyclic heterocycle, or a tricyclic heterocycle. The monocyclic heterocycle is a three-, four-, five-, six-, seven-, or eight-membered ring containing at least one heteroatom independently selected from the group consisting of O, N, and S. The three- or four-membered ring contains zero or one double bond and one heteroatom selected from the group consisting of O, N, and S. The five-membered ring contains zero or one double bond and one, two, or three heteroatoms selected from the group consisting of O, N, and S. The six-membered ring contains zero, one, or two double bonds and one, two, or three heteroatoms selected from the group consisting of O, N, and S. The seven- and eight-membered rings contain zero, one, two, or three double bonds and one, two, or three heteroatoms selected from the group consisting of O, N, and S. Non-limiting examples of monocyclic heterocycles include azetidiny, azepanyl, aziridinyl, diazepanyl, 1,3-dioxanyl, 1,3-dioxolanyl, 1,3-dithiolanyl, 1,3-dithianyl, imidazoliny, imidazolidiny, isothiazoliny, isothiazolidiny,

isoxazoliny, isoxazolidiny, morpholiny, oxadiazoliny, oxadiazolidiny, oxazoliny, oxazolidiny, oxetany, piperaziny, piperidiny, pyran, pyrazoliny, pyrazolidiny, pyrroliny, pyrrolidiny (including, but not limited thereto, pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl), tetrahydrofurany (including, but not limited thereto, tetrahydrofuran-3-yl), tetrahydropyran, tetrahydrothien, 5 thiadiazoliny, thiadiazolidiny, thiazoliny, thiazolidiny, thiomorpholiny, 1,1-dioxidothiomorpholiny (thiomorpholine sulfone), thiopyran, and trithian. The bicyclic heterocycle is a monocyclic heterocycle fused to a phenyl group, or a monocyclic heterocycle fused to a monocyclic cycloalkyl, or a monocyclic heterocycle fused to a monocyclic cycloalkenyl, or a monocyclic heterocycle fused to a monocyclic heterocycle. Non-limiting examples of bicyclic 10 heterocycles include benzopyran, benzothiopyran, 2,3-dihydrobenzofuran, 2,3-dihydrobenzothien, benzo[*d*][1,3]dioxol, chroman and 2,3-dihydro-1H-indol. Tricyclic heterocycles are exemplified by a bicyclic heterocycle fused to a phenyl group, or a bicyclic heterocycle fused to a monocyclic cycloalkyl, or a bicyclic heterocycle fused to a monocyclic cycloalkenyl, or a bicyclic heterocycle fused to a monocyclic heterocycle. The monocyclic and the 15 bicyclic heterocycles may contain an alkenylene bridge of two, three, or four carbon atoms, or one or two alkylene bridges of 1, 2, 3, or 4 carbon atoms, or combinations thereof, wherein each bridge links two non-adjacent atoms of the ring system. Non-limiting examples of such bridged heterocycles include octahydro-2,5-epoxypentalene, azabicyclo[2.2.1]heptyl (including 2-azabicyclo[2.2.1]hept-2-yl), hexahydro-2*H*-2,5-methanocyclopenta[*b*]furan, hexahydro-1*H*-1,4-methanocyclopenta[*c*]furan, 20 aza-admantane (1-azatricyclo[3.3.1.1^{3,7}]decane), and oxa-admantane (2-oxatricyclo[3.3.1.1^{3,7}]decane). The monocyclic, bicyclic, and tricyclic heterocycles can be unsubstituted or substituted, and are connected to the parent molecular moiety through any substitutable carbon atom or any substitutable nitrogen atom contained within the rings. The nitrogen and sulfur heteroatoms in the heterocycle rings may optionally be oxidized and the nitrogen atoms 25 may optionally be quaternized. The term "N-heterocyclyl" refers to a nitrogen-containing heterocyclic group attached to the parent molecular moiety through a nitrogen atom.

The term "heterocyclalkyl," as used herein, refers to a heterocyclyl group attached to the parent molecular moiety through an alkyl group.

The term "heteroaryl" as used herein, means a monocyclic heteroaryl or a bicyclic heteroaryl. 30 The monocyclic heteroaryl is a five- or six-membered ring. The five-membered ring contains two double bonds. The five membered ring may contain one heteroatom selected from O or S; or one, two, three, or four nitrogen atoms and optionally one oxygen or one sulfur atom. The six-membered ring contains three double bonds and one, two, three or four nitrogen atoms. Representative examples of monocyclic heteroaryl include, but are not limited to, furan (including, but not limited thereto, 35 furan-2-yl), imidazol (including, but not limited thereto, 1*H*-imidazol-1-yl), isoxazol, isothiazol, oxadiazol, 1,3-oxazol, pyridin (e.g. pyridin-4-yl, pyridin-2-yl, pyridin-3-yl), pyridazin, pyrimidin, pyrazin, pyrazol, pyrrol, tetrazol, thiadiazol, 1,3-thiazol, thien (including,

but not limited thereto, thien-2-yl, thien-3-yl), triazolyl, and triazinyl. The bicyclic heteroaryl consists of a monocyclic heteroaryl fused to a phenyl, or a monocyclic heteroaryl fused to a monocyclic cycloalkyl, or a monocyclic heteroaryl fused to a monocyclic cycloalkenyl, or a monocyclic heteroaryl fused to a monocyclic heteroaryl, or a monocyclic heteroaryl fused to a monocyclic heterocycle. Non-limiting examples of bicyclic heteroaryl groups include benzofuranyl, benzothieryl, benzoxazolyl, benzimidazolyl, benzoxadiazolyl, 6,7-dihydro-1,3-benzothiazolyl, furo[3,2-*c*]pyridazinyl, furo[3,2-*d*]pyrimidinyl, furo[2,3-*b*]pyrazinyl, furo[2,3-*c*]pyridazinyl, furo[2,3-*d*]pyrimidinyl, furo[3,2-*b*]pyridinyl, furo[3,2-*c*]pyridinyl, furo[2,3-*c*]pyridinyl, furo[2,3-*b*]pyridine, imidazo[2,1-*b*]oxazolyl, imidazo[1,2-*a*]pyridinyl, imidazo[2,1-*b*][1,3,4]thiadiazolyl, imidazo[2,1-*b*][1,3,4]thiadiazolyl, imidazo[1,2-*d*][1,2,4]thiadiazolyl, imidazo[2,1-*b*]thiazolyl, indazolyl, indoliziny, indolyl, isoindolyl, isoquinoliny, naphthyridinyl, pyrazolo[1,5-*a*]pyridinyl, pyrazolo[1,5-*c*]pyrimidinyl, pyrazolo[1,5-*a*]pyrimidinyl, pyrazolo[5,1-*c*][1,2,4]triazinyl, pyridoimidazolyl, quinoliny, thiazolo[5,4-*b*]pyridin-2-yl, thiazolo[5,4-*d*]pyrimidin-2-yl, and 5,6,7,8-tetrahydroquinolin-5-yl. The monocyclic and bicyclic heteroaryl groups can be substituted or unsubstituted and are connected to the parent molecular moiety through any substitutable carbon atom or any substitutable nitrogen atom contained within the ring systems.

The term "heteroarylalkyl," as used herein, refers to a heteroaryl group attached to the parent molecular moiety through an alkyl group.

The term "heteroatom" as used herein, means a nitrogen, oxygen, or sulfur atom.

The term "hydroxyl" or "hydroxy" means a -OH group.

The term "monocyclic heteroarylalkyl," as used herein, refers to a monocyclic heteroaryl group attached to the parent molecular moiety through an alkyl group.

The term "oxo" as used herein, means a =O group.

The term "phenylalkyl," as used herein, refers to a phenyl group attached to the parent molecular moiety through an alkyl group.

In some instances, the number of carbon atoms in a hydrocarbyl substituent (*e.g.*, alkyl or cycloalkyl) is indicated by the prefix "C_x-C_y-", wherein x is the minimum and y is the maximum number of carbon atoms in the substituent. Thus, for example, "C₁-C₆-alkyl" refers to an alkyl substituent containing from 1 to 6 carbon atoms. Illustrating further, C₃-C₆-cycloalkyl means a saturated hydrocarbyl ring containing from 3 to 6 carbon ring atoms.

A substituent is "substitutable" if it comprises at least one carbon or nitrogen atom that is bonded to one or more hydrogen atoms. Thus, for example, hydrogen, halogen, and cyano do not fall within this definition. In addition, a sulfur atom in a heterocyclyl containing such atom is substitutable with one or two oxo substituents.

If a substituent is described as being "substituted", a non-hydrogen radical is in the place of hydrogen radical on a carbon or nitrogen of the substituent. Thus, for example, a substituted alkyl

substituent is an alkyl substituent in which at least one non-hydrogen radical is in the place of a hydrogen radical on the alkyl substituent. To illustrate, monofluoroalkyl is alkyl substituted with a fluoro radical, and difluoroalkyl is alkyl substituted with two fluoro radicals. It should be recognized that if there is more than one substitution on a substituent, each non-hydrogen radical may be identical or different (unless otherwise stated).

If a substituent is described as being "optionally substituted", the substituent may be either (1) not substituted or (2) substituted. If a substituent is described as being optionally substituted with up to a particular number of non-hydrogen radicals, that substituent may be either (1) not substituted; or (2) substituted by up to that particular number of non-hydrogen radicals or by up to the maximum number of substitutable positions on the substituent, whichever is less. Thus, for example, if a substituent is described as a heteroaryl optionally substituted with up to 3 non-hydrogen radicals, then any heteroaryl with less than 3 substitutable positions would be optionally substituted by up to only as many non-hydrogen radicals as the heteroaryl has substitutable positions. To illustrate, tetrazolyl (which has only one substitutable position) would be optionally substituted with up to one non-hydrogen radical. To illustrate further, if an amino nitrogen is described as being optionally substituted with up to 2 non-hydrogen radicals, then a primary amino nitrogen will be optionally substituted with up to 2 non-hydrogen radicals, whereas a secondary amino nitrogen will be optionally substituted with up to only 1 non-hydrogen radical.

This patent application uses the terms "substituent" and "radical" interchangeably.

The prefix "halo" indicates that the substituent to which the prefix is attached is substituted with one or more independently selected halogen radicals. For example, haloalkyl means an alkyl substituent in which at least one hydrogen radical is replaced with a halogen radical. Examples of haloalkyls include chloromethyl, 1-bromoethyl, fluoromethyl, difluoromethyl, trifluoromethyl, and 1,1,1-trifluoroethyl. It should be recognized that if a substituent is substituted by more than one halogen radical, those halogen radicals may be identical or different (unless otherwise stated).

The prefix "perhalo" indicates that every hydrogen radical on the substituent to which the prefix is attached is replaced with independently selected halogen radicals, *i.e.*, each hydrogen radical on the substituent is replaced with a halogen radical. If all the halogen radicals are identical, the prefix typically will identify the halogen radical. Thus, for example, the term "perfluoro" means that every hydrogen radical on the substituent to which the prefix is attached is substituted with a fluorine radical. To illustrate, the term "perfluoroalkyl" means an alkyl substituent wherein a fluorine radical is in the place of each hydrogen radical.

A prefix attached to a multi-component substituent only applies to the first component. To illustrate, the term "alkylcycloalkyl" contains two components: alkyl and cycloalkyl. Thus, the C₁-C₆-prefix on C₁-C₆-alkylcycloalkyl means that the alkyl component of the alkylcycloalkyl contains from 1 to 6 carbon atoms; the C₁-C₆-prefix does not describe the cycloalkyl component. To illustrate further, the prefix "halo" on haloalkoxyalkyl indicates that only the alkoxy component of the

alkoxyalkyl substituent is substituted with one or more halogen radicals. If halogen substitution may alternatively or additionally occur on the alkyl component, the substituent would instead be described as "halogen-substituted alkoxyalkyl" rather than "haloalkoxyalkyl." And finally, if the halogen substitution may only occur on the alkyl component, the substituent would instead be described as

5 "alkoxyhaloalkyl."

If substituents are described as being "independently selected" from a group, each substituent is selected independent of the other. Each substituent, therefore, may be identical to or different from the other substituent(s).

10 When words are used to describe a substituent, the rightmost-described component of the substituent is the component that has the free valence.

When a chemical formula is used to describe a substituent, the dash on the left side of the formula indicates the portion of the substituent that has the free valence.

15 When a chemical formula is used to describe a linking element between two other elements of a depicted chemical structure, the leftmost dash of the substituent indicates the portion of the substituent that is bound to the left element in the depicted structure. The rightmost dash, on the other hand, indicates the portion of the substituent that is bound to the right element in the depicted structure. To illustrate, if the depicted chemical structure is W-L-Y and L is described as -C(O)-N(H)-, then the chemical would be W-C(O)-N(H)-Y.

20 Compounds of formula (I) are as described herein.

Particular values of variable groups in compounds of formula (I) are as follows. Such values may be used where appropriate with any of the other values, definitions, claims or embodiments defined herein.

25 In certain embodiments, R¹ is C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₃-C₈-cycloalkyl, C₃-C₈-cycloalkyl-C₁-C₆-alkyl, phenyl, bicyclic aryl, phenyl-C₁-C₆-alkyl, heterocyclyl, heterocyclyl-C₁-C₆-alkyl, monocyclic heteroaryl, or monocyclic heteroaryl-C₁-C₆-alkyl; wherein the C₃-C₈-cycloalkyl, the C₃-C₈-cycloalkyl of C₃-C₈-cycloalkyl-C₁-C₆-alkyl, heterocyclyl, and heterocyclyl of heterocyclyl-C₁-C₆-alkyl are optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of

30 C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkynyl, C₁-C₁₀-haloalkyl, C₂-C₁₀-haloalkenyl, C₂-C₁₀-haloalkynyl, halogen, oxo, cyano, hydroxy, -O-C₁-C₆-alkyl, -O-C₁-C₆-haloalkyl, -C₁-C₃-alkylene-O-H, -C₁-C₃-alkylene-O-C₁-C₆-alkyl, -C₁-C₃-alkylene-O-C₁-C₆-haloalkyl, -C₁-C₃-alkylene-NH₂, -NH₂, -C(O)O-C₁-C₆-alkyl, -N(R^{b1})C(O)R^{b1}, -CON(R^{a1})(R^{b1}), -C(O)R^{b1}, -OC(O)R^{b1}, -OS(O)₂N(R^{a1})(R^{b1}), -CO₂H, -CO₂R^{b1}, -N(R^{b1})C(O)N(R^{b1})₂, -S-R^{b1}, -S(O)₂R^{b1}, -S(O)R^{b1}, -SO₂N(R^{a1})(R^{b1}), -N(R^{a1})(R^{b1}), -N(R^{b1})S(O)₂R^{b1}, -N(R^{b1})C(O)O(R^{b1}), -N(R^{b1})S(O)₂O(R^{b1}), -L^{1a}-O-R^{b1},

35 -L^{1a}-CN, -L^{1a}-N(R^{b1})C(O)R^{b1}, -L^{1a}-CON(R^{a1})(R^{b1}), -L^{1a}-C(O)R^{b1}, -L^{1a}-OC(O)R^{b1}, -L^{1a}-CO₂H, -L^{1a}-CO₂R^{b1}, -L^{1a}-N(R^{b1})C(O)N(R^{b1})₂, -L^{1a}-S-R^{b1}, -L^{1a}-S(O)₂R^{b1}, -L^{1a}-S(O)R^{b1}, -L^{1a}-SO₂N(R^{a1})(R^{b1}), -L^{1a}-N(R^{a1})(R^{b1}), -L^{1a}-N(R^{b1})S(O)₂R^{b1}, and -L^{1a}-N(R^{b1})C(O)O(R^{b1}); wherein the phenyl, the bicyclic

- aryl, the phenyl of phenyl-C₁-C₆-alkyl, the monocyclic heteroaryl and monocyclic heteroaryl of monocyclic heteroaryl-C₁-C₆-alkyl are optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, C₁-C₆-alkyl, C₁-C₆-haloalkyl, -OCH₂O-, -O-R^b, -CN, -N(R^b)C(O)R^b, -CON(R^a)(R^b), -C(O)R^b, -OC(O)R^b, -OS(O)₂N(R^a)(R^b), -CO₂H, -CO₂R^b,
 5 -N(R^b)C(O)N(R^b)₂, -S-R^b, -S(O)₂R^b, -S(O)R^b, -SO₂N(R^a)(R^b), -N(R^a)(R^b), -N(R^b)S(O)₂R^b,
 -N(R^b)C(O)O(R^b), -N(R^b)S(O)₂O(R^b), -L¹-O-R^b, -L¹-CN, -L¹-N(R^b)C(O)R^b, -L¹-CON(R^a)(R^b),
 -L¹-C(O)R^b, -L¹-OC(O)R^b, -L¹-CO₂H, -L¹-CO₂R^b, -L¹-N(R^b)C(O)N(R^b)₂, -L¹-S-R^b, -L¹-S(O)₂R^b,
 -L¹-S(O)R^b, -L¹-SO₂N(R^a)(R^b), -L¹-N(R^a)(R^b), -L¹-N(R^b)S(O)₂R^b, and -L¹-N(R^b)C(O)O(R^b); wherein L¹, L^{1a}, R^a, R^{a1}, R^b and R^{b1} are as described herein.
- 10 In certain embodiments, R¹ is C₁-C₆-alkyl or C₁-C₆-haloalkyl.
- In certain embodiments, R¹ is C₃-C₈-cycloalkyl, C₃-C₈-cycloalkyl-C₁-C₆-alkyl, phenyl, bicyclic aryl, phenyl-C₁-C₆-alkyl, heterocyclyl, heterocyclyl-C₁-C₆-alkyl, monocyclic heteroaryl, or monocyclic heteroaryl-C₁-C₆-alkyl; wherein the C₃-C₈-cycloalkyl, the C₃-C₈-cycloalkyl of C₃-C₈-cycloalkyl-C₁-C₆-alkyl, heterocyclyl, and heterocyclyl of heterocyclyl-C₁-C₆-alkyl are optionally
 15 substituted with 1, 2, 3, or 4 substituents selected from the group consisting of C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkynyl, C₁-C₁₀-haloalkyl, C₂-C₁₀-haloalkenyl, C₂-C₁₀-haloalkynyl, halogen, oxo, cyano, hydroxy, -O-C₁-C₆-alkyl, -O-C₁-C₆-haloalkyl, -C₁-C₃-alkylene-O-H, -C₁-C₃-alkylene-O-C₁-C₆-alkyl, -C₁-C₃-alkylene-O-C₁-C₆-haloalkyl, -C₁-C₃-alkylene-NH₂, -NH₂, -C(O)O-C₁-C₆-alkyl,
 -N(R^{b1})C(O)R^{b1}, -CON(R^{a1})(R^{b1}), -C(O)R^{b1}, -OC(O)R^{b1}, -OS(O)₂N(R^{a1})(R^{b1}), -CO₂H, -CO₂R^{b1},
 20 -N(R^{b1})C(O)N(R^{b1})₂, -S-R^{b1}, -S(O)₂R^{b1}, -S(O)R^{b1}, -SO₂N(R^{a1})(R^{b1}), -N(R^{a1})(R^{b1}), -N(R^{b1})S(O)₂R^{b1},
 -N(R^{b1})C(O)O(R^{b1}), -N(R^{b1})S(O)₂O(R^{b1}), -L^{1a}-O-R^{b1}, -L^{1a}-CN, -L^{1a}-N(R^{b1})C(O)R^{b1},
 -L^{1a}-CON(R^{a1})(R^{b1}), -L^{1a}-C(O)R^{b1}, -L^{1a}-OC(O)R^{b1}, -L^{1a}-CO₂H, -L^{1a}-CO₂R^{b1}, -L^{1a}-N(R^{b1})C(O)N(R^{b1})₂,
 -L^{1a}-S-R^{b1}, -L^{1a}-S(O)₂R^{b1}, -L^{1a}-S(O)R^{b1}, -L^{1a}-SO₂N(R^{a1})(R^{b1}), -L^{1a}-N(R^{a1})(R^{b1}), -L^{1a}-N(R^{b1})S(O)₂R^{b1},
 and -L^{1a}-N(R^{b1})C(O)O(R^{b1}); wherein the phenyl, the bicyclic aryl, the phenyl of phenyl-C₁-C₆-alkyl,
 25 the monocyclic heteroaryl and monocyclic heteroaryl of monocyclic heteroaryl-C₁-C₆-alkyl are optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, C₁-C₆-alkyl, C₁-C₆-haloalkyl, -OCH₂O-, -O-R^b, -CN, -N(R^b)C(O)R^b, -CON(R^a)(R^b), -C(O)R^b,
 -OC(O)R^b, -OS(O)₂N(R^a)(R^b), -CO₂H, -CO₂R^b, -N(R^b)C(O)N(R^b)₂, -S-R^b, -S(O)₂R^b, -S(O)R^b,
 -SO₂N(R^a)(R^b), -N(R^a)(R^b), -N(R^b)S(O)₂R^b, -N(R^b)C(O)O(R^b), -N(R^b)S(O)₂O(R^b), -L¹-O-R^b, -L¹-CN,
 30 -L¹-N(R^b)C(O)R^b, -L¹-CON(R^a)(R^b), -L¹-C(O)R^b, -L¹-OC(O)R^b, -L¹-CO₂H, -L¹-CO₂R^b,
 -L¹-N(R^b)C(O)N(R^b)₂, -L¹-S-R^b, -L¹-S(O)₂R^b, -L¹-S(O)R^b, -L¹-SO₂N(R^a)(R^b), -L¹-N(R^a)(R^b),
 -L¹-N(R^b)S(O)₂R^b, and -L¹-N(R^b)C(O)O(R^b); wherein L¹, L^{1a}, R^a, R^{a1}, R^b and R^{b1} are as described herein.

- In certain embodiments, R¹ is C₃-C₈-cycloalkyl, phenyl, bicyclic aryl, heterocyclyl, or
 35 monocyclic heteroaryl; wherein the C₃-C₈-cycloalkyl and heterocyclyl are optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkynyl, C₁-C₁₀-haloalkyl, C₂-C₁₀-haloalkenyl, C₂-C₁₀-haloalkynyl, halogen, oxo, cyano, hydroxy,

-O-C₁-C₆-alkyl, -O-C₁-C₆-haloalkyl, -C₁-C₃-alkylene-O-H, -C₁-C₃-alkylene-O-C₁-C₆-alkyl, -C₁-C₃-alkylene-O-C₁-C₆-haloalkyl, -C₁-C₃-alkylene-NH₂, -NH₂, -C(O)O-C₁-C₆-alkyl, -N(R^{bl})C(O)R^{bl},
 -CON(R^{al})(R^{bl}), -C(O)R^{bl}, -OC(O)R^{bl}, -OS(O)₂N(R^{al})(R^{bl}), -CO₂H, -CO₂R^{bl}, -N(R^{bl})C(O)N(R^{bl})₂,
 -S-R^{bl}, -S(O)₂R^{bl}, -S(O)R^{bl}, -SO₂N(R^{al})(R^{bl}), -N(R^{al})(R^{bl}), -N(R^{bl})S(O)₂R^{bl}, -N(R^{bl})C(O)O(R^{bl}),
 5 -N(R^{bl})S(O)₂O(R^{bl}), -L^{1a}-O-R^{bl}, -L^{1a}-CN, -L^{1a}-N(R^{bl})C(O)R^{bl}, -L^{1a}-CON(R^{al})(R^{bl}), -L^{1a}-C(O)R^{bl},
 -L^{1a}-OC(O)R^{bl}, -L^{1a}-CO₂H, -L^{1a}-CO₂R^{bl}, -L^{1a}-N(R^{bl})C(O)N(R^{bl})₂, -L^{1a}-S-R^{bl}, -L^{1a}-S(O)₂R^{bl},
 -L^{1a}-S(O)R^{bl}, -L^{1a}-SO₂N(R^{al})(R^{bl}), -L^{1a}-N(R^{al})(R^{bl}), -L^{1a}-N(R^{bl})S(O)₂R^{bl}, and
 -L^{1a}-N(R^{bl})C(O)O(R^{bl}); wherein the phenyl, the bicyclic aryl, and the monocyclic heteroaryl are
 optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen,
 10 C₁-C₆-alkyl, C₁-C₆-haloalkyl, -OCH₂O-, -O-R^b, -CN, -N(R^b)C(O)R^b, -CON(R^a)(R^b), -C(O)R^b,
 -OC(O)R^b, -OS(O)₂N(R^a)(R^b), -CO₂H, -CO₂R^b, -N(R^b)C(O)N(R^b)₂, -S-R^b, -S(O)₂R^b, -S(O)R^b,
 -SO₂N(R^a)(R^b), -N(R^a)(R^b), -N(R^b)S(O)₂R^b, -N(R^b)C(O)O(R^b), -N(R^b)S(O)₂O(R^b), -L¹-O-R^b, -L¹-CN,
 -L¹-N(R^b)C(O)R^b, -L¹-CON(R^a)(R^b), -L¹-C(O)R^b, -L¹-OC(O)R^b, -L¹-CO₂H, -L¹-CO₂R^b,
 -L¹-N(R^b)C(O)N(R^b)₂, -L¹-S-R^b, -L¹-S(O)₂R^b, -L¹-S(O)R^b, -L¹-SO₂N(R^a)(R^b), -L¹-N(R^a)(R^b),
 15 -L¹-N(R^b)S(O)₂R^b, and -L¹-N(R^b)C(O)O(R^b); wherein L¹, L^{1a}, R^a, R^{al}, R^b and R^{bl} are as described
 herein.

In certain embodiments, R¹ is C₃-C₈-cycloalkyl or heterocyclyl; wherein the C₃-C₈-cycloalkyl
 and heterocyclyl are optionally substituted with 1, 2, 3, or 4 substituents selected from the group
 consisting of C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkynyl, C₁-C₁₀-haloalkyl, C₂-C₁₀-haloalkenyl, C₂-
 20 C₁₀-haloalkynyl, halogen, oxo, cyano, hydroxy, -O-C₁-C₆-alkyl, -O-C₁-C₆-haloalkyl, -C₁-C₃-
 alkylene-O-H, -C₁-C₃-alkylene-O-C₁-C₆-alkyl, -C₁-C₃-alkylene-O-C₁-C₆-haloalkyl, -C₁-C₃-
 alkylene-NH₂, -NH₂, -C(O)O-C₁-C₆-alkyl, -N(R^{bl})C(O)R^{bl}, -CON(R^{al})(R^{bl}), -C(O)R^{bl}, -OC(O)R^{bl},
 -OS(O)₂N(R^{al})(R^{bl}), -CO₂H, -CO₂R^{bl}, -N(R^{bl})C(O)N(R^{bl})₂, -S-R^{bl}, -S(O)₂R^{bl}, -S(O)R^{bl},
 -SO₂N(R^{al})(R^{bl}), -N(R^{al})(R^{bl}), -N(R^{bl})S(O)₂R^{bl}, -N(R^{bl})C(O)O(R^{bl}), -N(R^{bl})S(O)₂O(R^{bl}), -L^{1a}-O-R^{bl},
 25 -L^{1a}-CN, -L^{1a}-N(R^{bl})C(O)R^{bl}, -L^{1a}-CON(R^{al})(R^{bl}), -L^{1a}-C(O)R^{bl}, -L^{1a}-OC(O)R^{bl}, -L^{1a}-CO₂H,
 -L^{1a}-CO₂R^{bl}, -L^{1a}-N(R^{bl})C(O)N(R^{bl})₂, -L^{1a}-S-R^{bl}, -L^{1a}-S(O)₂R^{bl}, -L^{1a}-S(O)R^{bl}, -L^{1a}-SO₂N(R^{al})(R^{bl}),
 -L^{1a}-N(R^{al})(R^{bl}), -L^{1a}-N(R^{bl})S(O)₂R^{bl}, and -L^{1a}-N(R^{bl})C(O)O(R^{bl}); wherein L^{1a}, R^{al} and R^{bl} are as
 described herein.

In certain embodiments, R¹ is C₃-C₈-cycloalkyl selected from the group consisting of
 30 cyclobutane, cyclopentane, cyclohexane, cycloheptane and norbornyl; wherein the C₃-C₈-cycloalkyl is
 optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of C₁-C₁₀-alkyl,
 C₂-C₁₀-alkenyl, C₂-C₁₀-alkynyl, C₁-C₁₀-haloalkyl, C₂-C₁₀-haloalkenyl, C₂-C₁₀-haloalkynyl, halogen,
 oxo, cyano, hydroxy, -O-C₁-C₆-alkyl, -O-C₁-C₆-haloalkyl, -C₁-C₃-alkylene-O-H, -C₁-C₃-
 alkylene-O-C₁-C₆-alkyl, -C₁-C₃-alkylene-O-C₁-C₆-haloalkyl, -C₁-C₃-alkylene-NH₂, -NH₂, -C(O)O-C₁-
 35 C₆-alkyl, -N(R^{bl})C(O)R^{bl}, -CON(R^{al})(R^{bl}), -C(O)R^{bl}, -OC(O)R^{bl}, -OS(O)₂N(R^{al})(R^{bl}), -CO₂H,
 -CO₂R^{bl}, -N(R^{bl})C(O)N(R^{bl})₂, -S-R^{bl}, -S(O)₂R^{bl}, -S(O)R^{bl}, -SO₂N(R^{al})(R^{bl}), -N(R^{al})(R^{bl}),
 -N(R^{bl})S(O)₂R^{bl}, -N(R^{bl})C(O)O(R^{bl}), -N(R^{bl})S(O)₂O(R^{bl}), -L^{1a}-O-R^{bl}, -L^{1a}-CN, -L^{1a}-N(R^{bl})C(O)R^{bl},

$-L^{1a}-CON(R^{al})(R^{bl})$, $-L^{1a}-C(O)R^{bl}$, $-L^{1a}-OC(O)R^{bl}$, $-L^{1a}-CO_2H$, $-L^{1a}-CO_2R^{bl}$, $-L^{1a}-N(R^{bl})C(O)N(R^{bl})_2$, $-L^{1a}-S-R^{bl}$, $-L^{1a}-S(O)_2R^{bl}$, $-L^{1a}-S(O)R^{bl}$, $-L^{1a}-SO_2N(R^{al})(R^{bl})$, $-L^{1a}-N(R^{al})(R^{bl})$, $-L^{1a}-N(R^{bl})S(O)_2R^{bl}$, and $-L^{1a}-N(R^{bl})C(O)O(R^{bl})$; wherein L^{1a} , R^{al} and R^{bl} are as described herein.

In certain embodiments, R^1 is C_3 - C_8 -cycloalkyl selected from the group consisting of cyclobutane, cyclopentane, cyclohexane, cycloheptane and norbornyl; wherein the C_3 - C_8 -cycloalkyl is optionally substituted with 1, 2, or 3, or 4 substituents selected from the group consisting of halogen, hydroxy, hydroxymethyl, methyl, and trifluoromethyl.

In certain embodiments, R^1 is heterocyclyl selected from the group consisting of tetrahydro-2H-pyran-4-yl, 3,4-dihydro-2H-chromen-4-yl, tetrahydrothiophen-3-yl and piperidin-4-yl; wherein the heterocyclyl is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of C_1 - C_{10} -alkyl, C_2 - C_{10} -alkenyl, C_2 - C_{10} -alkynyl, C_1 - C_{10} -haloalkyl, C_2 - C_{10} -haloalkenyl, C_2 - C_{10} -haloalkynyl, halogen, oxo, cyano, hydroxy, $-O$ - C_1 - C_6 -alkyl, $-O$ - C_1 - C_6 -haloalkyl, $-C_1$ - C_3 -alkylene- O -H, $-C_1$ - C_3 -alkylene- O - C_1 - C_6 -alkyl, $-C_1$ - C_3 -alkylene- O - C_1 - C_6 -haloalkyl, $-C_1$ - C_3 -alkylene- NH_2 , $-NH_2$, $-C(O)O$ - C_1 - C_6 -alkyl, $-N(R^{bl})C(O)R^{bl}$, $-CON(R^{al})(R^{bl})$, $-C(O)R^{bl}$, $-OC(O)R^{bl}$, $-OS(O)_2N(R^{al})(R^{bl})$, $-CO_2H$, $-CO_2R^{bl}$, $-N(R^{bl})C(O)N(R^{bl})_2$, $-S-R^{bl}$, $-S(O)_2R^{bl}$, $-S(O)R^{bl}$, $-SO_2N(R^{al})(R^{bl})$, $-N(R^{al})(R^{bl})$, $-N(R^{bl})S(O)_2R^{bl}$, $-N(R^{bl})C(O)O(R^{bl})$, $-N(R^{bl})S(O)_2O(R^{bl})$, $-L^{1a}-O-R^{bl}$, $-L^{1a}-CN$, $-L^{1a}-N(R^{bl})C(O)R^{bl}$, $-L^{1a}-CON(R^{al})(R^{bl})$, $-L^{1a}-C(O)R^{bl}$, $-L^{1a}-OC(O)R^{bl}$, $-L^{1a}-CO_2H$, $-L^{1a}-CO_2R^{bl}$, $-L^{1a}-N(R^{bl})C(O)N(R^{bl})_2$, $-L^{1a}-S-R^{bl}$, $-L^{1a}-S(O)_2R^{bl}$, $-L^{1a}-S(O)R^{bl}$, $-L^{1a}-SO_2N(R^{al})(R^{bl})$, $-L^{1a}-N(R^{al})(R^{bl})$, $-L^{1a}-N(R^{bl})S(O)_2R^{bl}$, and $-L^{1a}-N(R^{bl})C(O)O(R^{bl})$; wherein L^{1a} , R^{al} and R^{bl} are as described herein.

In certain embodiments, R^1 is heterocyclyl selected from the group consisting of tetrahydro-2H-pyran-4-yl, 3,4-dihydro-2H-chromen-4-yl, tetrahydrothiophen-3-yl and piperidin-4-yl; wherein the heterocyclyl is optionally substituted with 1, 2, or 3, or 4 substituents selected from the group consisting of oxo, methyl, and $-C(O)O$ - C_1 - C_6 -alkyl.

In certain embodiments, R^1 is phenyl, bicyclic aryl, or monocyclic heteroaryl; wherein the phenyl, the bicyclic aryl, and the monocyclic heteroaryl are optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, C_1 - C_6 -alkyl, C_1 - C_6 -haloalkyl, $-OCH_2O$ -, $-O-R^b$, $-CN$, $-N(R^b)C(O)R^b$, $-CON(R^a)(R^b)$, $-C(O)R^b$, $-OC(O)R^b$, $-OS(O)_2N(R^a)(R^b)$, $-CO_2H$, $-CO_2R^b$, $-N(R^b)C(O)N(R^b)_2$, $-S-R^b$, $-S(O)_2R^b$, $-S(O)R^b$, $-SO_2N(R^a)(R^b)$, $-N(R^a)(R^b)$, $-N(R^b)S(O)_2R^b$, $-N(R^b)C(O)O(R^b)$, $-N(R^b)S(O)_2O(R^b)$, $-L^1-O-R^b$, $-L^1-CN$, $-L^1-N(R^b)C(O)R^b$, $-L^1-CON(R^a)(R^b)$, $-L^1-C(O)R^b$, $-L^1-OC(O)R^b$, $-L^1-CO_2H$, $-L^1-CO_2R^b$, $-L^1-N(R^b)C(O)N(R^b)_2$, $-L^1-S-R^b$, $-L^1-S(O)_2R^b$, $-L^1-S(O)R^b$, $-L^1-SO_2N(R^a)(R^b)$, $-L^1-N(R^a)(R^b)$, $-L^1-N(R^b)S(O)_2R^b$, and $-L^1-N(R^b)C(O)O(R^b)$; wherein L^1 , R^a , and R^b are as described herein.

In certain embodiments, R^1 is phenyl; wherein the phenyl is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, C_1 - C_6 -alkyl, C_1 - C_6 -haloalkyl, $-OCH_2O$ -, $-O-R^b$, $-CN$, $-N(R^b)C(O)R^b$, $-CON(R^a)(R^b)$, $-C(O)R^b$, $-OC(O)R^b$, $-OS(O)_2N(R^a)(R^b)$, $-CO_2H$, $-CO_2R^b$, $-N(R^b)C(O)N(R^b)_2$, $-S-R^b$, $-S(O)_2R^b$, $-S(O)R^b$, $-SO_2N(R^a)(R^b)$, $-N(R^a)(R^b)$, $-N(R^b)S(O)_2R^b$,

$-N(R^b)C(O)O(R^b)$, $-N(R^b)S(O)_2O(R^b)$, $-L^1-O-R^b$, $-L^1-CN$, $-L^1-N(R^b)C(O)R^b$, $-L^1-CON(R^a)(R^b)$, $-L^1-C(O)R^b$, $-L^1-OC(O)R^b$, $-L^1-CO_2H$, $-L^1-CO_2R^b$, $-L^1-N(R^b)C(O)N(R^b)_2$, $-L^1-S-R^b$, $-L^1-S(O)_2R^b$, $-L^1-S(O)R^b$, $-L^1-SO_2N(R^a)(R^b)$, $-L^1-N(R^a)(R^b)$, $-L^1-N(R^b)S(O)_2R^b$, and $-L^1-N(R^b)C(O)O(R^b)$; wherein L^1 , R^a , and R^b are as described herein.

5 In certain embodiments, R^1 is phenyl; wherein the phenyl is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, C_1 - C_6 -alkyl, C_1 - C_6 -haloalkyl, $-OCH_2O-$, $-O-R^b$; wherein R^b is as described in the Summary.

In certain embodiments, R^1 is bicyclic aryl selected from the group consisting of 2,3-dihydro-1*H*-inden-1-yl, 1,2,3,4-tetrahydronaphthalen-1-yl, and 2,3-dihydro-1*H*-inden-2-yl; wherein the
10 bicyclic aryl is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, C_1 - C_6 -alkyl, C_1 - C_6 -haloalkyl, $-OCH_2O-$, $-O-R^b$, $-CN$, $-N(R^b)C(O)R^b$, $-CON(R^a)(R^b)$, $-C(O)R^b$, $-OC(O)R^b$, $-OS(O)_2N(R^a)(R^b)$, $-CO_2H$, $-CO_2R^b$, $-N(R^b)C(O)N(R^b)_2$, $-S-R^b$, $-S(O)_2R^b$, $-S(O)R^b$, $-SO_2N(R^a)(R^b)$, $-N(R^a)(R^b)$, $-N(R^b)S(O)_2R^b$, $-N(R^b)C(O)O(R^b)$, $-N(R^b)S(O)_2O(R^b)$, $-L^1-O-R^b$, $-L^1-CN$, $-L^1-N(R^b)C(O)R^b$, $-L^1-CON(R^a)(R^b)$, $-L^1-C(O)R^b$, $-L^1-OC(O)R^b$, $-L^1-CO_2H$,
15 $-L^1-CO_2R^b$, $-L^1-N(R^b)C(O)N(R^b)_2$, $-L^1-S-R^b$, $-L^1-S(O)_2R^b$, $-L^1-S(O)R^b$, $-L^1-SO_2N(R^a)(R^b)$, $-L^1-N(R^a)(R^b)$, $-L^1-N(R^b)S(O)_2R^b$, and $-L^1-N(R^b)C(O)O(R^b)$; wherein L^1 , R^a , and R^b are as described herein.

In certain embodiments, R^1 is bicyclic aryl selected from the group consisting of 2,3-dihydro-1*H*-inden-1-yl, 1,2,3,4-tetrahydronaphthalen-1-yl, and 2,3-dihydro-1*H*-inden-2-yl.

20 In certain embodiments, R^1 is monocyclic heteroaryl; wherein the monocyclic heteroaryl is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen, C_1 - C_6 -alkyl, C_1 - C_6 -haloalkyl, $-OCH_2O-$, $-O-R^b$, $-CN$, $-N(R^b)C(O)R^b$, $-CON(R^a)(R^b)$, $-C(O)R^b$, $-OC(O)R^b$, $-OS(O)_2N(R^a)(R^b)$, $-CO_2H$, $-CO_2R^b$, $-N(R^b)C(O)N(R^b)_2$, $-S-R^b$, $-S(O)_2R^b$, $-S(O)R^b$, $-SO_2N(R^a)(R^b)$, $-N(R^a)(R^b)$, $-N(R^b)S(O)_2R^b$, $-N(R^b)C(O)O(R^b)$, $-N(R^b)S(O)_2O(R^b)$, $-L^1-O-R^b$, $-L^1-CN$,
25 $-L^1-N(R^b)C(O)R^b$, $-L^1-CON(R^a)(R^b)$, $-L^1-C(O)R^b$, $-L^1-OC(O)R^b$, $-L^1-CO_2H$, $-L^1-CO_2R^b$, $-L^1-N(R^b)C(O)N(R^b)_2$, $-L^1-S-R^b$, $-L^1-S(O)_2R^b$, $-L^1-S(O)R^b$, $-L^1-SO_2N(R^a)(R^b)$, $-L^1-N(R^a)(R^b)$, $-L^1-N(R^b)S(O)_2R^b$, and $-L^1-N(R^b)C(O)O(R^b)$; wherein L^1 , R^a , and R^b are as described herein.

In certain embodiments, R^1 is monocyclic heteroaryl; wherein the monocyclic heteroaryl is selected from the group consisting of pyrazolyl, pyridinyl, thiazolyl, and isoxazolyl optionally
30 substituted with 1, 2, or 3 methyl.

In certain embodiments, R^1 is C_3 - C_8 -cycloalkyl- C_1 - C_6 -alkyl, phenyl- C_1 - C_6 -alkyl, heterocyclyl- C_1 - C_6 -alkyl, or monocyclic heteroaryl- C_1 - C_6 -alkyl; wherein the C_3 - C_8 -cycloalkyl of C_3 - C_8 -cycloalkyl- C_1 - C_6 -alkyl and heterocyclyl of heterocyclyl- C_1 - C_6 -alkyl are optionally substituted with
35 1, 2, 3, or 4 substituents selected from the group consisting of C_1 - C_{10} -alkyl, C_2 - C_{10} -alkenyl, C_2 - C_{10} -alkynyl, C_1 - C_{10} -haloalkyl, C_2 - C_{10} -haloalkenyl, C_2 - C_{10} -haloalkynyl, halogen, oxo, cyano, hydroxy, $-O-C_1$ - C_6 -alkyl, $-O-C_1$ - C_6 -haloalkyl, $-C_1$ - C_3 -alkylene-O-H, $-C_1$ - C_3 -alkylene-O- C_1 - C_6 -alkyl, $-C_1$ - C_3 -alkylene-O- C_1 - C_6 -haloalkyl, $-C_1$ - C_3 -alkylene-NH₂, -NH₂, $-C(O)O-C_1$ - C_6 -alkyl, $-N(R^b)C(O)R^{b1}$,

-CON(R^{al})(R^{bl}), -C(O)R^{bl}, -OC(O)R^{bl}, -OS(O)₂N(R^{al})(R^{bl}), -CO₂H, -CO₂R^{bl}, -N(R^{bl})C(O)N(R^{bl})₂,
 -S-R^{bl}, -S(O)₂R^{bl}, -S(O)R^{bl}, -SO₂N(R^{al})(R^{bl}), -N(R^{al})(R^{bl}), -N(R^{bl})S(O)₂R^{bl}, -N(R^{bl})C(O)O(R^{bl}),
 -N(R^{bl})S(O)₂O(R^{bl}), -L^{1a}-O-R^{bl}, -L^{1a}-CN, -L^{1a}-N(R^{bl})C(O)R^{bl}, -L^{1a}-CON(R^{al})(R^{bl}), -L^{1a}-C(O)R^{bl},
 -L^{1a}-OC(O)R^{bl}, -L^{1a}-CO₂H, -L^{1a}-CO₂R^{bl}, -L^{1a}-N(R^{bl})C(O)N(R^{bl})₂, -L^{1a}-S-R^{bl}, -L^{1a}-S(O)₂R^{bl},
 5 -L^{1a}-S(O)R^{bl}, -L^{1a}-SO₂N(R^{al})(R^{bl}), -L^{1a}-N(R^{al})(R^{bl}), -L^{1a}-N(R^{bl})S(O)₂R^{bl}, and
 -L^{1a}-N(R^{bl})C(O)O(R^{bl}); wherein the phenyl of phenyl-C₁-C₆-alkyl and monocyclic heteroaryl of
 monocyclic heteroaryl-C₁-C₆-alkyl are optionally substituted with 1, 2, 3, 4, or 5 substituents selected
 from the group consisting of halogen, C₁-C₆-alkyl, C₁-C₆-haloalkyl, -OCH₂O-, -O-R^b, -CN,
 -N(R^b)C(O)R^b, -CON(R^a)(R^b), -C(O)R^b, -OC(O)R^b, -OS(O)₂N(R^a)(R^b), -CO₂H, -CO₂R^b,
 10 -N(R^b)C(O)N(R^b)₂, -S-R^b, -S(O)₂R^b, -S(O)R^b, -SO₂N(R^a)(R^b), -N(R^a)(R^b), -N(R^b)S(O)₂R^b,
 -N(R^b)C(O)O(R^b), -N(R^b)S(O)₂O(R^b), -L¹-O-R^b, -L¹-CN, -L¹-N(R^b)C(O)R^b, -L¹-CON(R^a)(R^b),
 -L¹-C(O)R^b, -L¹-OC(O)R^b, -L¹-CO₂H, -L¹-CO₂R^b, -L¹-N(R^b)C(O)N(R^b)₂, -L¹-S-R^b, -L¹-S(O)₂R^b,
 -L¹-S(O)R^b, -L¹-SO₂N(R^a)(R^b), -L¹-N(R^a)(R^b), -L¹-N(R^b)S(O)₂R^b, and -L¹-N(R^b)C(O)O(R^b); wherein
 L¹, L^{1a}, R^a, R^{al}, R^b and R^{bl} are as described herein.

15 In certain embodiments, R¹ is C₃-C₈-cycloalkyl-C₁-C₆-alkyl or heterocyclyl-C₁-C₆-alkyl;
 wherein the C₃-C₈-cycloalkyl of C₃-C₈-cycloalkyl-C₁-C₆-alkyl and heterocyclyl of heterocyclyl-C₁-C₆-
 alkyl are optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of C₁-
 C₁₀-alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkynyl, C₁-C₁₀-haloalkyl, C₂-C₁₀-haloalkenyl, C₂-C₁₀-haloalkynyl,
 halogen, oxo, cyano, hydroxy, -O-C₁-C₆-alkyl, -O-C₁-C₆-haloalkyl, -C₁-C₃-alkylene-O-H, -C₁-C₃-
 20 alkylene-O-C₁-C₆-alkyl, -C₁-C₃-alkylene-O-C₁-C₆-haloalkyl, -C₁-C₃-alkylene-NH₂, -NH₂, -C(O)O-C₁-
 C₆-alkyl, -N(R^{bl})C(O)R^{bl}, -CON(R^{al})(R^{bl}), -C(O)R^{bl}, -OC(O)R^{bl}, -OS(O)₂N(R^{al})(R^{bl}), -CO₂H,
 -CO₂R^{bl}, -N(R^{bl})C(O)N(R^{bl})₂, -S-R^{bl}, -S(O)₂R^{bl}, -S(O)R^{bl}, -SO₂N(R^{al})(R^{bl}), -N(R^{al})(R^{bl}),
 -N(R^{bl})S(O)₂R^{bl}, -N(R^{bl})C(O)O(R^{bl}), -N(R^{bl})S(O)₂O(R^{bl}), -L^{1a}-O-R^{bl}, -L^{1a}-CN, -L^{1a}-N(R^{bl})C(O)R^{bl},
 -L^{1a}-CON(R^{al})(R^{bl}), -L^{1a}-C(O)R^{bl}, -L^{1a}-OC(O)R^{bl}, -L^{1a}-CO₂H, -L^{1a}-CO₂R^{bl}, -L^{1a}-N(R^{bl})C(O)N(R^{bl})₂,
 25 -L^{1a}-S-R^{bl}, -L^{1a}-S(O)₂R^{bl}, -L^{1a}-S(O)R^{bl}, -L^{1a}-SO₂N(R^{al})(R^{bl}), -L^{1a}-N(R^{al})(R^{bl}), -L^{1a}-N(R^{bl})S(O)₂R^{bl},
 and -L^{1a}-N(R^{bl})C(O)O(R^{bl}); wherein L^{1a}, R^{al}, and R^{bl} are as described herein.

In certain embodiments, R¹ is C₃-C₈-cycloalkyl-C₁-C₆-alkyl or heterocyclyl-C₁-C₆-alkyl;
 wherein the C₃-C₈-cycloalkyl-C₁-C₆-alkyl and heterocyclyl-C₁-C₆-alkyl are selected from the group
 consisting of cyclopentylmethyl, cyclohexylmethyl and tetrahydrofuranlylmethyl.

30 In certain embodiments, R¹ is phenyl-C₁-C₆-alkyl or monocyclic heteroaryl-C₁-C₆-alkyl;
 wherein the phenyl of phenyl-C₁-C₆-alkyl and monocyclic heteroaryl of monocyclic heteroaryl-C₁-C₆-
 alkyl are optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of
 halogen, C₁-C₆-alkyl, C₁-C₆-haloalkyl, -OCH₂O-, -O-R^b, -CN, -N(R^b)C(O)R^b, -CON(R^a)(R^b),
 -C(O)R^b, -OC(O)R^b, -OS(O)₂N(R^a)(R^b), -CO₂H, -CO₂R^b, -N(R^b)C(O)N(R^b)₂, -S-R^b, -S(O)₂R^b,
 35 -S(O)R^b, -SO₂N(R^a)(R^b), -N(R^a)(R^b), -N(R^b)S(O)₂R^b, -N(R^b)C(O)O(R^b), -N(R^b)S(O)₂O(R^b), -L¹-O-R^b,
 -L¹-CN, -L¹-N(R^b)C(O)R^b, -L¹-CON(R^a)(R^b), -L¹-C(O)R^b, -L¹-OC(O)R^b, -L¹-CO₂H, -L¹-CO₂R^b,

$-L^1-N(R^b)C(O)N(R^b)_2$, $-L^1-S-R^b$, $-L^1-S(O)_2R^b$, $-L^1-S(O)R^b$, $-L^1-SO_2N(R^a)(R^b)$, $-L^1-N(R^a)(R^b)$, $-L^1-N(R^b)S(O)_2R^b$, and $-L^1-N(R^b)C(O)O(R^b)$; wherein L^1 , R^a , and R^b are as described herein.

In certain embodiments, R^1 is phenyl- C_1 - C_6 -alkyl; wherein the phenyl- C_1 - C_6 -alkyl is benzyl; wherein the phenyl of phenyl- C_1 - C_6 -alkyl is optionally substituted with halogen or C_1 - C_6 -alkyl.

5 In certain embodiments, R^2 is methyl or ethyl.

In certain embodiments, R^2 is methyl.

In certain embodiments, R^2 is ethyl.

In certain embodiments, R^3 is methyl or ethyl.

In certain embodiments, R^3 is methyl.

10 In certain embodiments, R^3 is ethyl.

In certain embodiments, R^2 is methyl and R^3 is methyl.

In certain embodiments, R^2 is methyl and R^3 is ethyl.

In certain embodiments, R^2 is ethyl and R^3 is methyl.

In certain embodiments, R^2 is ethyl and R^3 is ethyl.

15 In certain embodiments, R^4 and R^5 are independently selected from hydrogen, C_1 - C_6 -alkyl, or C_1 - C_6 -haloalkyl.

In certain embodiments, R^4 and R^5 are each hydrogen.

In certain embodiments, R^4 and R^5 are independently selected from C_1 - C_6 -alkyl or C_1 - C_6 -haloalkyl.

20 In certain embodiments, R^4 is hydrogen and R^5 is selected from C_1 - C_6 -alkyl or C_1 - C_6 -haloalkyl.

In certain embodiments, R^6 is selected from the group consisting of hydrogen, C_1 - C_6 -alkyl, and C_1 - C_6 -haloalkyl.

In certain embodiments, R^6 is hydrogen.

25 In certain embodiments, R^6 is C_1 - C_6 -alkyl.

In certain embodiments, R^6 is C_1 - C_6 -haloalkyl.

In certain embodiments, G^1 is phenyl or monocyclic heteroaryl, wherein the phenyl or monocyclic heteroaryl are optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, C_1 - C_6 -alkyl, C_1 - C_6 -haloalkyl, $-O-R^f$, $-CN$, $-N(R^f)C(O)R^f$, $-CON(R^e)(R^f)$, $-C(O)R^f$, $-OC(O)R^f$, $-CO_2H$, $-CO_2R^f$, $-N(R^f)C(O)N(R^f)_2$, $-S-R^f$, $-S(O)_2R^f$, $-S(O)R^f$, $-SO_2N(R^e)(R^f)$, $-N(R^e)(R^f)$, $-N(R^f)S(O)_2R^f$, $-N(R^f)C(O)O(R^f)$, $-L^3-O-R^f$, $-L^3-CN$, $-L^3-N(R^f)C(O)R^f$, $-L^3-CON(R^e)(R^f)$, $-L^3-C(O)R^f$, $-L^3-OC(O)R^f$, $-L^3-CO_2H$, $-L^3-CO_2R^f$, $-L^3-N(R^f)C(O)N(R^f)_2$, $-L^3-S-R^f$, $-L^3-S(O)_2R^f$, $-L^3-S(O)R^f$, $-L^3-SO_2N(R^e)(R^f)$, $-L^3-N(R^e)(R^f)$, $-L^3-N(R^f)S(O)_2R^f$, and $-L^3-N(R^f)C(O)O(R^f)$; wherein L^3 , R^e and R^f are as described herein.

35 In certain embodiments, G^1 is phenyl, wherein the phenyl is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, C_1 - C_6 -alkyl, C_1 - C_6 -haloalkyl, $-O-R^f$, $-CN$, $-N(R^f)C(O)R^f$, $-CON(R^e)(R^f)$, $-C(O)R^f$, $-OC(O)R^f$, $-CO_2H$, $-CO_2R^f$, $-N(R^f)C(O)N(R^f)_2$,

-S-R^f, -S(O)₂R^f, -S(O)R^f, -SO₂N(R^e)(R^f), -N(R^e)(R^f), -N(R^f)S(O)₂R^f, -N(R^f)C(O)O(R^f), -L³-O-R^f, -L³-CN, -L³-N(R^f)C(O)R^f, -L³-CON(R^e)(R^f), -L³-C(O)R^f, -L³-OC(O)R^f, -L³-CO₂H, -L³-CO₂R^f, -L³-N(R^f)C(O)N(R^f)₂, -L³-S-R^f, -L³-S(O)₂R^f, -L³-S(O)R^f, -L³-SO₂N(R^e)(R^f), -L³-N(R^e)(R^f), -L³-N(R^f)S(O)₂R^f, and -L³-N(R^f)C(O)O(R^f); wherein L³, R^e and R^f are as described herein.

5 In certain embodiments, G¹ is phenyl, wherein the phenyl is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, C₁-C₆-alkyl, C₁-C₆-haloalkyl or -O-R^f; wherein R^f is as described in the Summary.

In certain embodiments, G¹ is monocyclic heteroaryl, wherein the monocyclic heteroaryl is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, C₁-C₆-alkyl, C₁-C₆-haloalkyl, -O-R^f, -CN, -N(R^f)C(O)R^f, -CON(R^e)(R^f), -C(O)R^f, -OC(O)R^f, -CO₂H, -CO₂R^f, -N(R^f)C(O)N(R^f)₂, -S-R^f, -S(O)₂R^f, -S(O)R^f, -SO₂N(R^e)(R^f), -N(R^e)(R^f), -N(R^f)S(O)₂R^f, -N(R^f)C(O)O(R^f), -L³-O-R^f, -L³-CN, -L³-N(R^f)C(O)R^f, -L³-CON(R^e)(R^f), -L³-C(O)R^f, -L³-OC(O)R^f, -L³-CO₂H, -L³-CO₂R^f, -L³-N(R^f)C(O)N(R^f)₂, -L³-S-R^f, -L³-S(O)₂R^f, -L³-S(O)R^f, -L³-SO₂N(R^e)(R^f), -L³-N(R^e)(R^f), -L³-N(R^f)S(O)₂R^f, and -L³-N(R^f)C(O)O(R^f); wherein L³, R^e and R^f are as described
15 herein.

In certain embodiments, G¹ is monocyclic heteroaryl; wherein the monocyclic heteroaryl is selected from the group consisting of pyridyl, pyrazolyl, imidazolyl, isoxazolyl, and thienyl; wherein the monocyclic heteroaryl is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen, C₁-C₆-alkyl, C₁-C₆-haloalkyl or -O-R^f; wherein R^f is as described in the
20 Summary.

In certain embodiments, X is selected from O, S, NR^g, or C(R^hRⁱ).

In certain embodiments, X is O or S.

In certain embodiments, X is NR^g; wherein R^g is hydrogen or C₁-C₆-alkyl.

In certain embodiments, X is NR^g; wherein R^g is hydrogen.

25 In certain embodiments, X is NR^g; wherein R^g is C₁-C₆-alkyl.

In certain embodiments, X is C(R^hRⁱ); wherein R^h and Rⁱ are independently hydrogen, C₁-C₆-alkyl, or C₁-C₆-haloalkyl.

In certain embodiments, X is C(R^hRⁱ); wherein R^h and Rⁱ are each hydrogen.

In certain embodiments, X is C(R^hRⁱ); wherein R^h is hydrogen and Rⁱ is C₁-C₆-alkyl, or C₁-C₆-
30 haloalkyl.

In certain embodiments, X is C(R^hRⁱ); wherein R^h and Rⁱ are independently C₁-C₆-alkyl or C₁-C₆-haloalkyl.

In one aspect of the disclosure are compounds of formula (I) wherein:

35 R¹ is C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₃-C₈-cycloalkyl, C₃-C₈-cycloalkyl-C₁-C₆-alkyl, phenyl, bicyclic aryl, phenyl-C₁-C₆-alkyl, heterocyclyl, heterocyclyl-C₁-C₆-alkyl, monocyclic heteroaryl, or monocyclic heteroaryl-C₁-C₆-alkyl; wherein the C₃-C₈-cycloalkyl, the C₃-C₈-cycloalkyl of C₃-C₈-

- cycloalkyl-C₁-C₆-alkyl, heterocyclyl, and heterocyclyl of heterocyclyl-C₁-C₆-alkyl are optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkynyl, C₁-C₁₀-haloalkyl, C₂-C₁₀-haloalkenyl, C₂-C₁₀-haloalkynyl, halogen, oxo, cyano, hydroxy, -O-C₁-C₆-alkyl, -O-C₁-C₆-haloalkyl, -C₁-C₃-alkylene-O-H, -C₁-C₃-alkylene-O-C₁-C₆-alkyl, -C₁-C₃-alkylene-O-C₁-C₆-haloalkyl, -C₁-C₃-alkylene-NH₂, -NH₂, -C(O)O-C₁-C₆-alkyl, -N(R^{bl})C(O)R^{bl}, -CON(R^{al})(R^{bl}), -C(O)R^{bl}, -OC(O)R^{bl}, -OS(O)₂N(R^{al})(R^{bl}), -CO₂H, -CO₂R^{bl}, -N(R^{bl})C(O)N(R^{bl})₂, -S-R^{bl}, -S(O)₂R^{bl}, -S(O)R^{bl}, -SO₂N(R^{al})(R^{bl}), -N(R^{al})(R^{bl}), -N(R^{bl})S(O)₂R^{bl}, -N(R^{bl})C(O)O(R^{bl}), -N(R^{bl})S(O)₂O(R^{bl}), -L^{1a}-O-R^{bl}, -L^{1a}-CN, -L^{1a}-N(R^{bl})C(O)R^{bl}, -L^{1a}-CON(R^{al})(R^{bl}), -L^{1a}-C(O)R^{bl}, -L^{1a}-OC(O)R^{bl}, -L^{1a}-CO₂H, -L^{1a}-CO₂R^{bl}, -L^{1a}-N(R^{bl})C(O)N(R^{bl})₂, -L^{1a}-S-R^{bl}, -L^{1a}-S(O)₂R^{bl}, -L^{1a}-S(O)R^{bl}, -L^{1a}-SO₂N(R^{al})(R^{bl}), -L^{1a}-N(R^{al})(R^{bl}), -L^{1a}-N(R^{bl})S(O)₂R^{bl}, and -L^{1a}-N(R^{bl})C(O)O(R^{bl}); wherein the phenyl, the bicyclic aryl, the phenyl of phenyl-C₁-C₆-alkyl, the monocyclic heteroaryl and monocyclic heteroaryl of monocyclic heteroaryl-C₁-C₆-alkyl are optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, C₁-C₆-alkyl, C₁-C₆-haloalkyl, -OCH₂O-, -O-R^b, -CN, -N(R^b)C(O)R^b, -CON(R^a)(R^b), -C(O)R^b, -OC(O)R^b, -OS(O)₂N(R^a)(R^b), -CO₂H, -CO₂R^b, -N(R^b)C(O)N(R^b)₂, -S-R^b, -S(O)₂R^b, -S(O)R^b, -SO₂N(R^a)(R^b), -N(R^a)(R^b), -N(R^b)S(O)₂R^b, -N(R^b)C(O)O(R^b), -N(R^b)S(O)₂O(R^b), -L¹-O-R^b, -L¹-CN, -L¹-N(R^b)C(O)R^b, -L¹-CON(R^a)(R^b), -L¹-C(O)R^b, -L¹-OC(O)R^b, -L¹-CO₂H, -L¹-CO₂R^b, -L¹-N(R^b)C(O)N(R^b)₂, -L¹-S-R^b, -L¹-S(O)₂R^b, -L¹-S(O)R^b, -L¹-SO₂N(R^a)(R^b), -L¹-N(R^a)(R^b), -L¹-N(R^b)S(O)₂R^b, and -L¹-N(R^b)C(O)O(R^b);
- 20 R² is methyl or ethyl;
R³ is methyl or ethyl;
R⁴ and R⁵ are independently selected from the group consisting of hydrogen, C₁-C₆-alkyl, and C₁-C₆-haloalkyl;
R⁶ is selected from the group consisting of hydrogen, C₁-C₆-alkyl, and C₁-C₆-haloalkyl;
- 25 G¹ is phenyl or monocyclic heteroaryl, wherein the phenyl or monocyclic heteroaryl are optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, C₁-C₆-alkyl, C₁-C₆-haloalkyl, -O-R^f, -CN, -N(R^f)C(O)R^f, -CON(R^e)(R^f), -C(O)R^f, -OC(O)R^f, -CO₂H, -CO₂R^f, -N(R^f)C(O)N(R^f)₂, -S-R^f, -S(O)₂R^f, -S(O)R^f, -SO₂N(R^e)(R^f), -N(R^e)(R^f), -N(R^f)S(O)₂R^f, -N(R^f)C(O)O(R^f), -L³-O-R^f, -L³-CN, -L³-N(R^f)C(O)R^f, -L³-CON(R^e)(R^f), -L³-C(O)R^f, -L³-OC(O)R^f, -L³-CO₂H, -L³-CO₂R^f, -L³-N(R^f)C(O)N(R^f)₂, -L³-S-R^f, -L³-S(O)₂R^f, -L³-S(O)R^f, -L³-SO₂N(R^e)(R^f), -L³-N(R^e)(R^f), -L³-N(R^f)S(O)₂R^f, and -L³-N(R^f)C(O)O(R^f); and
- 30 X is selected from O or S; wherein
L¹, L^{1a}, L³, R^a, R^{al}, R^b, R^{bl}, R^c, and R^f are as described herein.

35 In one aspect of the disclosure are compounds of formula (I) wherein:

R¹ is C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₃-C₈-cycloalkyl, C₃-C₈-cycloalkyl-C₁-C₆-alkyl, phenyl, bicyclic aryl, phenyl-C₁-C₆-alkyl, heterocyclyl, heterocyclyl-C₁-C₆-alkyl, monocyclic heteroaryl, or

monocyclic heteroaryl-C₁-C₆-alkyl; wherein the C₃-C₈-cycloalkyl, the C₃-C₈-cycloalkyl of C₃-C₈-cycloalkyl-C₁-C₆-alkyl, heterocyclyl, and heterocyclyl of heterocyclyl-C₁-C₆-alkyl are optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkynyl, C₁-C₁₀-haloalkyl, C₂-C₁₀-haloalkenyl, C₂-C₁₀-haloalkynyl, halogen, oxo, cyano, hydroxy, -O-C₁-C₆-alkyl, -O-C₁-C₆-haloalkyl, -C₁-C₃-alkylene-O-H, -C₁-C₃-alkylene-O-C₁-C₆-alkyl, -C₁-C₃-alkylene-O-C₁-C₆-haloalkyl, -C₁-C₃-alkylene-NH₂, -NH₂, -C(O)O-C₁-C₆-alkyl, -N(R^{bl})C(O)R^{bl}, -CON(R^{al})(R^{bl}), -C(O)R^{bl}, -OC(O)R^{bl}, -OS(O)₂N(R^{al})(R^{bl}), -CO₂H, -CO₂R^{bl}, -N(R^{bl})C(O)N(R^{bl})₂, -S-R^{bl}, -S(O)₂R^{bl}, -S(O)R^{bl}, -SO₂N(R^{al})(R^{bl}), -N(R^{al})(R^{bl}), -N(R^{bl})S(O)₂R^{bl}, -N(R^{bl})C(O)O(R^{bl}), -N(R^{bl})S(O)₂O(R^{bl}), -L^{1a}-O-R^{bl}, -L^{1a}-CN, -L^{1a}-N(R^{bl})C(O)R^{bl}, -L^{1a}-CON(R^{al})(R^{bl}), -L^{1a}-C(O)R^{bl}, -L^{1a}-OC(O)R^{bl}, -L^{1a}-CO₂H, -L^{1a}-CO₂R^{bl}, -L^{1a}-N(R^{bl})C(O)N(R^{bl})₂, -L^{1a}-S-R^{bl}, -L^{1a}-S(O)₂R^{bl}, -L^{1a}-S(O)R^{bl}, -L^{1a}-SO₂N(R^{al})(R^{bl}), -L^{1a}-N(R^{al})(R^{bl}), -L^{1a}-N(R^{bl})S(O)₂R^{bl}, and -L^{1a}-N(R^{bl})C(O)O(R^{bl}); wherein the phenyl, the bicyclic aryl, the phenyl of phenyl-C₁-C₆-alkyl, the monocyclic heteroaryl and monocyclic heteroaryl of monocyclic heteroaryl-C₁-C₆-alkyl are optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, C₁-C₆-alkyl, C₁-C₆-haloalkyl, -OCH₂O-, -O-R^b, -CN, -N(R^b)C(O)R^b, -CON(R^a)(R^b), -C(O)R^b, -OC(O)R^b, -OS(O)₂N(R^a)(R^b), -CO₂H, -CO₂R^b, -N(R^b)C(O)N(R^b)₂, -S-R^b, -S(O)₂R^b, -S(O)R^b, -SO₂N(R^a)(R^b), -N(R^a)(R^b), -N(R^b)S(O)₂R^b, -N(R^b)C(O)O(R^b), -N(R^b)S(O)₂O(R^b), -L¹-O-R^b, -L¹-CN, -L¹-N(R^b)C(O)R^b, -L¹-CON(R^a)(R^b), -L¹-C(O)R^b, -L¹-OC(O)R^b, -L¹-CO₂H, -L¹-CO₂R^b, -L¹-N(R^b)C(O)N(R^b)₂, -L¹-S-R^b, -L¹-S(O)₂R^b, -L¹-S(O)R^b, -L¹-SO₂N(R^a)(R^b), -L¹-N(R^a)(R^b), -L¹-N(R^b)S(O)₂R^b, and -L¹-N(R^b)C(O)O(R^b);

R² is methyl or ethyl;

R³ is methyl or ethyl;

R⁴ and R⁵ are independently selected from the group consisting of hydrogen, C₁-C₆-alkyl, and C₁-C₆-haloalkyl;

R⁶ is selected from the group consisting of hydrogen, C₁-C₆-alkyl, and C₁-C₆-haloalkyl;

G¹ is phenyl or monocyclic heteroaryl, wherein the phenyl or monocyclic heteroaryl are optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, C₁-C₆-alkyl, C₁-C₆-haloalkyl, -O-R^f, -CN, -N(R^f)C(O)R^f, -CON(R^e)(R^f), -C(O)R^f, -OC(O)R^f, -CO₂H, -CO₂R^f, -N(R^f)C(O)N(R^f)₂, -S-R^f, -S(O)₂R^f, -S(O)R^f, -SO₂N(R^e)(R^f), -N(R^e)(R^f), -N(R^f)S(O)₂R^f, -N(R^f)C(O)O(R^f), -L³-O-R^f, -L³-CN, -L³-N(R^f)C(O)R^f, -L³-CON(R^e)(R^f), -L³-C(O)R^f, -L³-OC(O)R^f, -L³-CO₂H, -L³-CO₂R^f, -L³-N(R^f)C(O)N(R^f)₂, -L³-S-R^f, -L³-S(O)₂R^f, -L³-S(O)R^f, -L³-SO₂N(R^e)(R^f), -L³-N(R^e)(R^f), -L³-N(R^f)S(O)₂R^f, and -L³-N(R^f)C(O)O(R^f); and

X is C(R^hRⁱ); wherein

L¹, L^{1a}, L³, R^a, R^{al}, R^b, R^{bl}, R^e, R^f, R^h and Rⁱ are as described herein.

35

In one aspect of the disclosure are compounds of formula (I) wherein:

R¹ is C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₃-C₈-cycloalkyl, C₃-C₈-cycloalkyl-C₁-C₆-alkyl, phenyl,

- bicyclic aryl, phenyl-C₁-C₆-alkyl, heterocyclyl, heterocyclyl-C₁-C₆-alkyl, monocyclic heteroaryl, or monocyclic heteroaryl-C₁-C₆-alkyl; wherein the C₃-C₈-cycloalkyl, the C₃-C₈-cycloalkyl of C₃-C₈-cycloalkyl-C₁-C₆-alkyl, heterocyclyl, and heterocyclyl of heterocyclyl-C₁-C₆-alkyl are optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkynyl, C₁-C₁₀-haloalkyl, C₂-C₁₀-haloalkenyl, C₂-C₁₀-haloalkynyl, halogen, oxo, cyano, hydroxy, -O-C₁-C₆-alkyl, -O-C₁-C₆-haloalkyl, -C₁-C₃-alkylene-O-H, -C₁-C₃-alkylene-O-C₁-C₆-alkyl, -C₁-C₃-alkylene-O-C₁-C₆-haloalkyl, -C₁-C₃-alkylene-NH₂, -NH₂, -C(O)O-C₁-C₆-alkyl, -N(R^{b1})C(O)R^{b1}, -CON(R^{a1})(R^{b1}), -C(O)R^{b1}, -OC(O)R^{b1}, -OS(O)₂N(R^{a1})(R^{b1}), -CO₂H, -CO₂R^{b1}, -N(R^{b1})C(O)N(R^{b1})₂, -S-R^{b1}, -S(O)₂R^{b1}, -S(O)R^{b1}, -SO₂N(R^{a1})(R^{b1}), -N(R^{a1})(R^{b1}), -N(R^{b1})S(O)₂R^{b1}, -N(R^{b1})C(O)O(R^{b1}), -N(R^{b1})S(O)₂O(R^{b1}), -L^{1a}-O-R^{b1}, -L^{1a}-CN, -L^{1a}-N(R^{b1})C(O)R^{b1}, -L^{1a}-CON(R^{a1})(R^{b1}), -L^{1a}-C(O)R^{b1}, -L^{1a}-OC(O)R^{b1}, -L^{1a}-CO₂H, -L^{1a}-CO₂R^{b1}, -L^{1a}-N(R^{b1})C(O)N(R^{b1})₂, -L^{1a}-S-R^{b1}, -L^{1a}-S(O)₂R^{b1}, -L^{1a}-S(O)R^{b1}, -L^{1a}-SO₂N(R^{a1})(R^{b1}), -L^{1a}-N(R^{a1})(R^{b1}), -L^{1a}-N(R^{b1})S(O)₂R^{b1}, and -L^{1a}-N(R^{b1})C(O)O(R^{b1}); wherein the phenyl, the bicyclic aryl, the phenyl of phenyl-C₁-C₆-alkyl, the monocyclic heteroaryl and monocyclic heteroaryl of monocyclic heteroaryl-C₁-C₆-alkyl are optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, C₁-C₆-alkyl, C₁-C₆-haloalkyl, -OCH₂O-, -O-R^b, -CN, -N(R^b)C(O)R^b, -CON(R^a)(R^b), -C(O)R^b, -OC(O)R^b, -OS(O)₂N(R^a)(R^b), -CO₂H, -CO₂R^b, -N(R^b)C(O)N(R^b)₂, -S-R^b, -S(O)₂R^b, -S(O)R^b, -SO₂N(R^a)(R^b), -N(R^a)(R^b), -N(R^b)S(O)₂R^b, -N(R^b)C(O)O(R^b), -N(R^b)S(O)₂O(R^b), -L¹-O-R^b, -L¹-CN, -L¹-N(R^b)C(O)R^b, -L¹-CON(R^a)(R^b), -L¹-C(O)R^b, -L¹-OC(O)R^b, -L¹-CO₂H, -L¹-CO₂R^b, -L¹-N(R^b)C(O)N(R^b)₂, -L¹-S-R^b, -L¹-S(O)₂R^b, -L¹-S(O)R^b, -L¹-SO₂N(R^a)(R^b), -L¹-N(R^a)(R^b), -L¹-N(R^b)S(O)₂R^b, and -L¹-N(R^b)C(O)O(R^b);
- R² is methyl or ethyl;
R³ is methyl or ethyl;
R⁴ and R⁵ are independently selected from the group consisting of hydrogen, C₁-C₆-alkyl, and C₁-C₆-haloalkyl;
- R⁶ is selected from the group consisting of hydrogen, C₁-C₆-alkyl, and C₁-C₆-haloalkyl;
G¹ is phenyl or monocyclic heteroaryl, wherein the phenyl or monocyclic heteroaryl are optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, C₁-C₆-alkyl, C₁-C₆-haloalkyl, -O-R^f, -CN, -N(R^f)C(O)R^f, -CON(R^e)(R^f), -C(O)R^f, -OC(O)R^f, -CO₂H, -CO₂R^f, -N(R^f)C(O)N(R^f)₂, -S-R^f, -S(O)₂R^f, -S(O)R^f, -SO₂N(R^e)(R^f), -N(R^e)(R^f), -N(R^f)S(O)₂R^f, -N(R^f)C(O)O(R^f), -L³-O-R^f, -L³-CN, -L³-N(R^f)C(O)R^f, -L³-CON(R^e)(R^f), -L³-C(O)R^f, -L³-OC(O)R^f, -L³-CO₂H, -L³-CO₂R^f, -L³-N(R^f)C(O)N(R^f)₂, -L³-S-R^f, -L³-S(O)₂R^f, -L³-S(O)R^f, -L³-SO₂N(R^e)(R^f), -L³-N(R^e)(R^f), -L³-N(R^f)S(O)₂R^f, and -L³-N(R^f)C(O)O(R^f); and
- X is NR^g; wherein
- L¹, L^{1a}, L³, R^a, R^{a1}, R^b, R^{b1}, R^c, R^f and R^g are as described herein.

In one particular subgroup, the present disclosure features compounds of formula (I), wherein

R^1 is C_1 - C_6 -alkyl, C_1 - C_6 -haloalkyl, C_3 - C_8 -cycloalkyl, or heterocyclyl; wherein the C_3 - C_8 -cycloalkyl and heterocyclyl are optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of C_1 - C_{10} -alkyl, C_2 - C_{10} -alkenyl, C_2 - C_{10} -alkynyl, C_1 - C_{10} -haloalkyl, C_2 - C_{10} -haloalkenyl, C_2 - C_{10} -haloalkynyl, halogen, oxo, cyano, hydroxy, -O- C_1 - C_6 -alkyl, -O- C_1 - C_6 -haloalkyl, - C_1 - C_3 -alkylene-O-H, - C_1 - C_3 -alkylene-O- C_1 - C_6 -alkyl, - C_1 - C_3 -alkylene-O- C_1 - C_6 -haloalkyl, - C_1 - C_3 -alkylene-NH₂, -NH₂, -C(O)O- C_1 - C_6 -alkyl, -N(R^{b1})C(O) R^{b1} , -CON(R^{a1})(R^{b1}), -C(O) R^{b1} , -OC(O) R^{b1} , -OS(O)₂N(R^{a1})(R^{b1}), -CO₂H, -CO₂ R^{b1} , -N(R^{b1})C(O)N(R^{b1})₂, -S- R^{b1} , -S(O)₂ R^{b1} , -S(O) R^{b1} , -SO₂N(R^{a1})(R^{b1}), -N(R^{a1})(R^{b1}), -N(R^{b1})S(O)₂ R^{b1} , -N(R^{b1})C(O)O(R^{b1}), -N(R^{b1})S(O)₂O(R^{b1}), -L^{1a}-O- R^{b1} , -L^{1a}-CN, -L^{1a}-N(R^{b1})C(O) R^{b1} , -L^{1a}-CON(R^{a1})(R^{b1}), -L^{1a}-C(O) R^{b1} , -L^{1a}-OC(O) R^{b1} , -L^{1a}-CO₂H, -L^{1a}-CO₂ R^{b1} , -L^{1a}-N(R^{b1})C(O)N(R^{b1})₂, -L^{1a}-S- R^{b1} , -L^{1a}-S(O)₂ R^{b1} , -L^{1a}-S(O) R^{b1} , -L^{1a}-SO₂N(R^{a1})(R^{b1}), -L^{1a}-N(R^{a1})(R^{b1}), -L^{1a}-N(R^{b1})S(O)₂ R^{b1} , and -L^{1a}-N(R^{b1})C(O)O(R^{b1});

R^2 is methyl or ethyl;

R^3 is methyl or ethyl;

R^4 and R^5 are independently selected from the group consisting of hydrogen, C_1 - C_6 -alkyl, and C_1 - C_6 -haloalkyl;

R^6 is selected from the group consisting of hydrogen, C_1 - C_6 -alkyl, and C_1 - C_6 -haloalkyl;

G^1 is phenyl or monocyclic heteroaryl, wherein the phenyl or monocyclic heteroaryl are optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, C_1 - C_6 -alkyl, C_1 - C_6 -haloalkyl, -O- R^f , -CN, -N(R^f)C(O) R^f , -CON(R^e)(R^f), -C(O) R^f , -OC(O) R^f , -CO₂H, -CO₂ R^f , -N(R^f)C(O)N(R^f)₂, -S- R^f , -S(O)₂ R^f , -S(O) R^f , -SO₂N(R^e)(R^f), -N(R^e)(R^f), -N(R^f)S(O)₂ R^f , -N(R^f)C(O)O(R^f), -L³-O- R^f , -L³-CN, -L³-N(R^f)C(O) R^f , -L³-CON(R^e)(R^f), -L³-C(O) R^f , -L³-OC(O) R^f , -L³-CO₂H, -L³-CO₂ R^f , -L³-N(R^f)C(O)N(R^f)₂, -L³-S- R^f , -L³-S(O)₂ R^f , -L³-S(O) R^f , -L³-SO₂N(R^e)(R^f), -L³-N(R^e)(R^f), -L³-N(R^f)S(O)₂ R^f , and -L³-N(R^f)C(O)O(R^f); and

X is NR^g; wherein

L^{1a}, L³, R^{a1}, R^{b1}, R^e, R^f and R^g are as described herein.

In one particular subgroup, the present disclosure features compounds of formula (I), wherein

R^1 is phenyl, bicyclic aryl or monocyclic heteroaryl; wherein the phenyl, the bicyclic aryl, and the monocyclic heteroaryl are optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, C_1 - C_6 -alkyl, C_1 - C_6 -haloalkyl, -OCH₂O-, -O- R^b , -CN, -N(R^b)C(O) R^b , -CON(R^a)(R^b), -C(O) R^b , -OC(O) R^b , -OS(O)₂N(R^a)(R^b), -CO₂H, -CO₂ R^b , -N(R^b)C(O)N(R^b)₂, -S- R^b , -S(O)₂ R^b , -S(O) R^b , -SO₂N(R^a)(R^b), -N(R^a)(R^b), -N(R^b)S(O)₂ R^b , -N(R^b)C(O)O(R^b), -N(R^b)S(O)₂O(R^b), -L¹-O- R^b , -L¹-CN, -L¹-N(R^b)C(O) R^b , -L¹-CON(R^a)(R^b), -L¹-C(O) R^b , -L¹-OC(O) R^b , -L¹-CO₂H, -L¹-CO₂ R^b , -L¹-N(R^b)C(O)N(R^b)₂, -L¹-S- R^b , -L¹-S(O)₂ R^b , -L¹-S(O) R^b , -L¹-SO₂N(R^a)(R^b), -L¹-N(R^a)(R^b), -L¹-N(R^b)S(O)₂ R^b , and -L¹-N(R^b)C(O)O(R^b);

R^2 is methyl or ethyl;

R^3 is methyl or ethyl;

R⁴ and R⁵ are independently selected from the group consisting of hydrogen, C₁-C₆-alkyl, and C₁-C₆-haloalkyl;

R⁶ is selected from the group consisting of hydrogen, C₁-C₆-alkyl, and C₁-C₆-haloalkyl;

G¹ is phenyl or monocyclic heteroaryl, wherein the phenyl or monocyclic heteroaryl are
 5 optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, C₁-C₆-alkyl, C₁-C₆-haloalkyl, -O-R^f, -CN, -N(R^f)C(O)R^f, -CON(R^e)(R^f), -C(O)R^f, -OC(O)R^f, -CO₂H, -CO₂R^f, -N(R^f)C(O)N(R^f)₂, -S-R^f, -S(O)₂R^f, -S(O)R^f, -SO₂N(R^e)(R^f), -N(R^e)(R^f), -N(R^f)S(O)₂R^f, -N(R^f)C(O)O(R^f), -L³-O-R^f, -L³-CN, -L³-N(R^f)C(O)R^f, -L³-CON(R^e)(R^f), -L³-C(O)R^f, -L³-OC(O)R^f, -L³-CO₂H, -L³-CO₂R^f, -L³-N(R^f)C(O)N(R^f)₂, -L³-S-R^f, -L³-S(O)₂R^f, -L³-S(O)R^f, -L³-SO₂N(R^e)(R^f),
 10 -L³-N(R^e)(R^f), -L³-N(R^f)S(O)₂R^f, and -L³-N(R^f)C(O)O(R^f); and

X is NR^g; wherein

L¹, L³, R^a, R^b, R^e, R^f and R^g are as described herein.

In another particular subgroup, the present disclosure features compounds of formula (I),
 15 wherein

R¹ is C₃-C₈-cycloalkyl-C₁-C₆-alkyl, phenyl-C₁-C₆-alkyl, heterocyclyl-C₁-C₆-alkyl, or monocyclic heteroaryl-C₁-C₆-alkyl; wherein the C₃-C₈-cycloalkyl of C₃-C₈-cycloalkyl-C₁-C₆-alkyl and heterocyclyl of heterocyclyl-C₁-C₆-alkyl are optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkynyl, C₁-C₁₀-haloalkyl,
 20 C₂-C₁₀-haloalkenyl, C₂-C₁₀-haloalkynyl, halogen, oxo, cyano, hydroxy, -O-C₁-C₆-alkyl, -O-C₁-C₆-haloalkyl, -C₁-C₃-alkylene-O-H, -C₁-C₃-alkylene-O-C₁-C₆-alkyl, -C₁-C₃-alkylene-O-C₁-C₆-haloalkyl, -C₁-C₃-alkylene-NH₂, -NH₂, -C(O)O-C₁-C₆-alkyl, -N(R^{b1})C(O)R^{b1}, -CON(R^{a1})(R^{b1}), -C(O)R^{b1}, -OC(O)R^{b1}, -OS(O)₂N(R^{a1})(R^{b1}), -CO₂H, -CO₂R^{b1}, -N(R^{b1})C(O)N(R^{b1})₂, -S-R^{b1}, -S(O)₂R^{b1}, -S(O)R^{b1}, -SO₂N(R^{a1})(R^{b1}), -N(R^{a1})(R^{b1}), -N(R^{b1})S(O)₂R^{b1}, -N(R^{b1})C(O)O(R^{b1}), -N(R^{b1})S(O)₂O(R^{b1}), -L^{1a}-O-R^{b1},
 25 -L^{1a}-CN, -L^{1a}-N(R^{b1})C(O)R^{b1}, -L^{1a}-CON(R^{a1})(R^{b1}), -L^{1a}-C(O)R^{b1}, -L^{1a}-OC(O)R^{b1}, -L^{1a}-CO₂H, -L^{1a}-CO₂R^{b1}, -L^{1a}-N(R^{b1})C(O)N(R^{b1})₂, -L^{1a}-S-R^{b1}, -L^{1a}-S(O)₂R^{b1}, -L^{1a}-S(O)R^{b1}, -L^{1a}-SO₂N(R^{a1})(R^{b1}), -L^{1a}-N(R^{a1})(R^{b1}), -L^{1a}-N(R^{b1})S(O)₂R^{b1}, and -L^{1a}-N(R^{b1})C(O)O(R^{b1}); wherein the phenyl of phenyl-C₁-C₆-alkyl and monocyclic heteroaryl of monocyclic heteroaryl-C₁-C₆-alkyl are optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, C₁-C₆-alkyl, C₁-C₆-haloalkyl, -OCH₂O-, -O-R^b, -CN, -N(R^b)C(O)R^b, -CON(R^a)(R^b), -C(O)R^b, -OC(O)R^b,
 30 -OS(O)₂N(R^a)(R^b), -CO₂H, -CO₂R^b, -N(R^b)C(O)N(R^b)₂, -S-R^b, -S(O)₂R^b, -S(O)R^b, -SO₂N(R^a)(R^b), -N(R^a)(R^b), -N(R^b)S(O)₂R^b, -N(R^b)C(O)O(R^b), -N(R^b)S(O)₂O(R^b), -L¹-O-R^b, -L¹-CN, -L¹-N(R^b)C(O)R^b, -L¹-CON(R^a)(R^b), -L¹-C(O)R^b, -L¹-OC(O)R^b, -L¹-CO₂H, -L¹-CO₂R^b, -L¹-N(R^b)C(O)N(R^b)₂, -L¹-S-R^b, -L¹-S(O)₂R^b, -L¹-S(O)R^b, -L¹-SO₂N(R^a)(R^b), -L¹-N(R^a)(R^b),
 35 -L¹-N(R^b)S(O)₂R^b, and -L¹-N(R^b)C(O)O(R^b);

R² is methyl or ethyl;

R³ is methyl or ethyl;

R^4 and R^5 are independently selected from the group consisting of hydrogen, C₁-C₆-alkyl, and C₁-C₆-haloalkyl;

R^6 is selected from the group consisting of hydrogen, C₁-C₆-alkyl, and C₁-C₆-haloalkyl;

G^1 is phenyl or monocyclic heteroaryl, wherein the phenyl or monocyclic heteroaryl are
 5 optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, C₁-C₆-alkyl, C₁-C₆-haloalkyl, -O-R^f, -CN, -N(R^f)C(O)R^f, -CON(R^e)(R^f), -C(O)R^f, -OC(O)R^f, -CO₂H, -CO₂R^f, -N(R^f)C(O)N(R^f)₂, -S-R^f, -S(O)₂R^f, -S(O)R^f, -SO₂N(R^e)(R^f), -N(R^e)(R^f), -N(R^f)S(O)₂R^f, -N(R^f)C(O)O(R^f), -L³-O-R^f, -L³-CN, -L³-N(R^f)C(O)R^f, -L³-CON(R^e)(R^f), -L³-C(O)R^f, -L³-OC(O)R^f, -L³-CO₂H, -L³-CO₂R^f, -L³-N(R^f)C(O)N(R^f)₂, -L³-S-R^f, -L³-S(O)₂R^f, -L³-S(O)R^f, -L³-SO₂N(R^e)(R^f),
 10 -L³-N(R^e)(R^f), -L³-N(R^f)S(O)₂R^f, and -L³-N(R^f)C(O)O(R^f); and

X is NR^g; wherein

L¹, L^{1a}, L³, R^a, R^{a1}, R^b, R^{b1}, R^e, R^f and R^g are as described herein.

In certain embodiments, R^1 is selected from the group consisting of phenyl, cyclohexyl, cyclopentyl, cycloheptyl, cyclobutyl, norbornyl, indanyl, benzodioxolyl, pyridinyl, pyrazolyl,
 15 morpholinyl, thiadiazolyl, tetrahydrothiophenyl, piperidinyl and isoxazolyl.

In certain embodiments, R^1 is selected from the group consisting of phenyl and cyclohexyl.

In certain embodiments, G^1 is selected from the group consisting of phenyl, pyridinyl, imidazolyl, pyrazolyl and isoxazolyl.

In certain embodiments, G^1 is selected from the group consisting of phenyl and pyridinyl.

20 In certain embodiments, R^1 is cyclohexyl, and G^1 is pyridinyl.

In certain embodiments, R^1 is phenyl, and G^1 is pyridinyl.

In certain embodiments, R^1 is an optionally substituted cyclohexyl; R^2 and R^3 are each methyl; R^4 , R^5 and R^6 are each hydrogen; X is NR^g, wherein R^g is hydrogen; and G^1 is an optionally substituted pyridinyl.

25 In certain embodiments, R^1 is an optionally substituted phenyl; R^2 and R^3 are each methyl; R^4 , R^5 and R^6 are each hydrogen; X is NR^g, wherein R^g is hydrogen; and G^1 is an optionally substituted pyridinyl.

Exemplary compounds include, but are not limited to:

30 N^4 -cyclohexyl-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;

N^4 -(2-methylbenzyl)- N^2 -(pyridin-2-ylmethyl)-6,7-dihydro-5H-cyclopenta[*d*]pyrimidine-2,4-diamine;

N^4 -cycloheptyl-6-methyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;

N^4 -cyclohexyl-6-methyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;

35 N^2 -benzyl- N^4 -cyclohexyl-5,6-dimethylpyrimidine-2,4-diamine;

N^4 -cyclohexyl-5,6-dimethyl- N^2 -(pyridin-3-ylmethyl)pyrimidine-2,4-diamine;

2-({[4-(cyclohexylamino)-5,6-dimethylpyrimidin-2-yl]amino} methyl)-6-methylpyridin-3-ol;

- N^4 -cyclohexyl- N^2 -(4-methoxybenzyl)-5,6-dimethylpyrimidine-2,4-diamine;
 N^4 -cyclohexyl- N^2 -(4-fluorobenzyl)-5,6-dimethylpyrimidine-2,4-diamine;
 N^4 -cyclohexyl-5,6-dimethyl- N^2 -[4-(trifluoromethoxy)benzyl]pyrimidine-2,4-diamine;
 N^4 -cyclohexyl- N^2 -(4-isopropylbenzyl)-5,6-dimethylpyrimidine-2,4-diamine;
5 N^4 -cyclohexyl-5,6-dimethyl- N^2 -[4-(trifluoromethyl)benzyl]pyrimidine-2,4-diamine;
 N^4 -cyclohexyl- N^2 -(3-fluorobenzyl)-5,6-dimethylpyrimidine-2,4-diamine;
 N^4 -cyclohexyl-5,6-dimethyl- N^2 -(1*H*-pyrazol-5-ylmethyl)pyrimidine-2,4-diamine;
 N^4 -cyclohexyl-5,6-dimethyl- N^2 -[(1*R*)-1-phenylethyl]pyrimidine-2,4-diamine;
 N^4 -cyclohexyl-5,6-dimethyl- N^2 -[(1*S*)-1-phenylethyl]pyrimidine-2,4-diamine;
10 N^4 -cyclohexyl-5,6-dimethyl- N^2 -[(4-methylpyridin-2-yl)methyl]pyrimidine-2,4-diamine;
 N^4 -cyclohexyl- N^2 -[(4-methoxypyridin-2-yl)methyl]-5,6-dimethylpyrimidine-2,4-diamine;
 N^4 -cyclohexyl-5,6-dimethyl- N^2 -[(6-methylpyridin-2-yl)methyl]pyrimidine-2,4-diamine;
 N^4 -cyclohexyl-5,6-dimethyl- N^2 -{[5-(trifluoromethyl)pyridin-2-yl]methyl}pyrimidine-2,4-
diamine;
15 N^2 -[(4-*tert*-butylpyridin-2-yl)methyl]- N^4 -cyclohexyl-5,6-dimethylpyrimidine-2,4-diamine;
 N^4 -cyclohexyl-5,6-dimethyl- N^2 -(2-thienylmethyl)pyrimidine-2,4-diamine;
 N^4 -cyclohexyl- N^2 -[(3,5-dimethyl-1,2-oxazol-4-yl)methyl]-5,6-dimethylpyrimidine-2,4-
diamine;
 N^4 -cyclohexyl-5,6-dimethyl- N^2 -[(1-methyl-1*H*-imidazol-4-yl)methyl]pyrimidine-2,4-diamine;
20 N^4 -cyclohexyl- N^2 -(3-methoxybenzyl)-5,6-dimethylpyrimidine-2,4-diamine;
 N^4 -cyclohexyl-5,6-dimethyl- N^2 -[(3-methylpyridin-2-yl)methyl]pyrimidine-2,4-diamine;
 N^2 -[(4-chloropyridin-2-yl)methyl]- N^4 -cyclohexyl-5,6-dimethylpyrimidine-2,4-diamine;
 N^4 -(4,4-difluorocyclohexyl)-5,6-dimethyl- N^2 -[(4-methylpyridin-2-yl)methyl]pyrimidine-2,4-
diamine;
25 N^4 -cyclopentyl-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)- N^4 -(tetrahydro-2*H*-pyran-4-yl)pyrimidine-2,4-diamine;
5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)- N^4 -[4-(trifluoromethyl)cyclohexyl]pyrimidine-2,4-
diamine;
 N^4 -(4,4-difluorocyclohexyl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
30 N^4 -(2,3-dihydro-1*H*-inden-1-yl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-
diamine;
3-({5,6-dimethyl-2-[(pyridin-2-ylmethyl)amino]pyrimidin-4-yl} amino)cyclopentanol;
5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)- N^4 -(1,2,3,4-tetrahydronaphthalen-1-yl)pyrimidine-2,4-
diamine;
35 N^4 -(3,4-dihydro-2*H*-chromen-4-yl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-
diamine;

- cis*-4-({5,6-dimethyl-2-[(pyridin-2-ylmethyl)amino]pyrimidin-4-yl} amino)-1-methylcyclohexanol;
- trans*-4-({5,6-dimethyl-2-[(pyridin-2-ylmethyl)amino]pyrimidin-4-yl} amino)-1-methylcyclohexanol;
- 5 N^4 -(bicyclo[2.2.1]hept-2-yl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
5,6-dimethyl- N^4 -(2-methylcyclohexyl)- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 N^4 -(2,3-dimethylcyclohexyl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
2-({5,6-dimethyl-2-[(pyridin-2-ylmethyl)amino]pyrimidin-4-yl} amino)cyclohexanol;
[(1*R*,2*S*)-2-({5,6-dimethyl-2-[(pyridin-2-ylmethyl)amino]pyrimidin-4-
- 10 yl} amino)cyclohexyl]methanol;
 N^4 -(cyclopentylmethyl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 N^4 -cycloheptyl-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 N^4 -(2,3-dihydro-1*H*-inden-2-yl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-
- diamine;
- 15 N^4 -cyclobutyl-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
5,6-dimethyl- N^4 -(pentan-3-yl)- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 N^4 -(3-fluorophenyl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 N^4 -(4-fluorophenyl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 N^4 -(2-fluorophenyl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
- 20 5,6-dimethyl- N^4 -phenyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)- N^4 -[3-(trifluoromethoxy)phenyl]pyrimidine-2,4-
- diamine;
- 5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)- N^4 -[3-(trifluoromethyl)phenyl]pyrimidine-2,4-diamine;
 N^4 -(2,6-difluorophenyl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
- 25 5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)- N^4 -[4-(trifluoromethoxy)phenyl]pyrimidine-2,4-
- diamine;
- 5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)- N^4 -[4-(trifluoromethyl)phenyl]pyrimidine-2,4-diamine;
 N^4 -(3,4-difluorophenyl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
- 30 5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)- N^4 -[2-(trifluoromethoxy)phenyl]pyrimidine-2,4-
- diamine;
- N^4 -(2,5-difluorophenyl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 N^4 -(1,3-benzodioxol-5-yl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 N^4 -(4-chlorophenyl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
5,6-dimethyl- N^4 -(4-methylphenyl)- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
- 35 N^4 -(3,5-difluorophenyl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 N^4 -(3-chlorophenyl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 N^4 -(2-chlorophenyl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;

- 5,6-dimethyl- N^4 -(2-methylphenyl)- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 N^4 -(2,6-dimethylphenyl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 5,6-dimethyl- N^4 -(3-methylphenyl)- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 N^4 -(1,1-dioxidotetrahydrothiophen-3-yl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-
 5 2,4-diamine;
 N^4 -(5-fluoro-2-methylphenyl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 N^4 -(2-fluoro-6-methylphenyl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 N^4 -(4,5-difluoro-2-methylphenyl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-
 diamine;
 10 5,6-dimethyl- N^4 -(1-methyl-1*H*-pyrazol-5-yl)- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 N^4 -(4-fluoro-2-methylphenyl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 N^4 -(3-fluoro-2-methylphenyl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 N^4 -cyclohexyl- N^4 ,5,6-trimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 N^4 -(3,3-difluorocyclopentyl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 15 *trans*-4-({5,6-dimethyl-2-[(pyridin-2-ylmethyl)amino]pyrimidin-4-yl} amino)cyclohexanol;
 N^4 -(3,3-difluorocyclohexyl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 5,6-dimethyl- N^4 -(1-methylpiperidin-4-yl)- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
tert-butyl 4-({5,6-dimethyl-2-[(pyridin-2-ylmethyl)amino]pyrimidin-4-yl} amino)piperidine-
 1-carboxylate;
 20 5,6-dimethyl- N^4 -(piperidin-4-yl)- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 N^4 -(2,6-diisopropylphenyl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 3-({5,6-dimethyl-2-[(pyridin-2-ylmethyl)amino]pyrimidin-4-yl} amino)cyclohexanol;
 N^4 -cyclohexyl-5,6-dimethyl- N^2 -[(5-methylpyridin-2-yl)methyl]pyrimidine-2,4-diamine;
 N^4 -cyclohexyl-5,6-dimethyl- N^2 -[1-(pyridin-2-yl)ethyl]pyrimidine-2,4-diamine;
 25 N^4 -(2,4-difluorophenyl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 5-ethyl- N^4 -(4-fluorophenyl)-6-methyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 N^4 -(4,4-difluorocyclohexyl)- N^2 -[(4-ethylpyridin-2-yl)methyl]-5,6-dimethylpyrimidine-2,4-
 diamine;
 5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)- N^4 -(tetrahydrofuran-2-ylmethyl)pyrimidine-2,4-
 30 diamine;
 N^4 -(cyclohexylmethyl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 5,6-dimethyl- N^4 -(pyridin-3-yl)- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)- N^4 -(1,3,4-thiadiazol-2-yl)pyrimidine-2,4-diamine;
 5,6-dimethyl- N^4 -(1,2-oxazol-3-yl)- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 35 5,6-dimethyl- N^4 -(5-methyl-1,2-oxazol-3-yl)- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 or
 N^4 -(4-fluorobenzyl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine.

Isomers

The present disclosure contemplates various stereoisomers and mixtures thereof, and these are specifically included within the scope of this disclosure. Stereoisomers include enantiomers and
5 diastereomers, and mixtures of enantiomers or diastereomers. Individual stereoisomers of compounds of the present application may be prepared synthetically from commercially available starting materials which contain asymmetric or chiral centers or by preparation of racemic mixtures followed by resolution which is well known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the
10 resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary, or (2) direct separation of the mixture of optical enantiomers on chiral chromatographic columns.

Geometric isomers may exist in the disclosed compounds. The present disclosure contemplates the various geometric isomers and mixtures thereof resulting from the disposition of
15 substituents around a carbon-carbon double bond, a carbon-nitrogen double bond, a cycloalkyl group, or a heterocycle group. Substituents around a carbon-carbon double bond or a carbon-nitrogen bond are designated as being of Z or E configuration and substituents around a cycloalkyl or a heterocycle are designated as being of *cis* or *trans* configuration.

It is to be understood that compounds disclosed herein may exhibit the phenomenon of
20 tautomerism.

Thus, the formulae drawings within this specification can represent only one of the possible tautomeric or stereoisomeric forms. It is to be understood that the disclosed compounds encompass any tautomeric or stereoisomeric forms, and mixtures thereof, and are not to be limited merely to any one tautomeric or stereoisomeric form utilized within the naming of the compounds or formulae
25 drawings.

Isotopes

The disclosure also include isotopically-labeled compounds, which are identical to disclosed compounds, but for the fact that one or more atoms are replaced by an atom having an atomic mass or
30 mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes suitable for inclusion in the disclosed compounds are hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, and chlorine, such as, but not limited to, ^2H , ^3H , ^{13}C , ^{14}C , ^{15}N , ^{18}O , ^{17}O , ^{31}P , ^{32}P , ^{35}S , ^{18}F , and ^{36}Cl , respectively. Substitution with heavier isotopes such as deuterium, i.e., ^2H , can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased
35 *in vivo* half-life or reduced dosage requirements and, hence, may be employed in some circumstances. Compounds incorporating positron-emitting isotopes are useful in medical imaging and positron-emitting tomography (PET) studies for determining the distribution of receptors. Suitable positron-

emitting isotopes that can be incorporated in compounds of formula (I) are ^{11}C , ^{13}N , ^{15}O , and ^{18}F . Isotopically-labeled compounds of the present disclosure can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples using appropriate isotopically-labeled reagent in place of non-isotopically-labeled reagent.

Salts

This disclosure is also directed, in part, to all salts of the disclosed compounds. A salt of a compound may be advantageous due to one or more of the salt's properties, such as, for example, enhanced pharmaceutical stability in differing temperatures and humidities, or a desirable solubility in water or other solvents. Where a salt is intended to be administered to a patient (as opposed to, for example, being in use in an *in vitro* context), the salt may be pharmaceutically acceptable and/or physiologically compatible. The term "pharmaceutically acceptable" is used adjectivally in this disclosure to mean that the modified noun is appropriate for use as a pharmaceutical product or as a part of a pharmaceutical product. Pharmaceutically acceptable salts include, for example, salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. In general, these salts typically may be prepared by conventional means by reacting, for example, the appropriate acid or base with a disclosed compound.

Pharmaceutically acceptable acid addition salts of the disclosed compounds can be prepared from an inorganic or organic acid. Examples of suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric, and phosphoric acid. Suitable organic acids generally include, for example, aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic classes of organic acids. Specific examples of suitable organic acids include acetate, trifluoroacetate, formate, propionate, succinate, glycolate, gluconate, digluconate, lactate, malate, tartaric acid, citrate, ascorbate, glucuronate, maleate, fumarate, pyruvate, aspartate, glutamate, benzoate, anthranilic acid, mesylate, stearate, salicylate, p-hydroxybenzoate, phenylacetate, mandelate, embonate (pamoate), ethanesulfonate, benzenesulfonate, pantothenate, 2-hydroxyethanesulfonate, sulfanilate, cyclohexylaminosulfonate, algenic acid, beta-hydroxybutyric acid, galactarate, galacturonate, adipate, alginate, bisulfate, butyrate, camphorate, camphorsulfonate, cyclopentanepropionate, dodecylsulfate, glycoheptanoate, glycerophosphate, heptanoate, hexanoate, nicotinate, oxalate, palmoate, pectinate, 2-naphthalesulfonate, 3-phenylpropionate, picrate, pivalate, thiocyanate, tosylate, and undecanoate.

Pharmaceutically acceptable base addition salts of the disclosed compounds include, for example, metallic salts and organic salts. Metallic salts may include alkali metal (group Ia) salts, alkaline earth metal (group IIa) salts, and other physiologically acceptable metal salts. Such salts may be made from aluminum, calcium, lithium, magnesium, potassium, sodium, and zinc. Organic salts can be made from amines, such as tromethamine, diethylamine, *N,N*-dibenzylethylenediamine,

chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (*N*-methylglucamine), and procaine. Basic nitrogen-containing groups can be quaternized with agents such as lower alkyl (C₁-C₆) halides (*e.g.*, methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides), dialkyl sulfates (*e.g.*, dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (*e.g.*, decyl, lauryl, myristyl, and stearyl chlorides, bromides, and iodides), arylalkyl halides (*e.g.*, benzyl and phenethyl bromides), and others.

Purity

The disclosed compounds (and salts thereof) with any level of purity (including pure and substantially pure) are within the scope of the present disclosure. The term "substantially pure" in reference to a compound/salt/isomer, means that the preparation/composition containing the compound/salt/isomer contains more than about 85% by weight of the compound/salt/isomer, more than about 90% by weight of the compound/salt/isomer, more than about 95% by weight of the compound/salt/isomer, more than about 97% by weight of the compound/salt/isomer, and more than about 99% by weight of the compound/salt/isomer.

Compositions

The disclosure is also directed, in part, to compositions comprising one or more of the disclosed compounds and/or salts thereof. In some embodiments, the compositions comprise one or more substantially phase pure crystalline forms. The compositions may be pharmaceutical compositions.

In some embodiments, the compositions further comprise one or more additional therapeutic agents. Such therapeutic agents may include, for example, one or more therapeutic agents used to treat respiratory syncytial virus (*e.g.*, the current standard of therapy).

The components of the compositions may depend on the method of administration, and may comprise one or more conventional pharmaceutically acceptable carriers, adjuvants, and/or vehicles (together referred to as "excipients"). Formulation of drugs is generally discussed in, for example, Hoover, J., *Remington's Pharmaceutical Sciences* (Mack Publishing Co., 1975) and Ansel's *Pharmaceutical Dosage Forms and Drug Delivery Systems* (Lippincott Williams & Wilkins, 2005).

The disclosed pharmaceutical compositions may be administered to a patient in need thereof via a variety of routes, such as orally, parenterally, sublingually, rectally, topically or by inhalation. Topical administration may involve the use of transdermal administration such as transdermal patches or iontophoresis devices. Parenteral administration includes, but is not limited to, subcutaneous, intravenous, intramuscular or intrasternal injections, and infusion techniques.

Solid dosage forms for oral administration include, for example, capsules, tablets, pills, powders, and granules. In such solid dosage forms, the disclosed compounds or salts are ordinarily combined with one or more excipients. If administered per os, the compounds or salts can be mixed with, for example, lactose, sucrose, starch powder, cellulose esters of alkanolic acids, cellulose alkyl

esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets can contain a controlled-release formulation, as can be provided in, for example, a dispersion
5 of the compound or salt in hydroxypropylmethyl cellulose. In the case of capsules, tablets, and pills, the dosage forms also can comprise buffering agents, such as sodium citrate, or magnesium or calcium carbonate or bicarbonate. Tablets and pills additionally can be prepared with enteric coatings.

Liquid dosage forms for oral administration include, for example, pharmaceutically
10 acceptable emulsions (including both oil-in-water and water-in-oil emulsions), solutions (including both aqueous and non-aqueous solutions), suspensions (including both aqueous and non-aqueous suspensions), syrups, and elixirs containing inert diluents commonly used in the art (*e.g.*, water). Such compositions may also comprise, for example, wetting, emulsifying, suspending, flavoring (*e.g.*, sweetening), and/or perfuming agents.

Parenteral administration includes subcutaneous injections, intravenous injections,
15 intramuscular injections, intrasternal injections, and infusion. Injectable preparations (*e.g.*, sterile injectable aqueous or oleaginous suspensions) can be formulated according to the known art using suitable dispersing, wetting agents, and/or suspending agents. Acceptable vehicles and solvents include, for example, water, 1,3-butanediol, Ringer's solution, isotonic sodium chloride solution,
20 bland fixed oils (*e.g.*, synthetic mono- or diglycerides), fatty acids (*e.g.*, oleic acid), dimethyl acetamide, surfactants (*e.g.*, ionic and non-ionic detergents), and/or polyethylene glycols.

Formulations for parenteral administration may, for example, be prepared from sterile
powders or granules having one or more of the excipients mentioned for use in the formulations for oral administration. A compound or salt of the invention can be dissolved in water, polyethylene
25 glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. The pH may be adjusted, if necessary, with a suitable acid, base, or buffer.

Suppositories for rectal administration may be prepared by, for example, mixing a compound
or salt of the invention with a suitable nonirritating excipient that is solid at ordinary temperatures, but
30 liquid at the rectal temperature, and will, therefore, melt in the rectum to release the drug. Suitable excipients include, for example, cocoa butter; synthetic mono-, di-, or triglycerides, fatty acids, and/or polyethylene glycols.

Topical administration includes the use of transdermal administration, such as transdermal
patches or iontophoresis devices.

The disclosed compounds or pharmaceutical compositions may be formulated to be suitable
35 for inhalation. The pharmaceutical composition may be in the form of a solution, suspension, powder or other suitable form for pulmonary administration. These compositions may be administered to the

lungs by any suitable delivery method such as, for example, in an aerosol, atomized, nebulized, or vaporized form through devices known in the art to affect such delivery. The amount of the disclosed pharmaceutical composition may be controlled by providing a valve to deliver a metered amount such as in a metered dose inhalers (MDI) that delivers a fixed dose in a spray with each actuation of the

5 device. The pharmaceutical compositions may be formulated with one or more suitable propellants, such as, for example, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. Capsules and cartridges for use in an inhaler or insufflator may be formulated containing a powder mix of the disclosed compounds or pharmaceutical compositions and a suitable powder base such as lactose or starch.

10 The pharmaceutical compositions may be formulated with one or more binding agent as a dry powder for inhalation.

The disclosed compounds or pharmaceutical compositions may be in the form of sustained- or controlled-delivery formulations. Techniques for making such sustained- and controlled-delivery formulations are well-known to those skilled in the art. Among these are delivery methods that use

15 liposome carriers, bio-erodible microparticles, porous beads, and semi-permeable polymer matrices.

Other excipients and modes of administration known in the pharmaceutical art also may be used.

The total daily dose of the disclosed compounds or salts thereof (administered in single or divided doses) may be from about 0.001 to about 100 mg/kg, from about 0.001 to about 30 mg/kg, or

20 from about 0.01 to about 10 mg/kg (*i.e.*, mg of the compound or salt per kg body weight). Dosage unit compositions may contain such amounts or submultiples thereof to make up the daily dose. In many instances, the administration of the disclosed compounds or salts thereof will be repeated a plurality of times. Multiple doses per day typically may be used to increase the total daily dose, if desired.

25 Factors affecting the dosage regimen include the type, age, weight, sex, diet, and condition of the patient; the severity of the pathological condition; the route of administration; pharmacological considerations, such as the activity, efficacy, pharmacokinetic, and toxicology profiles of the particular compound or salt used; whether a drug delivery system is utilized; the period of time during which RSV infection is most likely to occur such as during a defined RSV season; and whether the

30 compound or salt is administered as part of a drug combination. Thus, the dosage regimen actually employed can vary widely, and therefore, can derive from the dosage regimen set forth above.

Kits

This disclosure is also directed, in part, to kits comprising one or more of the disclosed compounds and/or salts thereof. The kits may optionally contain one or more additional therapeutic

35 agents and/or instructions for action such as using the kit.

Methods of Use.

This disclosure is directed, in part, to a method for inhibiting infection and/or replication of an RNA virus. The method comprises exposing the virus to one or more of the disclosed compounds and/or salts thereof. In embodiments, infection and/or replication of the RNA virus are inhibited *in vitro*. In embodiments, infection and/or replication of the RNA virus are inhibited *in vivo*. In 5 embodiments, the RNA virus whose infection and/or replication are being inhibited is a single-stranded, negative sense RNA virus. In embodiments, the RNA virus whose infection and/or replication are being inhibited is a virus from the *Paramyxoviridae* family. In embodiments, the RNA virus whose infection and/or replication is being inhibited is RSV.

10 The term "inhibiting" means reducing the level of infection and/or RNA virus replication either *in vitro* or *in vivo*. The inhibition may act on any stage of viral infection and/or replication, such as (but not exclusively) attachment, penetration, uncoating, genome replication, assembly, maturation or egress from infected cells. The target of the compound might be either a viral or host component (or rarely both) involved in viral infection and/or replication. For example, if a disclosed 15 compound/salt reduces the level of infection and/or RNA virus replication by at least about 10% compared to the level of RNA virus infection and/or replication before the virus is exposed to the compound/salt, then the compound/salt inhibits RNA virus infection and/or replication. In some embodiments, the compound/salt can inhibit RNA virus infection and/or replication by at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 20 70%, at least about 80%, at least about 90%, or at least about 95%.

This disclosure also is directed, in part, to a method for treating RSV infection in a subject in need of such treatment. These methods comprise administering to the subject one or more of the disclosed compounds and/or salts thereof, and, optionally, one or more additional therapeutic agents. In some embodiments, a therapeutically effective amount of the compound(s) and/or salt(s) thereof is 25 administered to the subject. "Treating" means ameliorating, suppressing, eradicating, preventing, reducing the risk of, and/or delaying the onset of the infection or disease being treated. For example, the disclosed compounds and/or salts thereof may be used for prophylaxis to prevent infection of uninfected subjects, and/or the spread of the virus to the lower respiratory tract in patients already infected with the virus. The term "treating" encompasses administration of the disclosed compounds 30 and/or salts thereof to a patient at risk for RSV infection. Patients at risk for RSV infection may include premature infants, children with bronchopulmonary dysplasia, children with congenital heart or lung disease, the elderly and immunocompromised and other patients who are unable to mount a sufficient immune responses due to their immature or weaker immune systems. The disclosed compounds and/or salts thereof may be administered to patients with a low tolerance to the side 35 effects of current therapies.

The methods of treatment are particularly suitable for use with humans, but may be used with other animals. A "therapeutically effective amount" or "effective amount" is an amount that will

substantially achieve the goal of treating the targeted condition.

In embodiments, the disclosed methods comprise combination therapy, wherein the disclosed compound(s) and/or salt(s) is/are co-administered with a second compound, such as, for example, another therapeutic agent used to treat RSV such as, for example, the current standard of therapy, and other antivirals. In these co-administration embodiments, the disclosed compound(s) and/or salt(s) and the second, etc. therapeutic agent(s) may be administered in a substantially simultaneous manner (e.g., within at least about 5 minutes of each other), in a sequential manner, or both. For example, the disclosed compound(s) and/or salt(s) may be administered to a patient before, during or after treatment with the current standard of therapy, if such an administration is deemed medically necessary and/or appropriate.

This disclosure also is directed, in part, to uses of one or more of the disclosed compounds and/or salts, and, optionally, in combination with one or more additional therapeutic agents to prepare a medicament. In some embodiments, the medicament is for co-administration with one or more additional therapeutic agents.

In some embodiments, the medicament is for inhibiting replication of an RNA virus.

In some embodiments, the medicament is for treating RSV.

In embodiments, one or more of the disclosed compounds and/or salts may be used to prevent and/or treat RSV infections caused by one or both groups A or B RSV virus.

In embodiments, one or more of the disclosed compounds and/or salts may be used to inhibiting infection and/or replication of one or both of group A or group B RSV virus.

This disclosure also is directed, in part, to one or more of the disclosed compounds and/or salts of the invention, and, optionally, in combination with one or more additional therapeutic agents, for use in inhibiting replication of an RNA virus or for use in treating RSV infection.

BIOLOGICAL ASSAYS

Cells and Virus

HEp-2 cells and RSV (Group A, Long Strain) were obtained from the American Type Culture Collection (Manassas, VA).

Antiviral (RSV) Assay

A cytopathic effect (CPE) protection assay was performed to determine the ability of a compound to protect the cells from viral infection and thus the CPE induced by viral infection. 96-well plates were first seeded with 3×10^3 HEp-2 cells per well in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS). One day after the cells were seeded, they were preincubated with serial dilutions of compounds prepared in 100 μ L assay medium (DMEM mixed with F12 medium at a 1:1 ratio, supplemented with 2% FBS and 1 mM sodium pyruvate) for 1 hour at

37 °C. 100 μ L of assay medium containing 0.2 multiplicity of infection (MOI) of RSV was then added to each well of cells. In addition to wells containing infected cells incubated with compounds, each plate also contained replicates of two kinds of controls: (1) Virus control contained cells infected with 0.2 MOI of RSV in assay medium, (2) Uninfected cell control contained cells incubated with assay medium only. After 4 days of incubation at 37 °C, the viability of cells was assessed using MTT (Thiazolyl blue tetrazolium bromide, Sigma). A stock solution of MTT, at a concentration of 4 mg/mL in phosphate-buffered saline, was added to all wells at 25 μ L per well. Plates were further incubated for 4 hours, and each well was then treated with 50 μ L of a solution containing 20% sodium dodecyl sulfate (SDS) and 0.02 *N* HCl. After an overnight incubation, the plates were measured on a BioTek[®] microtiter plate reader at wavelengths of 570 nm and 650 nm. The MTT detection is based on the fact that viable (uninfected) cells can reduce the tetrazolium salts into colored formazan products, which can then be quantitated by spectrometry. Based on the spectrometric absorbance of each sample, the percent of protection from CPE, which is an indicator of protection from viral infection, can be calculated for each compound and the 50% effective concentrations (EC₅₀) can be calculated using a nonlinear regression curve fitting equation provided by the GraphPad Prism[®] 4 software. Using the above-described assay, compounds of the present invention showed obvious inhibitory activities against RSV replication. Results are shown in Table 1.

Table 1.

Example	RSV EC₅₀ (μM)		Example	RSV EC₅₀ (μM)
1	0.25		50	0.1
2	2.05		51	0.32
3	2.79		52	0.27
4	23.5		53	0.038
5	0.24		54	0.025
6	0.24		55	0.14
7	>12		56	0.4
8	>3.7		57	0.23
9	>3.0		58	0.063
10	>1.5		59	0.03
11	>2.0		60	0.1
12	>0.95		61	0.04
13	>1.0		62	0.094
14	0.84		63	0.052
15	>1.9		64	0.04
16	>3.7		65	0.04

17	0.034		66	0.034
18	0.31		67	0.007
19	0.59		68	0.009
20	>8.7		69	0.11
21	>6.1		70	0.95
22	0.069		71	0.04
23	>10		72	0.078
24	0.045		73	0.024
25	>3.4		74	0.65
26	>5.8		75	0.026
27	0.042		76	0.025
28	0.061		77	1.2
29	0.92		78	0.19
30	1.1		79	0.62
31	>9.6		80	0.19
32	0.22		81	1.3
33	0.18		82	0.54
34	4.3		83	33
35	0.12		84	0.016
36	0.53		85	1.38
37	0.36		86	1.5
38	2.4		87	>32
39	1.25		88	0.038
40	0.065		89	0.48
41	0.04		90	0.51
42	0.3		91	2.2
43	0.19		92	1.1
44	24		93	0.93
45	0.018		94	2.4
46	0.32		95	5.3
47	>5.3		96	15
48	0.27		97	0.14
49	0.31			

Cytotoxicity (MTT) Assay

Cytotoxicity of the compounds was determined in experiments done in parallel with the antiviral assays. To do this, 100 μ L of assay medium was added to the wells of HEp-2 cells pretreated with 100 μ L serially diluted compounds as described above. After 4 days of incubation, the viability of the cells was determined by the MTT assay in the same way as detailed in the "Antiviral Assay" method. Results were expressed as 50% toxicity dose (TD₅₀) values. Results are shown in Table 2.

Compound Testing Strategy

Compounds were tested to determine both their antiviral and toxicity to determine their therapeutic window. Determination of the EC₅₀ and TD₅₀ of these active compounds were repeated one additional time to confirm the window. Results are shown in Table 2.


Table 2.

Example	RSV EC ₅₀ (μ M)	MTT TD ₅₀ (μ M)	Window (TD ₅₀ /EC ₅₀)
1	0.15	23.00	153
2	2.05	7.17	3
3	2.79	8.04	3
4	23.5	39.00	1.6

15 *General Synthesis*

Additional information about the preparation of compounds of formulas I (and their salts) is provided in the general discussion and/or specific synthesis examples below. In the discussion below, R¹, R², R³, R⁴, R⁵, R⁶, R^g, and G¹ have the meaning discussed above unless otherwise stated.


The disclosed compounds may be made by methods known in the art including the methods described below and variations thereof.



Certain disclosed compounds can be prepared as shown generally in Scheme 1.

25 Dichloropyrimidines of formula (1-1) can be reacted with amines, R¹-NH(R⁶), at ambient temperature or heated in a solvent such as ethanol as described by Martyn DC, et al. *Bioorganic and Medicinal Chemistry Letters* 2010; 20: 228-231 to give compounds of formula (1-2). Dichloropyrimidines of formula (1-1) can also be reacted with amines, R¹-NH(R⁶), at ambient temperature or heated in a solvent such as *N,N*-dimethylformamide in the presence of a base such as cesium carbonate or

triethylamine to give compounds of formula (1-2). Compounds of formula (1-2) can be reacted with amines of formula (1-3) heated either conventionally or by microwave irradiation in solvents such as acetonitrile, dioxane or isopropanol optionally in the presence of an acid such as hydrochloric acid in dioxane to give compounds of formula (1-4). Compounds of formula (1-4) are representative of
 5 compounds of formula (I).



Certain disclosed compounds can be prepared as shown generally in Scheme 2. Compounds
 10 of formula (2-1) can be reacted with amines of formula (1-3) heated either conventionally or by microwave irradiation in solvents such as dimethyl sulfoxide to give compounds of formula (2-2). Compounds of formula (2-2) can be reacted with phosphorus(V) oxychloride in the presence of a catalytic amount of *N,N*-dimethylformamide (DMF) with heating to give compounds of formula (2-3). Compounds of formula (2-3) can be reacted with amines, R¹-NH(R⁶), heated in a solvent such as
 15 acetonitrile optionally in the presence of an acid catalyst such as hydrochloric acid in dioxane to give compounds of formula (1-4). Compounds of formula (1-4) are representative of compounds of formula (I).

In the foregoing Schemes, compounds are shown wherein an aromatic ring (e.g., phenyl) is
 20 substituted with groups in a particular regiochemistry (e.g., para). A starting material or intermediate with para-substitution provides a final product with para-substitution in the foregoing Schemes. It is understood by one of skill in the art that substitution in the foregoing Schemes of a starting material or intermediate with a different regiochemistry (e.g., meta) would provide a final product with a different regiochemistry. For example, replacement of a para-substituted starting material or intermediate in

the foregoing Schemes with a meta substituted starting material or intermediate would lead to a meta-substituted product.

If a moiety described herein (e.g., -NH₂ or -OH) is not compatible with the synthetic methods, the moiety may be protected with a suitable protecting group that is stable to the reaction conditions used in the methods. The protecting group may be removed at any suitable point in the reaction sequence to provide a desired intermediate or target compound. Suitable protecting groups and methods for protecting or deprotecting moieties are well known in the art, examples of which can be found in Greene TW and Wuts PGM, *Protective Groups in Organic Synthesis*, (3rd ed., John Wiley & Sons, NY (1999)). Optimum reaction conditions and reaction times for each individual step may vary depending on the particular reactants employed and substituents present in the reactants used. Solvents, temperatures and other reaction conditions may be readily selected by one of ordinary skill in the art based on the present disclosure.

Other disclosed compounds can be similarly prepared according to the above-described schemes as well as the procedures described in the following disclosure of intermediates, procedures, and examples as appreciated by those skilled in the art. It should be understood that the above-described embodiments and schemes and the following intermediates, general procedures, and examples disclosure are given by way of illustration, not limitation. Various changes and modifications within the scope of the present disclosure will become apparent to those skilled in the art from the present description.

20 Examples

Abbreviations: DMSO for dimethyl sulfoxide; and ESI for electrospray ionization.

Example 1

25 *N*⁴-cyclohexyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

Step A

5,6-dimethyl-2-thioxo-2,3-dihydropyrimidin-4(1*H*)-one

To a stirred solution of potassium *tert*-butoxide (15.71 g, 0.140 mol) in tetrahydrofuran (200 mL) was added a solution of ethyl 2-methyl-3-oxobutanoate (20.0 g, 0.14 mol) and thiourea (10.55 g, 0.14 mol) in dry ethanol (150 mL). The resulting mixture was refluxed for 15 minutes and cooled down to ambient temperature. The formed precipitate was collected by filtration, washed with tetrahydrofuran (200 mL), and dissolved in water (200 mL). Acetic acid (100 mL) was added in to the resulting solution. The formed precipitate was collected by filtration and dried to yield 17g (78.5%) of the titled compound. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.74 (s, 3H) 2.09 (s, 3H) 12.19 (s, 1H).

Step B

5,6-dimethylpyrimidine-2,4(1*H*,3*H*)-dione

A solution of 5,6-dimethyl-2-thioxo-2,3-dihydropyrimidin-4(1*H*)-one (14.4 g, 0.09 mol, Step A) and chloroacetic acid (100.0 g, 1.06 mol) in water (43 mL) was refluxed overnight, cooled down to ambient temperature and quenched with water (500 mL). The formed precipitate was collected by filtration and dried to yield 10.3 g (79.7 %) of the titled compound. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.70 (s, 3H) 2.02 (s, 3H) 10.56 (s, 1H) 10.86 (s, 1H).

Step C

2,4-dichloro-5,6-dimethylpyrimidine

To a stirred solution of 5,6-dimethylpyrimidine-2,4(1*H*,3*H*)-dione (10.3 g, 0.07 mol, Step B) in phosphorus(V) oxychloride (150 mL) was added dimethylformamide (0.2 mL). The resulting mixture was refluxed overnight under argon and cooled down to ambient temperature. The resulting mixture was evaporated. Toluene (200 mL) was added to the residue. The resulting mixture was concentrated. Cold water with ice (400 mL) was added to the residue, and the mixture was extracted with chloroform (3 × 150 mL). The combined organic layers were washed with brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate/hexane mixture (1:2-1:1) to yield 9.5 g (73%) of the titled compound. ¹H NMR (400 MHz, CDCl₃) δ ppm 2.35 (s, 3H) 2.55 (s, 3H).

Step D

2-chloro-*N*-cyclohexyl-5,6-dimethylpyrimidin-4-amine

To a stirred solution of 2,4-dichloro-5,6-dimethylpyrimidine (9.3 g, 0.05 mol, Step C) in dimethylformamide (100 mL) was added cesium carbonate (37.6 g, 0.12 mol). Cyclohexylamine (5.7 g, 0.058 mol) was then added, keeping the temperature of the reaction mixture at 70 °C. After 48 hours, the reaction mixture was concentrated, and the residue was quenched with water (200 mL). The resulting mixture was extracted with dichloromethane (3 × 120 mL). The combined organic layers were washed with brine, dried over magnesium sulfate, filtered, and concentrated. The solvent was removed by distillation, and the crude product was purified by column chromatography on silica gel eluting with ethyl acetate/methanol (10:1---10:2) to yield 4.9 g (38.9%) of the titled compound. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.05 - 1.14 (m, 1H), 1.28 - 1.33 (m, 4H), 1.61 (d, *J*=12.36 Hz, 1H), 1.72 (s, 2H), 1.80 (s, 2H), 1.93 (s, 3H), 2.19 (s, 3H), 3.85 (d, *J*=7.52 Hz, 1H), 6.66 (d, *J*=7.79 Hz, 1H); MS (ESI) *m/z* 240.3 (M+1)⁺.

Step E

*N*⁴-cyclohexyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine hydrochloride

To a stirred solution of 2-chloro-*N*-cyclohexyl-5,6-dimethylpyrimidin-4-amine (0.1 g, 0.40 mmol) and (pyridin-2-ylmethyl)amine (0.04 g, 0.400 mmol) in acetonitrile (5 mL) was added a 3.5 M solution of hydrogen chloride in dioxane (0.2 mL). The resulting mixture was irradiated in CEM Focused Microwave™ Synthesis System at 160° C for 120 minutes. The resulting mixture was cooled to ambient temperature. The formed precipitate was collected by filtration and dried to yield 0.07g (48.2%) of the titled compound as the hydrochloride salt. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 0.99 - 1.03 (m, 2H), 1.13 (d, *J*=12.63 Hz, 1H), 1.20 - 1.26 (m, 2H), 1.51 - 1.59 (m, 2H), 1.60 - 1.63 (m, 3H), 1.89 (s, 3H), 2.24 (s, 3H), 3.70 (s, 1H), 4.62 (d, *J*=5.10 Hz, 2H), 7.24 (dd, *J*=7.25, 4.84 Hz, 1H), 7.31 (d, *J*=7.79 Hz, 1H), 7.58 (d, *J*=7.72 Hz, 1H), 7.74 (t, *J*=7.66 Hz, 1H), 8.1 (s, 1H), 8.50 (d, *J*=4.84 Hz, 1H); MS (ESI) *m/z* 312.3 (M+1)⁺.

Examples 2-4 can be prepared using the methodology described in Scheme 1 and the reference cited therein.

Example 2

*N*⁴-(2-methylbenzyl)-*N*²-(pyridin-2-ylmethyl)-6,7-dihydro-5*H*-cyclopenta[*d*]pyrimidine-2,4-diamine

¹H NMR (500 MHz, DMSO-*d*₆/D₂O) δ ppm 8.43 (d, *J* = 4.9 Hz, 1H), 7.59-7.64 (m, 1H), 7.08-7.25 (m, 5H), 7.02-7.07 (m, 1H), 4.47-4.47 (bs, 2H), 4.41-4.43 (m, 2H), 2.55-2.60 (m, 4H), 2.21-2.22 (m, 3H), 1.94 (p, *J* = 7.4 Hz, 2H); MS (ESI) (ESI+) *m/z* 346 (M+1)⁺.

20

Example 3

*N*⁴-cycloheptyl-6-methyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

¹H NMR (400 MHz, DMSO-*d*₆/D₂O, temperature 90 °C) δ ppm 8.48 (d, *J* = 4.0 Hz, 1H), 7.71 (td, *J* = 7.6, 1.8 Hz, 1H), 7.32 (d, *J* = 7.9 Hz, 1H), 7.21-7.26 (m, 1H), 6.59 (s, 2H), 5.71 (s, 1H), 4.58 (s, 2H), 3.75-3.87 (m, 1H), 2.09 (s, 3H), 1.67-1.81 (m, 2H), 1.30-1.63 (m, 10H).

25

Example 4

*N*⁴-cyclohexyl-6-methyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 12.23-12.39 (m, 1H), 8.52-8.56 (m, 2H), 8.26-8.30 (m, 1H), 7.84 (td, *J* = 7.7, 1.6 Hz, 1H), 7.40 (d, *J* = 7.8 Hz, 1H), 7.34 (dd, *J* = 7.4, 5.0 Hz, 1H), 5.83 (s, 1H), 4.65 (d, *J* = 5.6 Hz, 2H), 2.21 (s, 3H), 1.48-1.70 (m, 5H), 0.92-1.31 (m, 5H).

30

Example 5

*N*²-benzyl-*N*⁴-cyclohexyl-5,6-dimethylpyrimidine-2,4-diamine

The titled compound was synthesized according to the general procedure described for preparation of *N*⁴-cyclohexyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example

35

1) using benzylamine instead of (pyridin-2-ylmethyl)amine to afford the crude product. The solvent was removed by distillation, and the crude product was purified by HPLC (column: YMC-PACK ODS-AQ C18, 250 mm × 20 mm, 10 μm; gradient: 20-50% acetonitrile in 0.02% trifluoroacetic acid/water over fifteen minutes; 50-100% acetonitrile in 0.02% trifluoroacetic acid/water over five minutes; flow rate: 25 mL/min; temperature: 25 °C). The titled compound was obtained as the trifluoroacetic acid salt as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.03 - 1.15 (m, 1H), 1.22 - 1.31 (m, 4H), 1.60 (d, *J*=12.63 Hz, 1H), 1.68 (s, 4H), 1.86 (s, 3H), 2.21 (s, 3H), 3.86 - 3.90 (m, 1H), 4.52 (d, *J*=5.64 Hz, 2H), 7.20 - 7.25 (m, 1H), 7.27 - 7.33 (m, 4H), 7.4 (bs, 1H), 8.02 (bs, 1H); MS (ESI) *m/z* 311.5 (M+1)⁺.

10

Example 6

*N*⁴-cyclohexyl-5,6-dimethyl-*N*²-(pyridin-3-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the general procedure described for preparation of *N*⁴-cyclohexyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 1) using 1-pyridin-3-ylmethanamine instead of (pyridin-2-ylmethyl)amine to afford the crude product. The solvent was removed by distillation, and the crude product was purified by HPLC (column: YMC-PACK ODS-AQ C18, 250 mm × 20 mm, 10 μm; gradient: 20-50% acetonitrile in 0.02% trifluoroacetic acid/water over fifteen minutes; 50-100% acetonitrile in 0.02% trifluoroacetic acid/water over five minutes; flow rate: 25 mL/min; temperature: 25 °C) to afford the titled compound as the trifluoroacetate as a white solid. ¹H NMR (400 MHz, CDCl₃) δ ppm 1.08 - 1.34 (m, 5H), 1.50 - 1.61 (m, 3H) 1.62 - 1.69 (m, 2H), 1.87 (s, 3H), 2.23 (s, 3 H), 3.71 - 3.79 (m, 1H), 4.63 (d, *J*=5.10 Hz, 2H), 7.60 (d, *J*=7.79 Hz, 1H), 7.64 (dd, *J*=7.66, 5.24 Hz, 1H), 8.05 (d, *J*=7.79 Hz, 1H), 8.62 (d, *J*=4.57 Hz, 1H) 8.62 -8.69 (m, 1H) 8.71 (s, 1H), 12.61 (bs, 1H); MS (ESI) *m/z* 312.5 (M+1)⁺.

25

Example 7

2-({[4-(cyclohexylamino)-5,6-dimethylpyrimidin-2-yl]amino}methyl)-6-methylpyridin-3-ol

The titled compound was synthesized according to the general procedure described for preparation of *N*⁴-cyclohexyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 1) using 2-(aminomethyl)-6-methylpyridin-3-ol instead of (pyridin-2-ylmethyl)amine. The crude product was purified by HPLC (column: YMC-PACK ODS-AQ C18, 250 mm × 20 mm, 10 μm; gradient: 20-50% acetonitrile in 0.02% trifluoroacetic acid/water over fifteen minutes; 50-100% acetonitrile in 0.02% trifluoroacetic acid/water over five minutes; flow rate: 25 mL/min; temperature: 25 °C) to afford the titled compound as the trifluoroacetate salt as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.21 - 1.28 (m, 5H), 1.61 - 1.65 (m, 5H), 1.89 (s, 3H), 2.24 (s, 3H), 3.78 (s, 1H), 4.70 (d, *J*=4.82 Hz, 2H), 7.38 (d, *J*=8.55 Hz, 1 H), 7.59 (d, *J*=3.73 Hz, 2H), 8.31 (s, 1 H), 12.78 (bs, 1H); MS (ESI) *m/z* 342.8 (M+1)⁺.

35

Example 8

*N*⁴-cyclohexyl-*N*²-(4-methoxybenzyl)-5,6-dimethylpyrimidine-2,4-diamine

The titled compound was synthesized according to the general procedure described for preparation of *N*⁴-cyclohexyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 1) using (4-methoxybenzyl)amine instead of (pyridin-2-ylmethyl)amine. The product was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.10 - 1.13 (m, 1H), 1.24 - 1.35 (m, 3H), 1.62 (d, *J*=13.16 Hz, 1H), 1.72 (d, *J*=9.94 Hz, 4H), 1.87 (s, 3 H), 2.22 (s, 3H), 3.72 (s, 3H), 3.94 (s, 1H), 4.46 (d, *J*=5.37 Hz, 2H), 6.88 (s, 2H), 7.26 (s, 2H), 7.57 (s, 1H), 8.01 (s, 1H), 12.66 (bs, 1H); MS (ESI) *m/z* 341.7 (M+1)⁺.

Example 9

*N*⁴-cyclohexyl-*N*²-(4-fluorobenzyl)-5,6-dimethylpyrimidine-2,4-diamine

The titled compound was synthesized according to the general procedure described for preparation of *N*⁴-cyclohexyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 1) using (4-fluorobenzyl)amine instead of (pyridin-2-ylmethyl)amine. The product was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.03 - 1.10 (m, 1H), 1.20 - 1.34 (m, 2H), 1.59 (s, 1H), 1.68 (t, *J*=12.22 Hz, 4H), 1.87 (s, 3H), 2.23 (s, 3H), 3.86 (d, *J*=8.87 Hz, 1H), 4.52 (d, *J*=5.37 Hz, 2 H), 7.14 (t, *J*=8.60 Hz, 2 H), 7.33 - 7.38 (m, 2H), 7.57 (d, *J*=7.52 Hz, 1H), 8.10 (s, 1H), 12.78 (bs, 1H); MS (ESI) *m/z* 329.2 (M+1)⁺.

Example 10

*N*⁴-cyclohexyl-5,6-dimethyl-*N*²-[4-(trifluoromethoxy)benzyl]pyrimidine-2,4-diamine

The titled compound was synthesized according to the general procedure described for preparation of *N*⁴-cyclohexyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 1) using [4-(trifluoromethoxy)benzyl]amine instead of (pyridin-2-ylmethyl)amine. The product was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.19 - 1.28 (m, 3H), 1.59 (d, *J*=13.59 Hz, 4H), 1.67 (s, 1H), 1.86 (s, 3H), 2.23 (s, 3H), 3.79 (s, 1H), 4.56 (d, *J*=5.04 Hz, 2H), 7.30 (d, *J*=8.11 Hz, 2H), 7.40 - 7.45 (m, 2H), 7.57 (d, *J*=7.23 Hz, 1H), 8.18 (t, *J*=5.26 Hz, 1H), 12.85 (bs, 1H); MS (ESI) *m/z* 394.8 (M+1)⁺.

Example 11

*N*⁴-cyclohexyl-*N*²-(4-isopropylbenzyl)-5,6-dimethylpyrimidine-2,4-diamine

The titled compound was synthesized according to the general procedure described for preparation of *N*⁴-cyclohexyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 1) using (4-isopropylbenzyl)amine instead of (pyridin-2-ylmethyl)amine. The product was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.08 (d, *J*=15.04 Hz, 1H), 1.17 (d, *J*=6.72 Hz, 6H), 1.24 - 1.31 (m, 4H), 1.60 (s, 1H), 1.68 (t, *J*=11.95 Hz, 4H), 1.87 (s, 3H), 2.22 (s, 3H), 2.84 (t, *J*=13.90, 6.88 Hz, 1H), 3.89 (d, *J*=7.52 Hz, 1H), 4.48 (d, *J*=5.37 Hz, 2H), 7.14 - 7.28 (m, 4H), 7.55 (d, *J*=7.52 Hz, 1H), 8.06 (s, 1H), 12.69 (bs, 1H); MS (ESI) *m/z* 353.0 (M+1)⁺.

Example 12

*N*⁴-cyclohexyl-5,6-dimethyl-*N*²-[4-(trifluoromethyl)benzyl]pyrimidine-2,4-diamine

The titled compound was synthesized according to the general procedure described for preparation of *N*⁴-cyclohexyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 1) using [4-(trifluoromethyl)benzyl]amine instead of (pyridin-2-ylmethyl)amine. The product was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.12 - 1.21 (m, 5H), 1.44 - 1.59 (m, 5H), 1.86 (s, 3H), 2.24 (s, 3H), 3.71 (d, *J*=10.74 Hz, 1H), 4.62 (d, *J*=4.82 Hz, 2H), 7.50 - 7.58 (m, 3H), 7.67 (d, *J*=8.11 Hz, 2H), 8.20 (t, *J*=5.15 Hz, 1H), 12.99 (bs, 1H); MS (ESI) *m/z* 379.1 (M+1)⁺.

Example 13

*N*⁴-cyclohexyl-*N*²-(3-fluorobenzyl)-5,6-dimethylpyrimidine-2,4-diamine

The titled compound was synthesized according to the general procedure described for preparation of *N*⁴-cyclohexyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 1) using (3-fluorobenzyl)amine instead of (pyridin-2-ylmethyl)amine. The product was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.08 (t, *J*=13.57 Hz, 1H), 1.19 - 1.31 (m, 4H), 1.58 - 1.70 (m, 5H), 1.87 (s, 3H), 2.22 (s, 3H), 3.82 (d, *J*=6.98 Hz, 1H), 4.53 (d, *J*=5.91 Hz, 2H), 7.01 - 7.11 (m, 2H), 7.14 (d, *J*=7.25 Hz, 2H), 7.32 - 7.39 (m, 1H), 7.56 (d, *J*=7.79 Hz, 1H), 8.35 (s, 1H), 12.47 (s, 1H); MS (ESI) *m/z* 329.0 (M+1)⁺.

35

Example 14

*N*⁴-cyclohexyl-5,6-dimethyl-*N*²-(1*H*-pyrazol-5-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the general procedure described for preparation of *N*⁴-cyclohexyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 1) using (1*H*-pyrazol-5-ylmethyl)amine instead of (pyridin-2-ylmethyl)amine. The product was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a light-yellow solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.28 - 1.37 (m, 5H), 1.60 - 1.69 (m, 5H), 1.86 (s, 3H), 2.25 (s, 3H), 3.98 (d, *J*=10.74 Hz, 1H), 4.52 (d, *J*=4.82 Hz, 2H), 6.12 (s, 1H), 7.59 (s, 1H), 7.98 (s, 1H), 12.15 (bs, 1H); MS (ESI) *m/z* 301.5 (M+1)⁺.

Example 15

*N*⁴-cyclohexyl-5,6-dimethyl-*N*²-[(1*R*)-1-phenylethyl]pyrimidine-2,4-diamine

The titled compound was synthesized according to the general procedure described for preparation of *N*⁴-cyclohexyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 1) using [(1*R*)-1-phenylethyl]amine instead of (pyridin-2-ylmethyl)amine. The product was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a light-yellow solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.03-1.87 (m, 16 H), 2.13 (s, 3 H), 3.80 (s, 1 H), 4.95 - 5.02 (m, 1 H), 6.73 (s, 1 H), 7.14-7.41 (m, 5 H), 8.38 (s, 1 H); MS (ESI) *m/z* 325.1 (M+1)⁺.

Example 16

*N*⁴-cyclohexyl-5,6-dimethyl-*N*²-[(1*S*)-1-phenylethyl]pyrimidine-2,4-diamine

The titled compound was synthesized according to the general procedure described for preparation of *N*⁴-cyclohexyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 1) using [(1*S*)-1-phenylethyl]amine instead of (pyridin-2-ylmethyl)amine. The product was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a light-yellow solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.03-1.87 (m, 16 H), 2.13 (s, 3 H), 3.80 (s, 1 H), 4.95-5.02 (m, 1 H), 6.73 (s, 1 H), 7.14-7.41 (m, 5 H), 8.38 (s, 1 H); MS (ESI) *m/z* 325.8 (M+1)⁺.

Example 17

*N*⁴-cyclohexyl-5,6-dimethyl-*N*²-[(4-methylpyridin-2-yl)methyl]pyrimidine-2,4-diamine

The titled compound was synthesized according to the general procedure described for preparation of *N*⁴-cyclohexyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 1) using (4-methylpyridin-2-yl)methanamine instead of (pyridin-2-ylmethyl)amine. The product was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a light-grey solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 0.92-1.67 (m, 10H), 1.88 (s, 3H), 2.28 (s, 3H), 2.53 (s, 3H), 3.63 (bs, 1 H), 4.92 (d, *J*=4.30 Hz, 2H), 7.60-7.80 (m, 3H), 8.19 (bs, 1H), 8.66 (d, *J*=5.64 Hz, 1H), 13.34 (s, 1H); MS (ESI) *m/z* 326.0 (M+1)⁺.

Example 18

*N*⁴-cyclohexyl-*N*²-[(4-methoxypyridin-2-yl)methyl]-5,6-dimethylpyrimidine-2,4-diamine

The titled compound was synthesized according to the general procedure described for preparation of *N*⁴-cyclohexyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 1) using [(4-methoxypyridin-2-yl)methyl]amine instead of (pyridin-2-ylmethyl)amine. The product was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a light-grey solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.07 (d, *J*=11.01 Hz, 3H), 1.23 (d, *J*=11.01 Hz, 2H), 1.47 (d, *J*=9.94 Hz, 2H), 1.60 (s, 3H), 1.88 (s, 3H), 2.25 (s, 3H), 4.73 (d, *J*=5.37 Hz, 2H), 7.22 - 7.29 (m, 2H), 7.59 (d, *J*=7.79 Hz, 1H), 8.53 - 8.56 (m, 2H), 12.88 (bs, 1H); MS (ESI) *m/z* 342.7 (M+1)⁺.

Example 19

*N*⁴-cyclohexyl-5,6-dimethyl-*N*²-[(6-methylpyridin-2-yl)methyl]pyrimidine-2,4-diamine

The titled compound was synthesized according to the general procedure described for preparation of *N*⁴-cyclohexyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 1) using [(6-methylpyridin-2-yl)methyl]amine instead of (pyridin-2-ylmethyl)amine. The product was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a light-grey solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.13 - 1.18 (m, 5H), 1.56 - 1.59 (m, 5H), 1.87 (s, 3H), 2.21 (s, 3H), 2.49 (s, 3H), 3.63 (d, *J*=6.72 Hz, 1H), 4.62 (d, *J*=4.30 Hz, 2H), 7.21 - 7.23 (m, 2H), 7.56 (d, *J*=5.64 Hz, 1H), 7.76 - 7.80 (m, 1H), 8.24 (s, 1H), 12.39 (s, 1H); MS (ESI) *m/z* 326.5 (M+1)⁺.

Example 20

N^4 -cyclohexyl-5,6-dimethyl- N^2 -{[5-(trifluoromethyl)pyridin-2-yl]methyl}pyrimidine-2,4-diamine

The titled compound was synthesized according to the general procedure described for preparation of N^4 -cyclohexyl-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 1) using {5-(trifluoromethyl)pyridin-2-yl]methyl}amine instead of (pyridin-2-ylmethyl)amine. The product was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a light-grey solid. ^1H NMR (300 MHz, DMSO- d_6) δ ppm 1.04 - 1.16 (m, 3H), 1.16 - 1.19 (m, 2H), 1.38 (d, $J=10.21$ Hz, 2H), 1.55 (s, 3H), 1.86 (s, 3H), 2.26 (bs, 3H) 3.53 (d, $J=5.37$ Hz, 1H), 4.73 (s, 2H), 7.53 (d, $J=7.52$ Hz, 2H), 8.15 (d, $J=7.79$ Hz, 2H), 8.89 (s, 1H), 12.98 (bs, 1H); MS (ESI) m/z 380.0 (M+1) $^+$.

Example 21

N^2 -[(4-*tert*-butylpyridin-2-yl)methyl]- N^4 -cyclohexyl-5,6-dimethylpyrimidine-2,4-diamine

The titled compound was synthesized according to the general procedure described for preparation of N^4 -cyclohexyl-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 1) using [(4-*tert*-butylpyridin-2-yl)methyl]amine instead of (pyridin-2-ylmethyl)amine. The product was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a light-grey solid. ^1H NMR (300 MHz, DMSO- d_6) δ ppm 1.02 - 1.10 (m, 3H), 1.24 (d, $J=11.01$ Hz, 11H), 1.42 (d, $J=10.48$ Hz, 2H), 1.55 (d, $J=9.94$ Hz, 3H), 1.90 (s, 3H) 2.29 (s, 3H), 3.43 (s, 1H), 4.71 (d, $J=5.10$ Hz, 2H), 7.52 (s, 2H) 7.59 (d, $J=7.52$ Hz, 1H), 8.21 (s, 1H), 8.53 (d, $J=6.72$ Hz, 1H), 12.48 (s, 1H); MS (ESI) m/z 368.1 (M+1) $^+$.

Example 22

N^4 -cyclohexyl-5,6-dimethyl- N^2 -(2-thienylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the general procedure described for preparation of N^4 -cyclohexyl-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 1) using (2-thienylmethyl)amine instead of (pyridin-2-ylmethyl)amine. The crude product was purified by crystallization from ethanol (10 mL) to afford the titled compound as the hydrochloride salt as a light-grey solid. ^1H NMR (300 MHz, DMSO- d_6) δ ppm 1.20-1.35 (m, 5H), 1.65-1.79 (m, 5H), 1.89 (s, 3H), 2.23 (s, 3H), 4.08 (bs, 1H), 4.71 (d, $J=4.57$ Hz, 2H), 6.96 (s, 1H), 7.05 (s, 1H), 7.40 (d, $J=4.57$ Hz, 1H), 7.70 (d, $J=6.72$ Hz, 1H), 8.07 (s, 1H); MS (ESI) m/z 317.7 (M+1) $^+$.

Example 23

*N*⁴-cyclohexyl-*N*²-[(3,5-dimethyl-1,2-oxazol-4-yl)methyl]-5,6-dimethylpyrimidine-2,4-diamine

The titled compound was synthesized according to the general procedure described for preparation of *N*⁴-cyclohexyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 1) using [(3,5-dimethylisoxazol-4-yl)methyl]amine instead of (pyridin-2-ylmethyl)amine. The product was purified by HPLC (column: YMC-PACK ODS-AQ C18, 250 mm × 20 mm, 10 μm; gradient: 20-50% acetonitrile in 0.02% trifluoroacetic acid/water over fifteen minutes; 50-100% acetonitrile in 0.02% trifluoroacetic acid/water over five minutes; flow rate: 25 mL/min; temperature: 25 °C) to afford the titled compound as the trifluoroacetate salt as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.23 - 1.40 (m, 5H), 1.70 (d, *J*=12.90 Hz, 1H), 1.75 - 1.82 (m, 2H), 1.91 (s, 3H), 2.00 (d, *J*=12.63 Hz, 2H), 2.32 (d, *J*=9.40 Hz, 6H), 2.43 (s, 3H), 4.05 - 4.10 (m, 1H), 4.38 (d, *J*=5.64 Hz, 2H), 5.21 (d, *J*=7.79 Hz, 1H), 9.64 (s, 1H), 14.01 (s, 1H); MS (ESI) *m/z* 330.9 (M+1)⁺.

Example 24

*N*⁴-cyclohexyl-5,6-dimethyl-*N*²-[(1-methyl-1*H*-imidazol-4-yl)methyl]pyrimidine-2,4-diamine

The titled compound was synthesized according to the general procedure described for preparation of *N*⁴-cyclohexyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 1) using [(1-methyl-1*H*-imidazol-4-yl)methyl]amine instead of (pyridin-2-ylmethyl)amine. The product was purified by crystallization from ethanol (10 mL) to afford the titled compound as the hydrochloride salt as a white solid. ¹H NMR (300 MHz, methanol-*d*₄) δ ppm 1.25 - 1.38 (m, 5H), 1.70 - 1.85 (m, 5H), 1.97 (s, 3H), 2.30 (s, 3H), 2.71 (s, 1H), 3.72 (s, 3H), 4.08 (s, 1H), 4.53 (s, 2H), 7.07 (s, 1H), 7.72 (s, 1H); MS *m/z* 315.7 (M+1)⁺.

Example 25

*N*⁴-cyclohexyl-*N*²-(3-methoxybenzyl)-5,6-dimethylpyrimidine-2,4-diamine

The titled compound was synthesized according to the general procedure described for preparation of *N*⁴-cyclohexyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 1) using (3-methoxybenzyl)amine instead of (pyridin-2-ylmethyl)amine. The crude product was purified by crystallization from ethanol (10 mL) to afford the titled compound as the hydrochloride salt as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.15 - 1.28 (m, 5H), 1.60 - 1.80 (m, 5H), 1.87 (s, 3H), 2.21 (s, 3H), 3.72 (s, 3H), 3.86 (s, 1H), 4.48 (d, *J*=5.64 Hz, 2H), 6.75-6.89 (m, 3H), 7.23 (t, *J*=7.93 Hz, 1H), 7.56 (d, *J*=7.52 Hz, 1H), 8.40 - 8.55 (m, *J*=38.95 Hz, 1H), 12.56 (s, 1H); MS (ESI) *m/z* 341.5 (M+1)⁺.

35

Example 26

*N*⁴-cyclohexyl-5,6-dimethyl-*N*²-[(3-methylpyridin-2-yl)methyl]pyrimidine-2,4-diamine

The titled compound was synthesized according to the general procedure described for preparation of *N*⁴-cyclohexyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 1) using [(3-methylpyridin-2-yl)methyl]amine instead of (pyridin-2-ylmethyl)amine. The crude product was purified by crystallization from ethanol (10 mL) to afford the titled compound as the hydrochloride salt as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.10 - 1.20 (m, 5H), 1.55-1.75 (m, 5H), 1.89 (s, 3H), 2.25 (s, 3H), 2.33 (s, 3H), 3.83 (s, 1H), 4.63 (d, *J*=5.10 Hz, 2H), 7.15 - 7.25 (m, 1H), 7.50 - 7.65 (m, 2H), 7.91 (s, 1H), 8.34 (d, *J*=4.03 Hz, 1H), 12.62 (s, 1H); MS (ESI) *m/z* 326.9 (M+1)⁺.

Example 27

*N*²-[(4-chloropyridin-2-yl)methyl]-*N*⁴-cyclohexyl-5,6-dimethylpyrimidine-2,4-diamine

The titled compound was synthesized according to the general procedure described for preparation of *N*⁴-cyclohexyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 1) using [(4-chloropyridin-2-yl)methyl]amine instead of (pyridin-2-ylmethyl)amine. The crude product was purified by crystallization from ethanol (10 mL) to afford the titled compound as the hydrochloride salt as a white solid. ¹H NMR (300 MHz, methanol-*d*₄) δ ppm 1.16 - 1.28 (m, 5H), 1.55 - 1.75 (m, 5H), 1.96 (s, 3H), 2.32 (s, 3H), 3.80 (s, 1H), 4.70 (s, 2H), 7.39 (d, *J*=3.76 Hz, 1H), 7.48 (s, 1H), 8.46 (d, *J*=5.10 Hz, 1H); MS (ESI) *m/z* 346.0, 348.1 (M+1)⁺.

Example 28

*N*⁴-(4,4-difluorocyclohexyl)-5,6-dimethyl-*N*²-[(4-methylpyridin-2-yl)methyl]pyrimidine-2,4-diamine

Step A

2-chloro-*N*-(4,4-difluorocyclohexyl)-5,6-dimethylpyrimidin-4-amine

To the solution of 2,4-dichloro-5,6-dimethylpyrimidine (0.585g, 3.304 mmol, Example 1, Step C) in *N,N*-dimethylformamide (10 mL), (4,4-difluorocyclohexyl)amine hydrochloride (0.652 g, 3.800 mmol) and triethylamine (1.338 g, 13.218 mmol) were added, and reaction mixture was heated at 50 °C overnight. Volatiles were removed under reduced pressure, and the residue was poured into water (300 mL). The mixture was extracted with ether (3 × 50 mL), dried over sodium sulfate, filtered, and concentrated. The residue was subjected to column chromatography on silica eluting with a mixture of hexane/ethyl acetate (gradient 4:1 - 2:1) to provide 621 mg (68%) of the titled compound as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.18-1.24 (m, 1 H), 1.60-1.72 (m, 2 H), 1.80-2.10 (m, 8H) 2.21 (s, 3H), 4.00-4.10 (m, 1H), 6.73 (d, *J*=7.79 Hz, 1 H); MS (ESI) *m/z* 318.6 (M+1)⁺.

Step B

N^4 -(4,4-difluorocyclohexyl)-5,6-dimethyl- N^2 -[(4-methylpyridin-2-yl)methyl]pyrimidine-2,4-diamine

The titled compound was synthesized according to the general procedure described for preparation of N^4 -cyclohexyl-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 1) using [(4-methylpyridin-2-yl)methyl]amine instead of (pyridin-2-ylmethyl)amine and 2-chloro- N -(4,4-difluorocyclohexyl)-5,6-dimethylpyrimidin-4-amine (Step A) instead of 2-chloro- N -cyclohexyl-5,6-dimethylpyrimidin-4-amine. The product was purified by crystallization from ethanol to afford the titled compound (45% yield) as the hydrochloride salt as a light-yellow solid. ^1H NMR (300 MHz, DMSO- d_6) δ ppm 1.45-1.55 (m, 4H), 1.80-2.05 (m, 7H), 2.28 (s, 3H), 2.52 (s, 3H), 4.05 (bs, 1H), 4.99 (d, $J=5.37$ Hz, 2H), 7.65-7.78 (m, 3H) 8.31 (s, 1H), 8.67 (d, $J=5.91$ Hz, 1H), 13.42 (s, 1H); MS (ESI) m/z 362.4 (M+1) $^+$.

Example 29

N^4 -cyclopentyl-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

15

Step A

5,6-dimethyl-2-(methylthio)pyrimidin-4(3H)-one

To a stirred solution of 5,6-dimethyl-2-thioxo-2,3-dihydropyrimidin-4(1H)-one (10.0 g, 64.0 mmol, Example 1, Step A) and sodium hydroxide (10.0 g, 260.0 mmol) in water (150 mL) at ambient temperature was added methyl iodide (15.0 g, 320.0 mmol), and the reaction mixture was stirred at ambient temperature overnight. Then the reaction mixture was acidified with acetic acid (50 mL), and the solid was collected by filtration and dried to afford 7.0 g (64%) of the titled compound as a white solid. ^1H NMR (300 MHz, DMSO- d_6) δ ppm 1.87 (s, 3H), 2.18 (s, 3H), 2.45 (s, 3H), 12.38 (bs, 1H).

25

Step B

5,6-dimethyl-2-[(pyridin-2-ylmethyl)amino]pyrimidin-4(3H)-one

To a stirred solution of (pyridin-2-ylmethyl)amine (5.8g, 54 mmol) in dimethyl sulfoxide (15 mL) at ambient temperature was added 5,6-dimethyl-2-(methylthio)pyrimidin-4(3H)-one (7 g, 41 mmol, Step A), and the resulting mixture was stirred at 150 °C overnight. Then water (100 mL) was added carefully into the hot reaction mixture. Upon cooling to ambient temperature, diethyl ether (30 mL) was added. The formed precipitate was collected by filtration and dried to afford 7.0 g (74%) of the titled product as a white solid. ^1H NMR (300 MHz, DMSO- d_6) δ ppm 1.77 (s, 3H), 2.04 (s, 3H), 4.55 (s, 2H), 6.81 (bs, 1H), 7.23 - 7.40 (m, 2H), 7.77 (t, $J=7.5$ Hz, 1H), 8.53 (bs, 1H), 10.84 (bs, 1H).

35

Step C

4-chloro-5,6-dimethyl-*N*-(pyridin-2-ylmethyl)pyrimidin-2-amine

A solution of 5,6-dimethyl-2-[(pyridin-2-ylmethyl)amino]pyrimidin-4(3*H*)-one (7.0 g, 32.6 mmol, Step B) in phosphorus(V) oxychloride (30 mL) with addition of 1 drop of dimethylformamide
 5 was refluxed overnight under nitrogen. Then excess phosphorus(V) oxychloride was removed under reduced pressure. Toluene (30 mL) was added, and the reaction mixture was evaporated under reduced pressure. The residue was diluted with 5% aqueous sodium bicarbonate (100 mL) and extracted with ethyl acetate (2 × 200 mL). The solvent was evaporated under reduced pressure, and the residue was subjected to column chromatography eluted with hexane/ethyl acetate (2:1). The
 10 titled compound 6.1 g (74%) was obtained as a light-yellow solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 2.10 (s, 3H), 2.39 (s, 3H), 4.54 (s, 2H), 7.20-7.30 (m, 2H), 7.68-7.76 (m, 2H), 7.76 (bs, 1H).

Step D

*N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

15 A solution of 4-chloro-5,6-dimethyl-*N*-(pyridin-2-ylmethyl)pyrimidin-2-amine (200 mg, 0.8 mmol, Step C) and cyclopentanamine (85 mg, 1 mmol) in acetonitrile (5 mL) was treated with 3.5 M hydrogen chloride in dioxane (0.2 mL), and the resultant mixture was refluxed overnight. The reaction mixture was diluted with water (50 mL), and the resultant precipitate was collected by filtration. The precipitate was purified by crystallization from ethanol (10 mL) to afford 42 mg (19%)
 20 of the titled compound as the hydrochloride salt as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.40 - 1.50 (m, 4H), 1.50 - 1.67 (m, 4H), 1.88 (s, 3H), 2.27 (s, 3H), 4.00 - 4.12 (m, 1H), 4.92 (d, *J*=4.57 Hz, 2H), 7.71 - 4.83 (m, 2H), 7.83 (d, *J*=8.06 Hz, 1H), 8.17 - 8.25 (m, 1H), 8.33 - 8.39 (m, 1H), 8.76 (d, *J*=5.10 Hz, 1H), 13.24 (bs, 1H); MS (ESI) *m/z* 398.5 (ESI) (M+1)⁺.

25

Example 30

5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)-*N*⁴-(tetrahydro-2*H*-pyran-4-yl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using tetrahydro-2*H*-pyran-4-amine instead of cyclopentanamine. The crude material was purified by
 30 column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a light-yellow solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.39 (bs, 2H), 1.52 (bs, 2H), 1.79 (d, *J*=16.39 Hz, 3H), 2.06 (d, *J*=8.87 Hz, 3H), 3.17 (d, *J*=11.01 Hz, 2H), 3.74 (d, 2H), 3.85 (bs, 1H), 4.44 (d, *J*=6.18 Hz, 2H), 5.81 (d, *J*=7.52 Hz, 1H), 6.73 (s, 1H), 7.12 - 7.16 (m, 1H), 7.23 (d, *J*=7.79 Hz,
 35 1H), 7.65 (t, *J*=7.66 Hz, 1H), 8.45 (d, *J*=4.84 Hz, 1H); MS (ESI) *m/z* 314.4 (M+1)⁺.

Example 31

5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)-*N*⁴-[4-(trifluoromethyl)cyclohexyl]pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using 4-(trifluoromethyl)cyclohexanamine instead of cyclopentanamine. The crude material was purified by HPLC (column: YMC-PACK ODS-AQ C18, 250 mm × 20 mm, 10 μm; gradient: 20-50% acetonitrile in 0.02% trifluoroacetic acid/water over fifteen minutes; 50-100% acetonitrile in 0.02% trifluoroacetic acid/water over five minutes; flow rate: 25 mL/min; temperature: 25 °C) to afford the titled compound as the trifluoroacetate as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.19 (d, *J*=10.30 Hz, 2H), 1.28 - 1.36 (m, 2H), 1.50 - 1.62 (m, 2H), 1.78 (d, *J*=5 Hz, 2H), 1.88 (s, 3H), 2.10 - 2.22 (m, 1H), 2.25 (s, 3H), 3.60 - 3.68 (m, 1H), 4.69 (d, *J*=5.04 Hz, 2H), 7.36 - 7.49 (m, 2H), 7.66 (d, *J*=7.72 Hz, 1H), 7.90 (t, *J*=7.72 Hz, 1H), 8.39 - 8.43 (m, 1H), 8.56 (d, *J*=4.60 Hz, 1H), 12.66 (bs, 1H); MS (ESI) *m/z* 380.8 (M+1)⁺.

15

Example 32

*N*⁴-(4,4-difluorocyclohexyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

A solution of 4-chloro-5,6-dimethyl-*N*-(pyridin-2-ylmethyl)pyrimidin-2-amine (200 mg, 0.8 mmol, Example 29, Step C) and (4,4-difluorocyclohexyl)amine hydrochloride (172 mg, 1 mmol) in acetonitrile (5 mL) was refluxed overnight. The reaction mixture was diluted with water (50 mL) and a formed precipitate was collected by filtration. The crude material was purified by HPLC (column: YMC-PACK ODS-AQ C18, 250 mm × 20 mm, 10 μm; gradient: 20-50% acetonitrile in 0.02% trifluoroacetic acid/water over fifteen minutes; 50-100% acetonitrile in 0.02% trifluoroacetic acid/water over five minutes; flow rate: 25 mL/min; temperature: 25 °C) to afford 114 mg, 25% of the titled compound as the trifluoroacetic acid salt as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.45-1.55 (m, 4H), 1.70-1.82 (m, 2H), 1.88 (s, 3H), 1.90-2.00 (m, 2H), 2.25 (s, 3H), 3.90 (bs, 1H), 4.70 (d, *J*=5.37 Hz, 2H), 7.38 (t, *J*=6.25 Hz, 1H), 7.47 (d, *J*=7.52 Hz, 1H), 7.64 (d, *J*=7.52 Hz, 1H), 7.90 (t, *J*=7.52 Hz, 1H), 8.46-8.52 (m, 1H), 8.57 (d, *J*=4.57 Hz, 1H), 12.78 (bs, 1H); MS (ESI) *m/z* 348.8 (M+1)⁺. *N*⁴-(4,4-Difluorocyclohexyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine trifluoroacetate was purified by column chromatography eluting with mixture of chloroform/ethanol/20 % water solution of ammonia (200:10:1) to afford 58 mg (68%) of the titled compound as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.40 - 1.51 (m, 2H), 1.60 - 1.71 (m, 3H), 1.81 (bs, 4H), 1.90 - 1.98 (m, 2H), 2.07 (s, 3H), 3.76 - 3.84 (m, 1H), 4.46 (d, *J*=5.91 Hz, 2H), 5.84 (d, *J*=7.25 Hz, 1H), 6.70 - 6.75 (m, 1H), 7.10 - 7.22 (m, 1H), 7.24 (d, *J*=7.79 Hz, 1H), 7.67 (t, *J*=7.52 Hz, 1H), 8.45 (d, *J*=4.30 Hz, 1H); MS (ESI) *m/z* 348.8 (M+1)⁺.

35

Example 33

N^4 -(2,3-dihydro-1*H*-inden-1-yl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of N^4 -cyclopentyl-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using 2,3-dihydro-1*H*-inden-1-ylamine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. $^1\text{H NMR}$ (300 MHz, DMSO- d_6) δ ppm 1.85 (bs, 4H), 2.11 (s, 3H), 2.20 - 2.28 (m, 1H), 2.70 - 2.76 (m, 1H), 2.85 - 2.95 (m, 1H), 4.40 - 4.52 (m, 2H), 5.60 - 5.65 (m, 1H), 6.37 (d, $J=8.33$ Hz, 1H), 6.71 (s, 1H), 7.06 (s, 2H), 7.10 - 7.22 (m, 3H), 7.28 (d, $J=7.79$ Hz, 1H), 7.68 (t, $J=7.79$ Hz, 1H), 8.42 (s, 1H); MS (ESI) m/z 346.1 (M+1) $^+$.

Example 34

3-({5,6-dimethyl-2-[(pyridin-2-ylmethyl)amino]pyrimidin-4-yl}amino)cyclopentanol

The titled compound was synthesized according to the procedure described for preparation of N^4 -cyclopentyl-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using 3-aminocyclopentanol hydrochloride instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. $^1\text{H NMR}$ (300 MHz, methanol- d_4) δ ppm 1.50 - 1.58 (m, 1H), 1.70 - 1.78 (m, 3H), 1.96 (bs, 4H), 2.34 (s, 3H), 3.32 (s, 3H), 4.20 - 4.32 (m, 2H), 7.69 - 7.75 (m, 1H), 7.79 - 7.85 (m, 1H), 8.20 - 8.29 (m, 1H), 8.69 (bs, 1H); MS (ESI) m/z 314.8 (M+1) $^+$.

Example 35

5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)- N^4 -(1,2,3,4-tetrahydronaphthalen-1-yl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of N^4 -cyclopentyl-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using 1,2,3,4-tetrahydronaphthalen-1-ylamine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. $^1\text{H NMR}$ (300 MHz, DMSO- d_6) δ ppm 1.60-1.69 (m, 3H), 1.83 (bs, 4H), 2.09 (s, 3H), 2.66-2.75 (m, 2H), 4.46 (d, $J=5.37$ Hz, 2H), 5.31 (bs, 1H), 6.33 (d, $J=8.33$ Hz, 1H), 6.70-6.78 (m, 1H), 7.07 (dd, $J_1=15.31$ Hz, $J_2=6.45$ Hz, 4H), 7.15 (d, $J=5.64$ Hz, 1H), 7.26 (d, $J=7.52$ Hz, 1H), 7.64 (d, $J=7.25$ Hz, 1H), 8.42 (d, $J=4.03$ Hz, 1H); MS (ESI) m/z 361.0 (M+1) $^+$.

35

Example 36

*N*⁴-(3,4-dihydro-2*H*-chromen-4-yl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using 3,4-dihydro-2*H*-chromen-4-ylamine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (400 MHz, CDCl₃) δ ppm 1.89 (s, 3H), 2.10 (bs, 1H), 2.42 (s, 3H), 4.11 (bs, 1H), 4.27 (bs, 1H), 4.93 (bs, 1H), 5.04 (bs, 1H), 5.31 (bs, 1H), 5.48 (bs, 1H), 6.75 - 6.88 (m, 3H), 7.20 (bs, 1H), 7.27 (bs, 1H), 7.42 (bs, 1H), 7.74 (bs, 1H), 8.02 (bs, 1H), 8.59 (bs, 1H), 10.63 (bs, 1H); MS (ESI) *m/z* 362.9 (M+1)⁺.

Example 37

cis-4-({5,6-dimethyl-2-[(pyridin-2-ylmethyl)amino]pyrimidin-4-yl}amino)-1-methylcyclohexanol

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using *cis*-4-amino-1-methylcyclohexanol instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (400 MHz, CDCl₃) δ ppm 1.25 (s, 3H), 1.29 (bs, 1H), 1.40 - 1.52 (m, 3H), 1.55 - 1.65 (m, 2H), 1.67 - 1.78 (m, 2H), 1.87 (s, 3H) 2.26 (s, 3H) 3.70 - 3.82 (m, 1H), 4.34 (d, *J*=7 Hz, 1H), 4.71 (d, *J*=5.4 Hz, 2H), 7.13 (t, *J*=5.64 Hz, 1H), 7.35 (d, *J*=8.06 Hz, 1H), 7.54 - 7.62 (m, 1H), 8.54 (d, *J*=4.56 Hz, 1H); MS (ESI) *m/z* 342.4 (M+1)⁺.

Example 38

trans-4-({5,6-dimethyl-2-[(pyridin-2-ylmethyl)amino]pyrimidin-4-yl}amino)-1-methylcyclohexanol

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using *trans*-4-amino-1-methylcyclohexanol instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (400 MHz, CDCl₃) δ ppm 1.16 - 1.32 (m, 5H), 1.38 - 1.46 (m, 2H), 1.48 - 1.59 (m, 2H), 1.80 - 1.90 (m, 2H), 1.92 - 1.99 (m, 3H), 2.01 - 2.12 (m, 2H), 2.25 (s, 3H), 3.90 - 3.96 (m, 1H), 4.20 - 4.31 (m, 1H), 4.43 (d, *J*=5.91 Hz, 2H), 5.50 - 5.62 (m, 1H), 7.20 - 7.26 (m, 1H), 7.34 (d, *J*=7.79 Hz, 1H), 7.56 (dd, *J*₁=7.76 Hz, *J*₂=1.07 Hz, 1H), 8.54 (d, *J*=4.83 Hz, 1H); MS (ESI) *m/z* 342.8 (M+1)⁺.

Example 39

*N*⁴-(bicyclo[2.2.1]hept-2-yl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using bicyclo[2.2.1]hept-2-ylamine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 0.80 - 0.94 (m, 1H), 0.98 - 1.06 (m, 1H), 1.10 - 1.19 (m, 1H), 1.26 - 1.36 (m, 2H), 1.48 - 1.56 (m, 1H), 1.65 - 1.77 (m, 1H), 1.93 (s, 3H), 2.07 (s, 3H), 2.12 - 2.20 (m, 1H), 2.22 - 2.30 (m, 1H), 2.50 - 2.58 (m, 1H), 3.70 - 3.80 (m, 1H) 4.42 - 4.51 (m, 2H), 7.20 - 7.27 (m, 1H) 7.50 - 7.58 (m, 1H), 7.68 - 7.80 (m, 1H), 8.65 (d, *J*=4.92 Hz, 1H); MS (ESI) *m/z* 324.0 (M+1)⁺.

Example 40

5,6-dimethyl-*N*⁴-(2-methylcyclohexyl)-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using 2-methylcyclohexanamine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (400 MHz, CDCl₃) δ ppm 0.93 (bs, 3H), 1.28 - 1.42 (m, 6H), 1.62 - 1.70 (m, 1H), 1.78 - 1.89 (m, 2H), 1.93 (s, 3H), 2.07 (s, 3H), 2.95 - 3.04 (m, 1H), 4.43 (bs, 2H), 7.22 (t, *J*=7.30 Hz, 1H), 7.56 (d, *J*=7.76 Hz, 1H), 7.68-7.75 (m, 1H), 8.65 (d, *J*=4.92 Hz, 1 H); MS (ESI) *m/z* 326.40 (M+1)⁺.

25

Example 41

*N*⁴-(2,3-dimethylcyclohexyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using 2,3-dimethylcyclohexanamine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (400 MHz, CDCl₃) δ ppm 0.75-0.76 (m, 3H), 0.85-0.95 (m, 3H), 1.55-1.74 (m, 8H), 1.86-1.97 (m, 4H), 2.07 (s, 3H), 3.10-3.18 (m, 1H), 4.43 (bs, 2H), 7.20-7.26 (m, 1H), 7.50-7.57 (m, 1H), 7.67-7.73 (m, 1H), 8.60-8.68 (m, 1H); MS (ESI) *m/z* 340.4 (M+1)⁺.

35

Example 42

2-({5,6-dimethyl-2-[(pyridin-2-ylmethyl)amino]pyrimidin-4-yl}amino)cyclohexanol

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using 2-aminocyclohexanol instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (400 MHz, methanol-*d*₆) δ ppm 1.16-1.22 (m, 1H), 1.30-1.41 (m, 3H), 1.50-1.62 (m, 3H), 1.68-1.74 (m, 1H), 1.91 (s, 3H), 2.20 (s, 3H), 3.72 (bs, 1H), 3.79 (bs, 1H), 4.61 (bs, 2H), 7.18-7.26 (m, 1H), 7.34-7.45 (m, 1H), 7.70-7.82 (m, 1H), 8.47 (bs, 1H); MS (ESI) *m/z* 328.8 (M+1)⁺.

Example 43

rac-[(1*R*,2*S*)-2-({5,6-dimethyl-2-[(pyridin-2-ylmethyl)amino]pyrimidin-4-yl}amino)cyclohexyl]methanol

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using *rac*-[(1*R*,2*S*)-2-aminocyclohexyl]methanol instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (400 MHz, methanol-*d*₆) δ ppm 1.35 (bs, 2H), 1.50 (bs, 6H), 1.89 (bs, 3H), 2.20 (bs, 3H), 3.40-3.48 (m, 1H), 3.60-3.68 (m, 1H), 4.10-4.18 (m, 1H), 4.64 (bs, 2H), 7.26 (t, *J*=5.64 Hz, 1H), 7.40 (d, *J*=8.06 Hz, 1H), 7.75 (d, *J*=7.79 Hz, 1H), 8.46 (d, *J*=4.83, 1H); MS (ESI) *m/z* 342.8 (M+1)⁺.

Example 44

*N*⁴-(cyclopentylmethyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using (cyclopentylmethyl)amine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.00-1.09 (m, 2H), 1.30-1.38 (m, 2H), 1.38-1.49 (m, 4H), 1.80-1.94 (m, 4H), 2.26 (s, 3H), 3.14 (bs, 2H), 4.70 (bs, 2H), 7.37-7.42 (m, 2H), 7.91 (t, *J*=7.52, 1H), 8.09-8.13 (m, 1H), 8.43 (s, 1H), 8.55-8.62 (m, 1H), 12.65 (bs, 1H); MS (ESI) *m/z* 312.8 (M+1)⁺.

Example 45

*N*⁴-cycloheptyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using 1-cycloheptylamine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.26-1.32 (m, 2H), 1.38-1.50 (m, 8H), 1.68 (bs, 2H), 1.81 (s, 3H), 2.07 (s, 3H), 3.80-3.88 (m, 1H), 4.49 (d, *J*=9.91, 2H), 5.70 (d, *J*=7.25, H), 6.63 (brs, 1H), 7.15-7.20 (m, 1H), 7.21-7.28 (m, 1H), 7.68 (t, *J*=7.25, 1H), 8.46 (bs, 1H); MS (ESI) *m/z* 326.9 (M+1)⁺.

Example 46

*N*⁴-(2,3-dihydro-1*H*-inden-2-yl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using 2,3-dihydro-1*H*-inden-2-ylamine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.86 (s, 3H), 2.11 (s, 3H), 2.76 (bs, 2H), 2.99 (bs, 2H), 4.49 (bs, 2H), 4.61 (bs, 1H), 6.23 (bs, 1H), 6.72-6.79 (m, 1H), 7.12 (bs, 4H), 7.216-7.23 (m, 1H), 7.21-7.29 (m, 1H), 7.65-7.73 (m, 1H), 8.41 (bs, 1H); MS (ESI) *m/z* 346.8 (M+1)⁺.

Example 47

*N*⁴-cyclobutyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using cyclobutanamine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (400 MHz, methanol-*d*₄) δ ppm 1.60-1.68 (m, 2H), 1.83-1.96 (m, 5H), 2.108-2.15 (m, 2H), 2.20 (s, 3H), 4.26-4.32 (m, 1H), 4.62 (bs, 2H), 7.28 (t, *J*=6.4 Hz, 1H), 7.41 (d, *J*=8.1 Hz, 1H), 7.76 (t, *J*=5.9 Hz, 1H), 8.47 (d, *J*=4.4 Hz, 1H); MS (ESI) *m/z* 284.2 (M+1)⁺.

35

Example 48

5,6-dimethyl-*N*⁴-(pentan-3-yl)-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using cyclobutanamine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, CDCl₃) δ ppm 0.81 (t, *J*=7.3 Hz, 3H), 1.36-1.43 (m, 2H), 1.50-1.57 (m, 2H), 1.90 (s, 3H), 2.26 (s, 3H), 3.94-4.00 (m, 1H), 4.17 (bs, 1H), 4.72 (d, *J*=5.9 Hz, 2H), 5.72 (bs, 1H), 7.13 (t, *J*=7.5 Hz, 1H), 7.36 (d, *J*=7.3 Hz, 1H), 7.60 (t, *J*=7.5 Hz, 1H), 8.54 (d, *J*=4.8 Hz, 1H); MS (ESI) *m/z* 300.1 (M+1)⁺.

Example 49

*N*⁴-(3-fluorophenyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using (3-fluorophenyl)amine hydrochloride instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 2.04 (s, 3H), 2.20 (s, 3H), 4.51 (d, *J*=5.6 Hz, 2H), 6.67 (t, *J*=5.9 Hz, 1H), 7.05-7.29 (m, 4H), 7.60 (bs, 1H), 7.69 (t, *J*=8.1 Hz, 1H), 8.08 (s, 1H), 8.48 (d, *J*=4.0 Hz, 1H); MS (ESI) *m/z* 324.4 (M+1)⁺.

Example 50

*N*⁴-(4-fluorophenyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using (4-fluorophenyl)amine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, CDCl₃) δ ppm 2.07 (s, 3H), 2.34 (s, 3H), 4.69 (d, *J*=5.9 Hz, 2H), 5.98 (bs, 1H), 6.32 (s, 1H), 6.94 (t, *J*=8.3 Hz, 1H), 7.16 (t, *J*=7.5 Hz, 1H), 7.31 (d, *J*=7.6 Hz, 1H), 7.36-7.42 (m, 2H), 7.61 (t, *J*=7.5 Hz, 1H), 8.58 (d, *J*=5.4 Hz, 1H); MS (ESI) *m/z* 324.0 (M+1)⁺.

35

Example 51

*N*⁴-(2-fluorophenyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using (2-
5 fluorophenyl)amine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 2.03 (s, 3H), 2.18 (s, 3H), 4.38 (bs, 2H), 6.84 (bs, 1H), 6.96-7.22 (m, 5H), 7.45-7.78 (m, 3H), 8.15 (bs, 1H); MS (ESI) *m/z* 324.5 (M+1)⁺.

10

Example 52

5,6-dimethyl-*N*⁴-phenyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using
15 aniline instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a light-grey solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 2.03 (s, 3H), 2.19 (s, 3H), 4.48 (d, *J*=5.8 Hz, 2H), 6.88 (t, *J*=7.5 Hz, 1H), 6.95 (bs, 1H), 7.11 (bs, 2H), 7.20 (t, *J*=6.2 Hz, 1H), 7.26 (d, *J*=7.8 Hz, 1H), 7.52 (bs, 2H),
20 7.69 (t, *J*=6.9 Hz, 1H), 7.90 (s, 1H), 8.51 (d, *J*=4.3 Hz, 1H); MS (ESI) *m/z* 306.1 (M+1)⁺.

Example 53

5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)-*N*⁴-[3-(trifluoromethoxy)phenyl]pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of
25 *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using [3-(trifluoromethoxy)phenyl]amine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, CDCl₃) δ ppm 2.09 (s, 3H), 2.35 (s, 3H), 4.73 (d, *J*=5.6 Hz, 2H),
30 6.08 (bs, 1H), 6.48 (bs, 1H), 6.88 (d, *J*=7.3 Hz, 1H), 7.16 (t, *J*=7.3 Hz, 1H), 7.22-7.34 (m, 3H), 7.62 (t, *J*=9.4 Hz, 1H), 7.75 (s, 1H), 8.57 (d, *J*=3.2 Hz, 1H); MS (ESI) *m/z* 390.7 (M+1)⁺.

Example 54

5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)-*N*⁴-[3-(trifluoromethyl)phenyl]pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of
35 *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using [3-(trifluoromethyl)phenyl]amine instead of cyclopentanamine. The crude material was purified by

column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, CDCl₃) δ ppm 2.09 (s, 3H), 2.34 (s, 3H), 4.73 (d, *J*=5.6 Hz, 2H), 5.91 (bs, 1H), 6.47 (bs, 1H), 7.15 (t, *J*=8.2 Hz, 1H), 7.24-7.40 (m, 3H), 7.57-7.67 (m, 2H), 8.09 (s, 1H), 8.57 (d, *J*=2.4 Hz, 1H); MS (ESI) *m/z* 374.7 (M+1)⁺.

Example 55

*N*⁴-(2,6-difluorophenyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using (2,6-difluorophenyl)amine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, CDCl₃) δ ppm 2.11 (s, 3H), 2.33 (s, 3H), 4.50 (bs, 2H), 5.88 (bs, 2H), 6.80-7.01 (m, 2H), 7.03-7.21 (m, 3H), 7.53 (bs, 1H), 8.47 (bs, 1H); MS (ESI) *m/z* 342.6 (M+1)⁺.

Example 56

5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)-*N*⁴-[4-(trifluoromethoxy)phenyl]pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using [4-(trifluoromethoxy)phenyl]amine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a light-yellow solid. ¹H NMR (300 MHz, CDCl₃) δ ppm 2.07 (s, 3H), 2.34 (s, 3H), 4.70 (d, *J*=3.6 Hz, 2H), 5.92 (bs, 1H), 6.44 (bs, 1H), 7.01-7.21 (m, 3H), 7.16 (bs, 1H), 7.44-7.61 (m, 3H), 8.58 (bs, 1H); MS (ESI) *m/z* 390.7 (M+1)⁺.

Example 57

5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)-*N*⁴-[4-(trifluoromethyl)phenyl]pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using [4-(trifluoromethyl)phenyl]amine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a light-yellow solid. ¹H NMR (300 MHz, CDCl₃) δ ppm 2.10 (s, 3H), 2.37 (s, 3H), 4.72 (d, *J*=5.4 Hz, 2H), 6.07 (bs, 1H), 6.55 (bs, 1H), 7.18 (t, *J*=7.0 Hz, 1H), 7.34 (d, *J*=7.5 Hz, 1H), 7.48 (d, *J*=8.6 Hz, 2H), 7.58-7.65 (m 3H), 8.58 (d, *J*=3.2 Hz, 1H); MS (ESI) *m/z* 374.7 (M+1)⁺.

Example 58

*N*⁴-(3,4-difluorophenyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of
5 *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using
(3,4-difluorophenyl)amine instead of cyclopentanamine. The crude material was purified by column
chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia
(200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as
a light-yellow solid. ¹H NMR (300 MHz, CDCl₃) δ ppm 2.05 (s, 3H), 2.32 (s, 3H), 4.70 (d, *J*=5.5 Hz,
10 2H), 5.87 (bs, 1H), 6.32 (bs, 1H), 6.95-7.05 (m, 2H), 7.16 (t, *J*=7.0 Hz, 1H), 7.32 (d, *J*=8.1 Hz, 1H),
7.57-7.66 (m, 2H), 8.58 (d, *J*=3.6 Hz, 1H); MS (ESI) *m/z* 342.7 (M+1)⁺.

Example 59

5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)-*N*⁴-[2-(trifluoromethoxy)phenyl]pyrimidine-2,4-diamine

15 The titled compound was synthesized according to the procedure described for preparation of
*N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using [2-
(trifluoromethoxy)phenyl]amine instead of cyclopentanamine. The crude material was purified by
column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia
(200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as
20 a light-yellow solid. ¹H NMR (300 MHz, CDCl₃) δ ppm 1.09 (s, 3H), 2.35 (s, 3H), 4.74 (d, *J*=5.5 Hz,
2H), 6.81 (s, 1H), 6.98 (t, *J*=7.8 Hz, 1H), 7.16 (t, *J*=7.0 Hz, 2H), 7.23 (d, *J*=7.3 Hz, 1H), 7.36 (d,
J=7.8 Hz, 1H), 7.62 (t, *J*=7.3 Hz, 1H), 8.43 (d, *J*=7.5 Hz, 1H), 8.59 (d, *J*=3.8 Hz, 1H); MS (ESI) *m/z*
390.5 (M+1)⁺.

25

Example 60

*N*⁴-(2,5-difluorophenyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of
*N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using
(2,5-difluorophenyl)amine instead of cyclopentanamine. The crude material was purified by column
30 chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia
(200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as
a light-yellow solid. ¹H NMR (300 MHz, CDCl₃) δ ppm 2.09 (s, 3H), 2.35 (s, 3H), 4.75 (d, *J*=4.8 Hz,
2H), 5.96 (bs, 1H), 6.656-6.62 (m, 1H), 6.67 (bs, 1H), 7.01 (m, 1H), 7.16 (t, *J*=5.4 Hz, 1H), 7.37 (d,
J=7.8 Hz, 1H), 7.62 (t, *J*=7.8 Hz, 1H), 8.29 (bs, 1H), 8.59 (d, *J*=3.4 Hz, 1H); MS (ESI) *m/z* 342.7
35 (M+1)⁺.

Example 61

N^4 -(1,3-benzodioxol-5-yl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of N^4 -cyclopentyl-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using 1,3-
5 benzodioxol-5-amine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. $^1\text{H NMR}$ (300 MHz, CDCl_3) δ ppm 2.04 (s, 3H), 2.32 (s, 3H), 4.69 (d, $J=4.2$ Hz, 2H), 5.76 (bs, 1H), 5.95 (s, 2H), 6.22 (s, 1H), 6.67-7.75 (m, 2H), 7.14 (t, $J=6.4$ Hz, 1H), 7.21 (s, 1H), 7.32
10 (d, $J=7.8$ Hz, 1H), 7.60 (t, $J=7.6$ Hz, 1H), 8.56 (d, $J=3.6$ Hz, 1H); MS (ESI) m/z 350.7 (M+1) $^+$.

Example 62

N^4 -(4-chlorophenyl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of N^4 -cyclopentyl-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using (4-
15 chlorophenyl)amine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. $^1\text{H NMR}$ (300 MHz, CDCl_3) δ ppm 2.06 (s, 3H), 2.33 (s, 3H), 4.60 (d, $J=3.0$ Hz, 2H), 5.77 (bs, 1H), 6.30 (bs, 1H), 7.13-7.20 (m, 3H), 7.32 (d, $J=6.8$ Hz, 1H), 7.43 (d, $J=7.8$ Hz, 2H), 7.61
20 (t, $J=7.6$ Hz, 1H), 8.58 (d, $J=3.4$ Hz, 1H); MS (ESI) m/z 340.6 (M+1) $^+$.

Example 63

5,6-dimethyl- N^4 -(4-methylphenyl)- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of N^4 -cyclopentyl-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using *p*-
25 toluidine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. $^1\text{H NMR}$
30 (300 MHz, CDCl_3) δ ppm 2.06 (s, 3H), 2.31 (s, 3H), 2.33 (s, 3H), 4.71 (d, $J=2.8$ Hz, 2H), 5.75 (bs, 1H), 6.28 (s, 1H), 7.06 (d, $J=7.3$ Hz, 2H), 7.15 (t, $J=6.8$ Hz, 1H), 7.30-7.38 (m, 3H), 7.61 (t, $J=7.4$ Hz, 1H), 8.58 (d, $J=4.0$ Hz, 1H); MS (ESI) m/z 320.7 (M+1) $^+$.

Example 64

35 N^4 -(3,5-difluorophenyl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of N^4 -cyclopentyl-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using

(3,5-difluorophenyl)amine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, CDCl₃) δ ppm 2.07 (s, 3H), 2.34 (s, 3H), 4.73 (d, *J*=3.1 Hz, 2H),
 5 5.93 (bs, 1H), 6.39-6.49 (m, 2H), 7.13-7.22 (m, 3H), 7.34 (d, *J*=7.8 Hz, 1H), 7.63 (t, *J*=5.9 Hz, 1H),
 8.59 (d, *J*=3.8 Hz, 1H); MS (ESI) *m/z* 342.7 (M+1)⁺.

Example 65

*N*⁴-(3-chlorophenyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

10 The titled compound was synthesized according to the procedure described for preparation of
*N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using (3-
 chlorophenyl)amine instead of cyclopentanamine. The crude material was purified by column
 chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia
 (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as
 15 a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 2.03 (s, 3H), 2.20 (s, 3H), 4.51 (d, *J*=3.0 Hz,
 2H), 6.91 (d, *J*=6.8 Hz, 1H), 7.02-7.15 (m, 2H), 7.20 (t, *J*=6.4 Hz, 1H), 7.26 (d, *J*=8.1 Hz, 1H), 7.55
 (bs, 1H), 7.69 (t, *J*=7.9 Hz, 1H), 7.78 (s, 1H), 8.10 (s, 1H), 8.49 (d, *J*=3.8 Hz, 1H); MS (ESI) *m/z*
 340.1 (M+1)⁺.

20

Example 66

*N*⁴-(2-chlorophenyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of
*N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using (2-
 chlorophenyl)amine instead of cyclopentanamine. The crude material was purified by column
 25 chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia
 (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as
 a white solid. ¹H NMR (300 MHz, CDCl₃) δ ppm 2.13 (s, 3H), 2.38 (s, 3H), 4.75 (d, *J*=2.8 Hz, 2H),
 6.05 (bs, 1H), 6.94 (t, *J*=6.4 Hz, 1H), 7.06-7.20 (m, 3H), 7.36 (d, *J*=6.8 Hz, 2H), 7.62 (t, *J*=7.6 Hz,
 1H), 8.40 (d, *J*=5.8 Hz, 1H), 8.60 (d, *J*=3.4 Hz, 1H); MS (ESI) *m/z* 340.6 (M+1)⁺.

30

Example 67

5,6-dimethyl-*N*⁴-(2-methylphenyl)-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of
*N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using *o*-
 35 toluidine instead of cyclopentanamine. The crude material was purified by column chromatography
 eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the
 final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR

(300 MHz, CDCl₃) δ ppm 2.08 (s, 3H), 2.27 (s, 3H), 2.34 (s, 3H), 4.66 (d, *J*=3.2 Hz, 2H), 5.70 (bs, 1H), 6.14 (s, 1H), 7.01 (t, *J*=6.3 Hz, 1H), 7.13 (t, *J*=6.3 Hz, 2H), 7.18 (d, *J*=7.5 Hz, 1H), 7.24 (d, *J*=7.8 Hz, 1H), 7.58 (t, *J*=7.8 Hz, 1H), 7.84 (d, *J*=7.8 Hz, 1H), 8.54 (d, *J*=4.8 Hz, 1H); MS (ESI) *m/z* 320.7 (M+1)⁺.

5

Example 68

*N*⁴-(2,6-dimethylphenyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using (2,6-dimethylphenyl)amine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, CDCl₃) δ ppm 2.09 (s, 3H), 2.14 (s, 6H), 2.31 (s, 3H), 4.40 (d, *J*=3.2 Hz, 2H), 5.52 (bs, 1H), 5.71 (s, 1H), 6.90 (bs, 1H), 7.04-7.14 (m, 4H), 7.46 (t, *J*=9.4 Hz, 1H), 8.45 (d, *J*=4.8 Hz, 1H); MS (ESI) *m/z* 335.0 (M+1)⁺.

15

Example 69

5,6-dimethyl-*N*⁴-(3-methylphenyl)-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using *m*-toluidine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, CDCl₃) δ ppm 2.07 (s, 3H), 2.28 (s, 3H), 2.33 (s, 3H), 4.74 (d, *J*=3.0 Hz, 2H), 5.79 (bs, 1H), 6.31 (s, 1H), 6.84 (d, *J*=8.1 Hz, 1H), 7.10-7.17 (m, 2H), 7.30-7.40 (m, 3H), 7.60 (t, *J*=7.8 Hz, 1H), 8.57 (d, *J*=2.8 Hz, 1H); MS (ESI) *m/z* 320.7 (M+1)⁺.

25

Example 70

*N*⁴-(1,1-dioxidotetrahydrothiophen-3-yl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

30

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using (1,1-dioxidotetrahydro-3-thienyl)amine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, CDCl₃) δ ppm 1.91 (s, 3H), 2.22 (m, 1H), 2.29 (s, 3H), 2.20-2.26 (m, 1H), 2.80-2.91 (m, 1H), 2.95 (bs, 1H), 3.05-3.15 (m, 1H), 3.18-3.24 (m, 1H), 4.69

35

(bs, 2H), 4.80-4.89 (m, 2H), 5.92 (bs, 1H), 7.17 (t, $J=3.9$ Hz, 1H), 7.34 (d, $J=5.8$ Hz, 1H), 7.64 (t, $J=6.4$ Hz, 1H), 8.57 (d, $J=2.8$ Hz, 1H); MS (ESI) m/z 348.8 (M+1)⁺.

Example 71

5 N^4 -(5-fluoro-2-methylphenyl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of N^4 -cyclopentyl-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using (5-fluoro-2-methylphenyl)amine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia
10 (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, DMSO- d_6) δ ppm 2.03 (s, 3H), 2.11 (s, 3H), 2.17 (s, 3H), 4.39 (d, $J=1.6$ Hz, 2H), 7.77-7.88 (m, 2H), 7.09-7.20 (m, 3H), 7.34 (d, $J=9.8$ Hz, 1H), 7.45 (s, 1H), 7.64 (t, $J=7.5$ Hz, 1H), 8.43 (d, $J=2.8$ Hz, 1H); MS (ESI) m/z 338.8 (M+1)⁺.

15 Example 72

N^4 -(2-fluoro-6-methylphenyl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of N^4 -cyclopentyl-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using (2-fluoro-6-methylphenyl)amine instead of cyclopentanamine. The crude material was purified by
20 column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, methanol- d_4) δ ppm 2.07 (s, 3H), 2.11 (s, 3H), 2.23 (s, 3H), 4.29 (s, 2H), 6.88 (t, $J=9.1$ Hz, 1H), 6.97 (t, $J=5.9$ Hz, 2H), 7.13 (m, 1H), 7.26 (t, $J=7.3$ Hz, 1H), 7.61 (t, $J=7.3$ Hz, 1H), 8.34 (d, $J=5.0$ Hz, 1H); MS (ESI) m/z 338.8 (M+1)⁺.

25

Example 73

N^4 -(4,5-difluoro-2-methylphenyl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of N^4 -cyclopentyl-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using
30 (4,5-difluoro-2-methylphenyl)amine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, DMSO- d_6) δ ppm 2.02 (s, 3H), 2.06 (s, 3H), 2.16 (s, 3H), 4.34 (bs, 2H), 6.81 (bs, 1H), 7.07-7.41 (m, 4H), 7.56 (bs, 1H), 7.63 (d, $J=7.3$ Hz, 1H), 8.42 (d, $J=4.2$ Hz, 1H); MS (ESI) m/z 356.6 (M+1)⁺.

35

Example 74

5,6-dimethyl-*N*⁴-(1-methyl-1*H*-pyrazol-5-yl)-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using 1-methyl-1*H*-pyrazol-5-amine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, methanol-*d*₄) δ ppm 2.09 (s, 3H), 2.27 (s, 3H), 3.38 (s, 3H), 4.42 (s, 2H), 5.98 (s, 1H), 7.14 (d, *J*=7.5 Hz, 1H), 7.24 (t, *J*=6.7 Hz, 1H), 7.38 (s, 1H), 7.70 (t, *J*=7.0 Hz, 1H), 8.43 (d, *J*=5.2 Hz, 1H); MS (ESI) *m/z* 310.2 (M+1)⁺.

Example 75

*N*⁴-(4-fluoro-2-methylphenyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using (4-fluoro-2-methylphenyl)amine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 2.01 (s, 3H), 2.07 (s, 3H), 2.15 (s, 3H), 4.30 (bs, 2H), 6.68 (bs, 1H), 6.84-6.89 (m, 1H), 6.98-7.10 (m, 2H), 7.17 (t, *J*=7.3 Hz, 2H), 7.57-7.67 (m, 2H), 8.43 (d, *J*=4.2 Hz, 1H); MS (ESI) *m/z* 338.8 (M+1)⁺.

Example 76

*N*⁴-(3-fluoro-2-methylphenyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using (3-fluoro-2-methylphenyl)amine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.94 (s, 3H), 2.06 (s, 3H), 2.14 (s, 3H), 4.32 (bs, 2H), 6.76 (bs, 1H), 6.86-6.95 (m, 1H), 7.01-7.13 (m, 3H), 7.17 (t, *J*=6.4 Hz, 1H), 7.63 (t, *J*=8.4 Hz, 1H), 7.75 (s, 1H), 8.43 (d, *J*=4.2 Hz, 1H); MS (ESI) *m/z* 338.2 (M+1)⁺.

Example 77

*N*⁴-cyclohexyl-*N*⁴,5,6-trimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using *N*-

methylcyclohexanamine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, CDCl₃) δ ppm 1.09–1.31 (m, 3H), 1.39–1.52 (m, 2H), 1.59–1.80 (m, 5H), 2.02 (s, 3H), 2.27 (s, 3H), 2.73 (s, 3H), 3.49–3.59 (m, 1H), 4.71 (d, *J*=6.2, 2H), 5.54 (bs, 1H), 7.11–7.15 (m, 1H), 7.35 (d, *J*= 8.3, 1H), 7.57–7.62 (m, 1H), 8.52–8.55 (m, 1H); MS (ESI) *m/z* 326.2 (M+1)⁺.

Example 78

10 *N*⁴-(3,3-difluorocyclopentyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using 3,3-difluorocyclopentylamine hydrochloride instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, methanol-*d*₄) δ ppm 1.73–2.27 (m, 9H), 2.36 (s, 3H), 3.30–3.34 (m, 2H), 4.30–4.40 (m, 1H), 7.73 (t, *J*= 6.4, 1H), 7.84 (d, *J*= 8.1, 1H), 8.28 (t, *J*= 6.7, 1H), 8.70 (d, *J*= 5.1, 1H); MS (ESI) *m/z* 334 (M+1)⁺.

20 *trans*-4-({5,6-dimethyl-2-[(pyridin-2-ylmethyl)amino]pyrimidin-4-yl}amino)cyclohexanol

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using *trans*-4-aminocyclohexanol instead of cyclopentanamine. The crude material was purified by crystallization from ethanol to afford the titled compound as a hydrochloride salt as a white solid. ¹H NMR (300 MHz, methanol-*d*₄) δ ppm 1.18-1.26 (m, 2H), 1.32-1.44 (m, 2H), 1.67 (d, *J*=11.28 Hz, 2H), 1.80-1.99 (m, 5H), 2.33 (s, 3H), 3.45-3.55 (m, 1H), 3.75-3.83 (m, 1H), 4.72 (s, 2H), 7.33 (bs, 1H), 7.44 (d, *J*=7.79 Hz, 1H), 7.83 (t, *J*=7.12 Hz, 1H), 8.53 (d, *J*=4.30 Hz, 1H); MS (ESI) *m/z* 328.3 (M+1)⁺.

30 *N*⁴-(3,3-difluorocyclohexyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using (3,3-difluorocyclohexyl)amine hydrochloride instead of cyclopentanamine. The crude material was purified by HPLC (column: YMC-PACK ODS-AQ C18, 250 mm × 20 mm, 10 μm; gradient: 20-50% acetonitrile in 0.02% trifluoroacetic acid/water over fifteen minutes; 50-100% acetonitrile in 0.02%

trifluoroacetic acid/water over five minutes; flow rate: 25 mL/min; temperature: 25 °C) to afford the titled compound as a trifluoroacetate salt as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.80-2.11 (m, 14H), 3.75 (bs, 1 H), 4.40-4.49 (m, 2H), 5.31 (bs, 2H), 7.20-7.28 (m, 1H), 7.56 (bs, 1H), 7.73 (bs, 1H), 8.65 (bs, 1H); MS (ESI) *m/z* 348.1 (M+1)⁺.

5

Example 81

5,6-dimethyl-*N*⁴-(1-methylpiperidin-4-yl)-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using 1-methylpiperidin-4-amine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a light-grey solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.68 (bs, 4H) 1.85 (s, 3H) 2.13 (bs, 3H) 2.57 (bs, 3H) 2.66 (bs, 2 H) 3.13 (d, *J*=11.82 Hz, 2 H) 3.81 (bs, 1 H) 4.52 (d, *J*=5.91 Hz, 2 H) 6.52 (s, 1H) 7.15-7.22 (m, 1 H) 7.27 (d, *J*=7.79 Hz, 1 H) 7.70 (d, *J*=7.66 Hz, 1H) 8.48 (d, *J*=4.03 Hz, 1 H); MS (ESI) *m/z* 327.5 (M+1)⁺.

15

Example 82

tert-butyl 4-({5,6-dimethyl-2-[(pyridin-2-ylmethyl)amino]pyrimidin-4-yl}amino)piperidine-1-carboxylate

20

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using 1-methylpiperidin-4-amine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a light-grey solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.20-1.30 (m, 2H), 1.39 (s, 9H), 1.50-1.60 (m, 2H), 1.80 (s, 3H), 2.06 (s, 3H), 2.60-2.68 (m, 2H), 3.76-3.90 (m, 3H), 4.48 (d, *J*=5.4 Hz, 2H), 5.81 (d, *J*=5.4 Hz, 1H), 6.71 (bs, 1H), 7.18 (t, *J*=4.4 Hz, 1H), 7.22 (d, *J*=5.4 Hz, 1H), 7.67 (t, *J*=8.1 Hz, 1H), 8.45 (d, *J*=4.4 Hz, 1H); MS (ESI) *m/z* 413.2 (M+1)⁺.

25

30

Example 83

5,6-dimethyl-*N*⁴-(piperidin-4-yl)-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

tert-Butyl 4-({5,6-dimethyl-2-[(pyridin-2-ylmethyl)amino]pyrimidin-4-yl}amino)piperidine-1-carboxylate (100 mg, 0.24 mmol, Example 82) was suspended in a solution of 3 M hydrogen chloride in dioxane (10 mL). The reaction mixture was stirred at ambient temperature overnight, and then the solvent was removed under reduced pressure. The residue was purified by flash chromatography on silica gel eluted with mixture of chloroform/ethanol/20% water solution of

35

ammonia (200:10:1) to afford the titled compound as a light-grey solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.25-1.32 (m, 2H), 1.84-1.92 (m, 5H), 2.25 (s, 3H), 12.43 (bs, 1H), 2.60-2.65 (m, 2H), 3.02-3.08 (m, 2H), 3.985-3.94 (m, 1H), 4.25 (d, *J*=8.3 Hz, 2H), 4.68 (d, *J*=5.3 Hz, 2H), 5.59 (bs, 1H), 7.12 (t, *J*=4.6 Hz, 1H), 7.36 (d, *J*=8.1 Hz, 1H), 7.60 (t, *J*=6.4 Hz, 1H), 8.54 (d, *J*=4.2 Hz, 1H); MS (ESI) *m/z* 313.2 (M+1)⁺.

Example 84

*N*⁴-(2,6-diisopropylphenyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using (2,6-diisopropylphenyl)amine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, CDCl₃) δ ppm 1.13 (d, *J*=32.78 Hz, 12H), 2.12 (s, 3H), 2.31 (s, 3H), 3.00-3.12 (m, 2H), 4.40 (d, *J*=5.10 Hz, 2H), 5.40 (s, 1H), 5.65 (s, 1H), 6.85 (s, 1H), 7.04 (bs, 1H), 7.19 (d, *J*=7.52 Hz, 2H), 7.20-7.30 (m, 1H), 7.42 (t, *J*=7.52 Hz, 1H), 8.43 (d, *J*=4.03 Hz, 1H); MS (ESI) *m/z* 390.5 (M+1)⁺.

Example 85

3-({5,6-dimethyl-2-[(pyridin-2-ylmethyl)amino]pyrimidin-4-yl}amino)cyclohexanol

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using 3-aminocyclohexanol instead of cyclopentanamine. The crude material was purified by crystallization from ethanol to afford the titled compound as a hydrochloride salt as a white solid. ¹H NMR (300 MHz, methanol-*d*₄) δ ppm 1.35-1.65 (m, 11H), 2.33 (s, 3H), 3.90-4.15 (m, 2H), 4.80-4.95 (m, 2H), 7.68-7.75 (m, 2H), 8.20-8.26 (m, 1H), 8.66 (d, *J*=11.15 Hz, 1H); MS (ESI) *m/z* 328.8 (M+1)⁺.

Example 86

*N*⁴-cyclohexyl-5,6-dimethyl-*N*²-[(5-methylpyridin-2-yl)methyl]pyrimidine-2,4-diamine

The titled compound was synthesized according to the general procedure described for preparation of *N*⁴-cyclohexyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 1) using [(5-methylpyridin-2-yl)methyl]amine instead of (pyridin-2-ylmethyl)amine. The product was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 0.97-1.33 (m, 5H), 1.51-1.69 (m, 5H), 1.87 (s, 3H), 2.24 (d, *J*=6.0 Hz, 6H), 3.73 (s, 1H), 4.57 (d, *J*=5.6 Hz, 2H), 7.20 (d,

$J=7.79$ Hz, 1H), 7.56 (d, $J=8.06$ Hz, 2H), 8.06 (t, $J=5.6$ Hz, 1H), 8.33 (s, 1H), 12.90 (bs, 1H); MS (ESI) m/z 326.1 (M+1)⁺.

Example 87

5 N^4 -cyclohexyl-5,6-dimethyl- N^2 -[1-(pyridin-2-yl)ethyl]pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of N^4 -cyclohexyl-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 1) using (1-pyridin-2-ylethyl)amine instead of (pyridin-2-ylmethyl)amine. The product was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia
10 (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.12 - 1.28 (m, 6H), 1.43 - 11.52 (m, 5H), 1.71 - 1.74 (m, 2H), 1.88 (s, 3H), 2.22 (s, 3H), 5.06 - 5.10 (m, 1H), 7.31 (t, $J=8.06$ Hz, 1H), 7.44 (d, $J=8.06$ Hz, 1H), 7.58 (d, $J=8.06$ Hz, 1H), 7.84 (t, $J=8.06$ Hz, 2H), 8.22 (d, $J=2.0$ Hz, 1H), 8.58 (d, $J=2.0$ Hz, 1H), 12.21 (bs, 1H); MS (ESI) m/z 326.5 (M+1)⁺.

15

Example 88

N^4 -(2,4-difluorophenyl)-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of N^4 -cyclopentyl-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using
20 (2,4-difluorophenyl)amine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, CDCl₃) δ ppm 2.09 (s, 3H), 2.37 (s, 3H), 4.71 (d, $J=5.6$ Hz, 2H), 6.06 (bs, 1H), 6.47 (bs, 1H), 7.75 (t, $J=9.4$ Hz, 1H), 7.85 (t, $J=10.0$ Hz, 1H), 7.17 (t, $J=7.3$ Hz, 1H),
25 7.33 (d, $J=7.8$ Hz, 1H), 7.62 (t, $J=7.5$ Hz, 1H), 8.12 (bs, 1H), 8.58 (d, $J=2.8$ Hz, 1H); MS (ESI) m/z 342.6 (M+1)⁺.

30

Example 89

5-ethyl- N^4 -(4-fluorophenyl)-6-methyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

Step A

2-chloro-5-ethyl-*N*-(4-fluorophenyl)-6-methylpyrimidin-4-amine

The titled compound was synthesized according to the procedure described for preparation of 2-chloro-*N*-cyclohexyl-5,6-dimethylpyrimidin-4-amine (Example 1, Step D) using 2,4-dichloro-5-ethyl-6-methylpyrimidine instead 2,4-dichloro-5,6-dimethylpyrimidine and 4-fluoroaniline instead of cyclohexylamine. The titled compound was obtained as a white solid. MS (ESI) m/z 266.7, 268.7 (M+1)⁺
35

Step B

5-ethyl-*N*⁴-(4-fluorophenyl)-6-methyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the general procedure described for preparation of *N*⁴-cyclohexyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 1) using 2-chloro-5-ethyl-*N*-(4-fluorophenyl)-6-methylpyrimidin-4-amine (Step A) instead of 2-chloro-*N*-cyclohexyl-5,6-dimethylpyrimidin-4-amine. The product was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a light-grey solid. ¹H NMR (300 MHz, methanol-*d*₄) δ ppm 1.09-1.20 (m, 3H), 2.25-2.35 (m, 3H), 2.52-2.62 (m, 2H), 4.57 (bs, 2H), 6.80-6.88 (m, 2H), 7.20-7.36 (m, 4H) 7.65-7.76 (m, 1H) 8.50 (bm, 1H); MS (ESI) *m/z* 338.8 (M+1)⁺.

Example 90

15 *N*⁴-(4,4-difluorocyclohexyl)-*N*²-[(4-ethylpyridin-2-yl)methyl]-5,6-dimethylpyrimidine-2,4-diamine

Step A

2-chloro-*N*-(4,4-difluorocyclohexyl)-5,6-dimethylpyrimidin-4-amine

To the solution of 2,4-dichloro-5,6-dimethylpyrimidine (0.585 g, 3.304 mmol) in *N,N*-dimethylformamide (10 mL), (4,4-difluorocyclohexyl)amine hydrochloride (0.652 g, 3.800 mmol) and triethylamine (1.338 g, 13.218 mmol) were added, and reaction mixture was heated at 50 °C overnight. Volatiles were removed under reduced pressure, and the residue was poured into water (300 mL). The product was extracted with ether (3×50 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was subjected to column chromatography on silica eluting with a mixture of hexane/ethyl acetate (gradient 4:1 - 2:1) to provide 621 mg (68%) of the titled compound as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 1.18-1.24 (m, 1 H), 1.60-1.72 (m, 2 H), 1.80-2.10 (m, 8H) 2.21 (s, 3H), 4.00-4.10 (m, 1H), 6.73 (d, *J*=7.79 Hz, 1 H); MS (ESI) *m/z* 318.6 (M+1)⁺.

30

Step B

*N*⁴-(4,4-difluorocyclohexyl)-*N*²-[(4-ethylpyridin-2-yl)methyl]-5,6-dimethylpyrimidine-2,4-diamine

The titled compound was synthesized according to the general procedure described for preparation of *N*⁴-cyclohexyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 1) using [(4-ethylpyridin-2-yl)methyl]amine instead of (pyridin-2-ylmethyl)amine and 2-chloro-*N*-(4,4-difluorocyclohexyl)-5,6-dimethylpyrimidin-4-amine (Step A) instead of 2-chloro-*N*-cyclohexyl-5,6-dimethylpyrimidin-4-amine. The product was purified by crystallization from ethanol to afford the titled compound as the hydrochloride salt as a light-yellow solid. ¹H NMR (300 MHz, DMSO-*d*₆)

δ ppm 1.16 (t, $J=7.59$ Hz, 3H), 1.57-1.1.89 (m, 11 H) 2.25 (s, 3H) 2.62 (m, 2H) 3.95 (s, 1 H) 4.64 (d, $J=5.12$ Hz, 2 H) 7.17 (d, $J=5.12$ Hz, 1 H) 7.24 (s, 1 H) 7.64 (d, $J=6.40$ Hz, 1 H) 8.31 (s, 1 H) 8.40 (d, $J=4.94$ Hz, 1 H) 12.58 (bs, 1 H); MS (ESI) m/z 375.9 (M+1)⁺.

5 Example 91

5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)-*N*⁴-(tetrahydrofuran-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using (tetrahydrofuran-2-ylmethyl)amine instead of cyclopentanamine. The crude material was purified by
 10 HPLC (column: YMC-PACK ODS-AQ C18, 250 mm \times 20 mm, 10 μ m; gradient: 20-50% acetonitrile in 0.02% trifluoroacetic acid/water over fifteen minutes; 50-100% acetonitrile in 0.02% trifluoroacetic acid/water over five minutes; flow rate: 25 mL/min; temperature: 25 $^{\circ}$ C) to afford the titled compound as a trifluoroacetate salt as a light-grey solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm δ 1.34 (s, 1H), 1.59 - 1.78 (m, 3H), 1.88 (s, 3H), 2.25 (s, 3H), 3.23 - 3.29 (m, 2H), 3.46 - 3.50 (m, 1H), 3.64 (dd,
 15 $J_1=13.84$, $J_2=7.12$ Hz, 2H), 4.70 (m, 2H), 7.43 (m, 1H), 7.47 (d, $J=7.79$ Hz, 1H), 7.94 (t, $J=7.12$ Hz, 1H), 8.14 (d, $J=5.10$ Hz, 1H), 8.59 (d, $J=4.30$ Hz, 1H), 8.63 (t, $J=5.37$ Hz, 1H), 12.89 (bs, 1H); MS (ESI) m/z 314.1 (M+1)⁺.

Example 92

20 *N*⁴-(cyclohexylmethyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using 1-cyclohexylmethanamine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia
 25 (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 0.66-0.73 (m, 2H), 1.00 (bs, 3H), 1.35 (bs, 1H), 1.42-1.58 (m, 5H), 1.86 (s, 3H), 2.18 (s, 3H), 3.06 (bs, 2H), 4.58 (bs, 2H), 7.26 (bs, 2H), 7.40-7.46 (m, 1H), 7.68-7.74 (m, 1H), 8.49 (bs, 1 H); MS (ESI) m/z 326.5 (M+1)⁺.

30 Example 93

5,6-dimethyl-*N*⁴-(pyridin-3-yl)-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using pyridin-3-amine instead of cyclopentanamine. The crude material was purified by column
 35 chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, CDCl₃) δ ppm 2.11 (s, 3H), 2.35 (s, 3H), 4.71 (d, $J=3.0$ Hz, 2H),

5.97 (bs, 1H), 6.41 (bs, 1H), 7.13-7.20 (m, 2H), 7.31 (d, $J=7.4$ Hz, 1H), 7.62 (t, $J=7.6$ Hz, 1H), 8.05 (d, $J=4.0$ Hz, 1H), 8.26 (bs, 1H), 8.56-8.63 (m, 2H); MS (ESI) m/z 307.9 (M+1)⁺.

Example 94

5 5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)- N^4 -(1,3,4-thiadiazol-2-yl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of N^4 -cyclopentyl-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using 1,3,4-thiadiazol-2-amine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia
10 (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, DMSO- d_6) δ ppm 2.10 (s, 3H), 2.25 (s, 3H), 4.68 (d, $J=2.0$ Hz, 2H), 7.18-7.51 (m, 3H), 7.70 (t, $J=7.8$ Hz, 1H), 8.50 (s, 1H), 9.01 (s, 1H), 10.93 (bs, 1H); MS (ESI) m/z 314.1 (M+1)⁺.

15 Example 95

5,6-dimethyl- N^4 -(1,2-oxazol-3-yl)- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of N^4 -cyclopentyl-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using isoxazol-3-amine instead of cyclopentanamine. The crude material was purified by column
20 chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, CDCl₃) δ ppm 2.08 (s, 3H), 2.35 (s, 3H), 4.74 (d, $J=2.8$ Hz, 2H), 5.97 (bs, 1H), 6.98 (s, 1H), 7.17 (t, $J=6.4$ Hz, 1H), 7.31-7.44 (m, 2H), 7.63 (t, $J=6.5$ Hz, 1H), 8.17 (s, 1H), 8.56 (d, $J=4.6$ Hz, 1H); MS (ESI) m/z 297.8 (M+1)⁺.

25

Example 96

5,6-dimethyl- N^4 -(5-methyl-1,2-oxazol-3-yl)- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of N^4 -cyclopentyl-5,6-dimethyl- N^2 -(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using 5-
30 methylisoxazol-3-amine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, CDCl₃) δ ppm 2.06 (s, 3H), 2.35 (s, 3H), 4.75 (d, $J=2.8$ Hz, 2H), 5.92 (bs, 1H), 6.54 (s, 1H), 7.18 (m, 1H), 7.36 (d, $J=7.8$ Hz, 1H), 7.64 (t, $J=7.5$ Hz, 1H), 8.59 (d,
35 $J=4.0$ Hz, 1H); MS (ESI) m/z 311.5 (M+1)⁺.

Example 97


*N*⁴-(4-fluorobenzyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine

The titled compound was synthesized according to the procedure described for preparation of *N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine (Example 29) using (4-fluorobenzyl)amine instead of cyclopentanamine. The crude material was purified by column chromatography eluting with mixture of chloroform/ethanol/20% water solution of ammonia (200:10:1), and then the final product was washed with diethyl ether to afford the titled compound as a white solid. ¹H NMR (300 MHz, CDCl₃) δ ppm 1.92 (s, 3H), 2.27 (s, 3H), 4.56 (d, *J*=3.8 Hz, 2H), 4.72 (d, *J*=2.8 Hz, 2H), 4.78 (bs, 1H), 5.70 (bs, 1H), 6.94 (t, *J*=8.6 Hz, 2H), 7.13 (d, *J*=7.8 Hz, 1H), 7.20 (t, *J*=7.5 Hz, 2H), 7.29 (bs, 1H), 7.57 (t, *J*=7.5 Hz, 1H), 8.57 (d, *J*=3.2 Hz, 1H); MS (ESI) *m/z* 338.8 (M+1)⁺.

15 The discussion of references herein is intended merely to summarize the assertions made by their authors. No admission is made that any reference (or a portion of any reference) is relevant prior art (or prior art at all). Applicants reserve the right to challenge the accuracy and pertinence of the cited references.

What is claimed is:

1. A compound having formula (I), or a pharmaceutically acceptable salt thereof,



wherein:

R¹ is cyclohexyl optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkynyl, C₁-C₁₀-haloalkyl, C₂-C₁₀-haloalkenyl, C₂-C₁₀-haloalkynyl, halogen, oxo, cyano, hydroxy, -O-C₁-C₆-alkyl, -O-C₁-C₆-haloalkyl, -C₁-C₃-alkylene-O-H, -C₁-C₃-alkylene-O-C₁-C₆-alkyl, -C₁-C₃-alkylene-O-C₁-C₆-haloalkyl, -C₁-C₃-alkylene-NH₂, -NH₂, -C(O)O-C₁-C₆-alkyl, -N(R^{b1})C(O)R^{b1}, -CON(R^{a1})(R^{b1}), -C(O)R^{b1}, -OC(O)R^{b1}, -OS(O)₂N(R^{a1})(R^{b1}), -CO₂H, -CO₂R^{b1}, -N(R^{b1})C(O)N(R^{b1})₂, -S-R^{b1}, -S(O)₂R^{b1}, -S(O)R^{b1}, -SO₂N(R^{a1})(R^{b1}), -N(R^{a1})(R^{b1}), -N(R^{b1})S(O)₂R^{b1}, -N(R^{b1})C(O)O(R^{b1}), -N(R^{b1})S(O)₂O(R^{b1}), -L^{1a}-O-R^{b1}, -L^{1a}-CN, -L^{1a}-N(R^{b1})C(O)R^{b1}, -L^{1a}-CON(R^{a1})(R^{b1}), -L^{1a}-C(O)R^{b1}, -L^{1a}-OC(O)R^{b1}, -L^{1a}-CO₂H, -L^{1a}-CO₂R^{b1}, -L^{1a}-N(R^{b1})C(O)N(R^{b1})₂, -L^{1a}-S-R^{b1}, -L^{1a}-S(O)₂R^{b1}, -L^{1a}-S(O)R^{b1}, -L^{1a}-SO₂N(R^{a1})(R^{b1}), -L^{1a}-N(R^{a1})(R^{b1}), -L^{1a}-N(R^{b1})S(O)₂R^{b1}, and -L^{1a}-N(R^{b1})C(O)O(R^{b1});

R² is methyl or ethyl;

R³ is methyl or ethyl;

R⁴ and R⁵ are independently selected from the group consisting of hydrogen, C₁-C₆-alkyl, and C₁-C₆-haloalkyl;

R⁶ is selected from the group consisting of hydrogen, C₁-C₆-alkyl, and C₁-C₆-haloalkyl;

G¹ is pyridinyl optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, C₁-C₆-alkyl, C₁-C₆-haloalkyl,

-O-R^f, -CN, -N(R^f)C(O)R^f, -CON(R^e)(R^f), -C(O)R^f, -OC(O)R^f, -CO₂H, -CO₂R^f, -N(R^f)C(O)N(R^f)₂, -S-R^f, -S(O)₂R^f, -S(O)R^f, -SO₂N(R^e)(R^f), -N(R^e)(R^f), -N(R^f)S(O)₂R^f, -N(R^f)C(O)O(R^f), -L³-O-R^f, -L³-CN, -L³-N(R^f)C(O)R^f, -L³-CON(R^e)(R^f), -L³-C(O)R^f, -L³-OC(O)R^f, -L³-CO₂H, -L³-CO₂R^f, -L³-N(R^f)C(O)N(R^f)₂, -L³-S-R^f, -L³-S(O)₂R^f, -L³-S(O)R^f, -L³-SO₂N(R^e)(R^f), -L³-N(R^e)(R^f), -L³-N(R^f)S(O)₂R^f, and -L³-N(R^f)C(O)O(R^f);

X is O or NR^g;

R^{a1}, at each occurrence, is each independently hydrogen, C₁-C₆-alkyl, C₁-C₆-haloalkyl, or C₃-C₈-cycloalkyl, wherein the C₃-C₈-cycloalkyl is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen, oxo, C₁-C₃alkyl, and C₁-C₃-haloalkyl;

R^{b1} is each independently hydrogen, C₁-C₆-alkyl, or C₁-C₆-haloalkyl;

R^e, at each occurrence, is each independently hydrogen, C₁-C₆-alkyl, C₁-C₆-haloalkyl, or C₃-C₈-cycloalkyl, wherein the C₃-C₈-cycloalkyl is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen, oxo, C₁-C₃alkyl, and C₁-C₃-haloalkyl;

R^f is each independently hydrogen, C₁-C₆-alkyl, or C₁-C₆-haloalkyl;

R^g is hydrogen or C₁-alkyl;

L^{1a}, at each occurrence, is each independently C₁-C₆-alkylene or C₃-C₈-cycloalkylene, wherein L^{1a} is each optionally substituted with 1, 2, 3, or 4 halogen or 1 or 2 hydroxy; and

L³, at each occurrence, is each independently C₁-C₆-alkylene or C₃-C₈-cycloalkylene, wherein L³ is each optionally substituted with 1, 2, 3, or 4 halogen.

2. The compound of claim 1, wherein X is O.
3. The compound of claim 1, wherein X is NR^g.
4. The compound of claim 1, wherein R² and R³ are each methyl; R⁴, R⁵ and R⁶ are each hydrogen; and X is NR^g, wherein R^g is hydrogen.

5. A compound that is:

*N*⁴-cyclohexyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;

*N*²-benzyl-*N*⁴-cyclohexyl-5,6-dimethylpyrimidine-2,4-diamine;

*N*⁴-cyclohexyl-5,6-dimethyl-*N*²-(pyridin-3-ylmethyl)pyrimidine-2,4-diamine;

2-({[4-(cyclohexylamino)-5,6-dimethylpyrimidin-2-yl]amino}methyl)-6-methylpyridin-3-ol;

*N*⁴-cyclohexyl-*N*²-(4-methoxybenzyl)-5,6-dimethylpyrimidine-2,4-diamine;

*N*⁴-cyclohexyl-*N*²-(4-fluorobenzyl)-5,6-dimethylpyrimidine-2,4-diamine;

*N*⁴-cyclohexyl-5,6-dimethyl-*N*²-[4-(trifluoromethoxy)benzyl]pyrimidine-2,4-diamine;

*N*⁴-cyclohexyl-*N*²-(4-isopropylbenzyl)-5,6-dimethylpyrimidine-2,4-diamine;

*N*⁴-cyclohexyl-5,6-dimethyl-*N*²-[4-(trifluoromethyl)benzyl]pyrimidine-2,4-diamine;

*N*⁴-cyclohexyl-*N*²-(3-fluorobenzyl)-5,6-dimethylpyrimidine-2,4-diamine;

*N*⁴-cyclohexyl-5,6-dimethyl-*N*²-(1*H*-pyrazol-5-ylmethyl)pyrimidine-2,4-diamine;
*N*⁴-cyclohexyl-5,6-dimethyl-*N*²-[(1*R*)-1-phenylethyl]pyrimidine-2,4-diamine;
*N*⁴-cyclohexyl-5,6-dimethyl-*N*²-[(1*S*)-1-phenylethyl]pyrimidine-2,4-diamine;
*N*⁴-cyclohexyl-5,6-dimethyl-*N*²-[(4-methylpyridin-2-yl)methyl]pyrimidine-2,4-diamine;
*N*⁴-cyclohexyl-*N*²-[(4-methoxypyridin-2-yl)methyl]-5,6-dimethylpyrimidine-2,4-diamine;
*N*⁴-cyclohexyl-5,6-dimethyl-*N*²-[(6-methylpyridin-2-yl)methyl]pyrimidine-2,4-diamine;
*N*⁴-cyclohexyl-5,6-dimethyl-*N*²-[[5-(trifluoromethyl)pyridin-2-yl]methyl]pyrimidine-2,4-diamine;
*N*²-[(4-*tert*-butylpyridin-2-yl)methyl]-*N*⁴-cyclohexyl-5,6-dimethylpyrimidine-2,4-diamine;
*N*⁴-cyclohexyl-5,6-dimethyl-*N*²-(2-thienylmethyl)pyrimidine-2,4-diamine;
*N*⁴-cyclohexyl-*N*²-[(3,5-dimethyl-1,2-oxazol-4-yl)methyl]-5,6-dimethylpyrimidine-2,4-diamine;
*N*⁴-cyclohexyl-5,6-dimethyl-*N*²-[(1-methyl-1*H*-imidazol-4-yl)methyl]pyrimidine-2,4-diamine;
*N*⁴-cyclohexyl-*N*²-(3-methoxybenzyl)-5,6-dimethylpyrimidine-2,4-diamine;
*N*⁴-cyclohexyl-5,6-dimethyl-*N*²-[(3-methylpyridin-2-yl)methyl]pyrimidine-2,4-diamine;
*N*²-[(4-chloropyridin-2-yl)methyl]-*N*⁴-cyclohexyl-5,6-dimethylpyrimidine-2,4-diamine;
*N*⁴-(4,4-difluorocyclohexyl)-5,6-dimethyl-*N*²-[(4-methylpyridin-2-yl)methyl]pyrimidine-2,4-
diamine;
*N*⁴-cyclopentyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)-*N*⁴-(tetrahydro-2*H*-pyran-4-yl)pyrimidine-2,4-diamine;
5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)-*N*⁴-[4-(trifluoromethyl)cyclohexyl]pyrimidine-2,4-diamine;
*N*⁴-(4,4-difluorocyclohexyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
*N*⁴-(2,3-dihydro-1*H*-inden-1-yl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
3-({5,6-dimethyl-2-[(pyridin-2-ylmethyl)amino]pyrimidin-4-yl}amino)cyclopentanol;
5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)-*N*⁴-(1,2,3,4-tetrahydronaphthalen-1-yl)pyrimidine-2,4-
diamine;
*N*⁴-(3,4-dihydro-2*H*-chromen-4-yl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
cis-4-({5,6-dimethyl-2-[(pyridin-2-ylmethyl)amino]pyrimidin-4-yl}amino)-1-methylcyclohexanol;
trans-4-({5,6-dimethyl-2-[(pyridin-2-ylmethyl)amino]pyrimidin-4-yl}amino)-1-
methylcyclohexanol;
*N*⁴-(bicyclo[2.2.1]hept-2-yl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
5,6-dimethyl-*N*⁴-(2-methylcyclohexyl)-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
*N*⁴-(2,3-dimethylcyclohexyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
2-({5,6-dimethyl-2-[(pyridin-2-ylmethyl)amino]pyrimidin-4-yl}amino)cyclohexanol;

[(1*R*,2*S*)-2-({5,6-dimethyl-2-[(pyridin-2-ylmethyl)amino]pyrimidin-4-yl}amino)cyclohexyl]methanol;

*N*⁴-(cyclopentylmethyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
*N*⁴-cycloheptyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
*N*⁴-(2,3-dihydro-1*H*-inden-2-yl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
*N*⁴-cyclobutyl-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
5,6-dimethyl-*N*⁴-(pentan-3-yl)-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
*N*⁴-(3-fluorophenyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
*N*⁴-(4-fluorophenyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
*N*⁴-(2-fluorophenyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
5,6-dimethyl-*N*⁴-phenyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)-*N*⁴-[3-(trifluoromethoxy)phenyl]pyrimidine-2,4-diamine;
5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)-*N*⁴-[3-(trifluoromethyl)phenyl]pyrimidine-2,4-diamine;
*N*⁴-(2,6-difluorophenyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)-*N*⁴-[4-(trifluoromethoxy)phenyl]pyrimidine-2,4-diamine;
5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)-*N*⁴-[4-(trifluoromethyl)phenyl]pyrimidine-2,4-diamine;
*N*⁴-(3,4-difluorophenyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)-*N*⁴-[2-(trifluoromethoxy)phenyl]pyrimidine-2,4-diamine;
*N*⁴-(2,5-difluorophenyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
*N*⁴-(1,3-benzodioxol-5-yl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
*N*⁴-(4-chlorophenyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
5,6-dimethyl-*N*⁴-(4-methylphenyl)-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
*N*⁴-(3,5-difluorophenyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
*N*⁴-(3-chlorophenyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
*N*⁴-(2-chlorophenyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
5,6-dimethyl-*N*⁴-(2-methylphenyl)-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
*N*⁴-(2,6-dimethylphenyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
5,6-dimethyl-*N*⁴-(3-methylphenyl)-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
*N*⁴-(1,1-dioxidotetrahydrothiophen-3-yl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
*N*⁴-(5-fluoro-2-methylphenyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
*N*⁴-(2-fluoro-6-methylphenyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;

*N*⁴-(4,5-difluoro-2-methylphenyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 5,6-dimethyl-*N*⁴-(1-methyl-1*H*-pyrazol-5-yl)-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
*N*⁴-(4-fluoro-2-methylphenyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
*N*⁴-(3-fluoro-2-methylphenyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
*N*⁴-cyclohexyl-*N*⁴,5,6-trimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
*N*⁴-(3,3-difluorocyclopentyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
trans-4-({5,6-dimethyl-2-[(pyridin-2-ylmethyl)amino]pyrimidin-4-yl}amino)cyclohexanol;
*N*⁴-(3,3-difluorocyclohexyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 5,6-dimethyl-*N*⁴-(1-methylpiperidin-4-yl)-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
tert-butyl 4-({5,6-dimethyl-2-[(pyridin-2-ylmethyl)amino]pyrimidin-4-yl}amino)piperidine-1-carboxylate;
 5,6-dimethyl-*N*⁴-(piperidin-4-yl)-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
*N*⁴-(2,6-diisopropylphenyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 3-({5,6-dimethyl-2-[(pyridin-2-ylmethyl)amino]pyrimidin-4-yl}amino)cyclohexanol;
*N*⁴-cyclohexyl-5,6-dimethyl-*N*²-[(5-methylpyridin-2-yl)methyl]pyrimidine-2,4-diamine;
*N*⁴-cyclohexyl-5,6-dimethyl-*N*²-[1-(pyridin-2-yl)ethyl]pyrimidine-2,4-diamine;
*N*⁴-(2,4-difluorophenyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 5-ethyl-*N*⁴-(4-fluorophenyl)-6-methyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
*N*⁴-(4,4-difluorocyclohexyl)-*N*²-[(4-ethylpyridin-2-yl)methyl]-5,6-dimethylpyrimidine-2,4-diamine;
 5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)-*N*⁴-(tetrahydrofuran-2-ylmethyl)pyrimidine-2,4-diamine;
*N*⁴-(cyclohexylmethyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 5,6-dimethyl-*N*⁴-(pyridin-3-yl)-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)-*N*⁴-(1,3,4-thiadiazol-2-yl)pyrimidine-2,4-diamine;
 5,6-dimethyl-*N*⁴-(1,2-oxazol-3-yl)-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine;
 5,6-dimethyl-*N*⁴-(5-methyl-1,2-oxazol-3-yl)-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine; or
*N*⁴-(4-fluorobenzyl)-5,6-dimethyl-*N*²-(pyridin-2-ylmethyl)pyrimidine-2,4-diamine.

6. A pharmaceutical composition comprising one or more compounds of any one of claims 1-5 or pharmaceutically acceptable salts thereof; one or more excipients; and optionally one or more additional therapeutic agents.

7. Use of one or more compounds of any one of claims 1-5 or pharmaceutically acceptable salts thereof, optionally in combination with one or more therapeutic agents, for inhibiting replication of an respiratory syncytial virus.

8. The use of claim 7, wherein the respiratory syncytial virus is from a mutant of a respiratory syncytial virus.

